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Abstract
Illicit opioid use takes thousands of Americans’ lives each year, reduces the quality of
life for affected individuals, and results in sizable socioeconomic costs. Existing research
has supported medication-assisted treatment (MAT) for this condition; however, MAT
participants often continue to experience opioid craving and using behaviors.
Mindfulness based relapse prevention (MBRP) uses mindfulness meditation and
cognitive behavioral therapy to reduce likelihood of substance use relapse. This study
used a combination of physical dependence theory, positive incentive theory, and
classical conditioning theory to evaluate the impact of MBRP on illicit opioid use and
cravings in a quantitative randomized, controlled experimental design. Volunteer
participants (n=52) from a California Bay Area MAT program site were randomly
assigned to experimental and control groups. Illicit opioid use, opioid cravings, and
mindfulness data outcomes were evaluated at pretest, midtest, and posttest intervals for
the experimental group receiving MBRP and treatment as usual and a treatment as usual
control group. Multiple feasibility confounds including participant dropout interfered
with study implementation, resulting in insufficient statistical power for analysis. The
findings indicated the importance of anticipating feasibility problems in future similar
study designs; however, on an individual level MBRP participants did report positive
reactions to treatment. Empirically determining MBRP effectiveness in reducing illicit
opioid use and cravings for MAT program participant may foster positive social change
by reducing public health, behavioral, social, and legal problems, as well as human
suffering associated with illicit opioid use.
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Chapter 1: Introduction to the Study
Introduction
This pilot study involved evaluating the effectiveness of Mindfulness-Based
Relapse Prevention (MBRP; Bowen, Chawla, & Marlatt, 2011) manualized treatment in
reducing illicit opioid use for individuals with opioid use disorder. MBRP was planned
for implementation at a medication assisted treatment (MAT) program site located in the
California Bay Area, where patients with opioid use disorder receive comprehensive
treatment services for their condition. Despite MAT service provision efforts, opioid use
relapse remains a serious concern for MAT program participants. Relapse involving illicit
opioid use has strong and negative impacts on the physical, psychological, and social
wellbeing of MAT program patients. Prior to implementation of this study, the
effectiveness of MBRP as a treatment adjunct was not yet evaluated in MAT program
settings. This study is an attempt to address this research gap.
This study was intended to foster beneficial social change through increasing
awareness within medical, psychological, and treatment fields regarding indications and
effectiveness of MBRP applications in the context of MAT programs. Further, if found
effective, use of MBRP in the MAT program setting would likely reduce MAT program
patient relapse frequency, thus improving the quality of life and MAT program
effectiveness for patient participants. In addition, reduced relapse rates arising through
MBRP use in the MAT program setting would likely reduce health and safety risks and
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costs associated with relapse, as well as related demands and costs in terms of healthcare,
law enforcement, legal, and social services systems.
This chapter includes a description of the background for the study, summary of
relevant research, gaps in research this study attempted to fill, and need for the study.
Chapter 1 continues with the problem statement, relevance and significance to the field,
and the identified critical research gap. The study purpose is delineated, including core
methodological approaches, intent, and identified variables and potential mediating
variables. Next, study research questions and hypotheses are included along with a
description of measurement methods. Following this, I describe relevant theoretical and
conceptual frameworks and how they relate to the phenomena being evaluated, research
questions and hypotheses, and how they inform the study’s methodological design. The
nature of the study is then discussed including its design rationale, variables and potential
mediating variables, and methodology. All known variables and key terms are
operationally defined. Assumptions underlying the study are critically examined. The
scope and delimitations of the study are discussed, including an examination of internal
and external validity. Following this, limitations of the study are described, including
relevant internal and external validity threats, potential biases, and measures to address
these concerns. The significance of the study for the field is then addressed and social
change implications are discussed. Chapter 1 concludes with a summary of the chapter
along with a transition to Chapter 2.
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Background
Opioid use disorder has emerged as a growing societal problem over the past
several decades. The National Institute on Drug Abuse (NIDA, 2020) reported that in
2017, opioid overdose was implicated in the deaths of more than 47,000 Americans.
There was a 430% increase in U.S. hospitalizations associated with illicit opioid use
between 1999 and 2009 (Substance Abuse & Mental Health Administration (SAMHSA;
2011). The NIDA (2020) reported that as of the end of 2018, opioid overdose was the
primary cause of 128 deaths each day in the U.S. The Centers for Disease Control (CDC,
2021) reported that drug overdose deaths have increased by 400% since 1999, including a
6% increase in opioid-related deaths overall and a 15% increase in synthetic opioid
associated deaths during 2019. The Office of National Drug Control Policy (ONDCP,
2011) said there was an increase of 402% in prescription opioid use among Americans
from 1997 to 2007. The NIDA (2011) reported that of the 7 million individuals in the
U.S. in 2010 who used prescription drugs nonmedically, 5.1 million abused opioids. The
SAMHSA (2020a) said between 2018 and 2019, there were 10.1 million individuals who
misused opioids, and two-thirds of drug overdose deaths were opioid related. Taken
together, these reports suggest an increasing frequency of opioid misuse and opioid
associated deaths over the past 2 decades.
MAT has been established as a highly effective treatment for opioid use disorder
(Batki et al., 2005; Kosten & George, 2002; Parrino et al., 1993; SAMHSA, 2020b,
Volkow, 2007b). Despite the demonstrated effectiveness of MAT program participation,
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relapse among MAT program participants remains a significant liability (Kreek, 2007).
Relapse rates while enrolled in MAT tend to reduce over time, with an average rate of
19.7% measured over a 36-month treatment episode (Clark et al., 2014). Moreover,
discontinuance of MAT is associated with a relapse rate of almost 100% (Calsyn et al.,
2006), suggesting that whereas relapse while enrolled in MAT is a concern, it is a much
greater concern where treatment is discontinued. This suggests the need for effective
treatment adjuncts that are likely to reduce this propensity toward relapse within the
context of MAT program settings. MBRP, a manualized treatment approach for
substance use integrating mindfulness practices with cognitive behavioral therapy
techniques, has been found to be highly effective as a treatment for substance use
disorders (Bowen et al., 2009; Bowen et al., 2011; Bowen & Enkema, 2014; Bowen &
Kurz, 2012; Witkiewitz & Bowen, 2010; Witkiewitz et al., 2013a; 2013b). MBSR has not
yet been evaluated as a treatment adjunct for individuals participating in MAT programs.
This pilot study addressed a gap in research by evaluating MBRP for
effectiveness as an adjunctive treatment for individuals enrolled in a MAT program. This
study will lead to beneficial social change through increased researcher and clinican
awareness of effectiveness of MBRP applications in the context of MAT programs.
Further, if found effective, use of MBRP in the MAT program setting would likely
reduce MAT program patient relapse frequency, thus improving the quality of life and
MAT program effectiveness for patient participants. In addition, reduced relapse rates
arising through MBRP use in the MAT program setting would reduce health and safety
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risks and costs associated with relapse, as well as related use demands and costs in
healthcare, law enforcement, legal, and social services systems.
Problem Statement
Opioid use disorder is a current and pervasive problem in the U.S. Over 3.7
million individuals in the U.S. have used heroin (NIDA, 2005a). In 2004, approximately
314,000 individuals used heroin (NIDA, 2005a). This increased by over 47% to 669,000
heroin abusers in 2012 and 745,000 persons in 2019 (NIDA, 2014b). The NIDA (2014a)
said 5.1 million individuals used opioid medication illicitly in 2012. The SAMHSA
(2020a) said that 10.1 individuals abused opioids in 2019, an increase of almost 50%
from 2012. Chronic pain affects 33% of Americans and is a factor strongly implicated in
opioid use disorder (Johannes et al., 2010; NIDA, 2014a). The SAMHSA (2020a) said in
2019, 9.7 million individuals abused prescription opioids. Drug Awareness Warning
Network (DAWN) data indicated a 183% increase in ER visits associated with illicit
opioid use during the period from 2004 to 2011 (SAMHSA, 2013a). The SAMHSA
(2020a) reported a 30% increase for the period from July 2016 to September 2017. These
data trends strongly suggest that illicit opioid use is continuing to increase at a concerning
rate.
Opioid use disorder is characterized as a chronic relapsing condition where postremission relapse is highly likely (California Society of Addiction Medicine, 2008;
Dennis & Scott, 2007; Leshner, 1989; 2001; SAMHSA, 2020b, Volkow, 2007a; 2007b).
MAT participants are thus at increased risk for episodic relapse of illicit opioid use and
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are likely to benefit from adjunctive treatment interventions (Logan & Marlatt, 2010;
Parrino et al., 1993). Relapse into illicit opioid use is strongly associated with increased
risk of disease contraction, including hepatitis C (HCV) and human immunodeficiency
virus (HIV) and adverse medical complications, and is further associated with elevated
risk of oversedation, coma, and death due to central nervous system suppression
(California Society of Addiction Medicine, 2008; Parrino et al., 1993; Volkow, 2007a;
2007b). Further associated risks include secondary general medical conditions,
symptomatic exacerbation of concomitant psychiatric disorders, criminal behavior in
order to sustain illicit opioid use, and social dysfunction leading to marginalization by
and alienation from familial and other potential supportive resources (California Society
of Addiction Medicine, 2008; Parrino et al., 1993; Volkow, 2007a; 2007b). Any
therapeutic adjunct associated with reduced relapse risk is likely to benefit the health and
wellbeing of MAT program participants.
Mindfulness-based practices are effective in treatment of several general medical
conditions including fibromyalgia, cancer, multiple sclerosis, eating disorders, and
impaired immune system response (Chang et al., 2004; Jain et al., 2007; Kabat-Zinn,
2002; 2009; Zeidan et al., 2011). Mindfulness-based practices have been found to be
effective as treatments for anxiety, depression, posttraumatic stress disorders, and
substance use disorders (Brantley, 2007; Brewer et al., 2010; Davidson, 2010; Farb et al.,
2012; Marlatt, 2006; Modinos et al., 2010). A research gap exists in that MBRP has not
yet been evaluated as a treatment for opioid use disorder within the population of
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individuals being treated at MAT programs. This pilot study was used to address this
research gap by examining the effectiveness of MBRP in reducing illicit opioid use for
participants currently enrolled in a MAT program in California.
Purpose of the Study
Study Intent
The purpose of this quantitative pilot study design was to evaluate the
effectiveness of MBRP as a therapeutic adjunct to MAT program participation. I
examined the relationship between mindfulness of MAT program participants and
frequency of illicit opioid using and craving behaviors.
Study Variables
I used a concurrent mixed methods design, including quantitative, randomized,
and controlled experimental single-site pilot designs using repeated measures.
Multivariate analysis of covariance (MANCOVA) was used to evaluate relationships
between the dependent and independent variables over time.
The dependent variables (DVs) in the study were based on the outcomes of two
standardized measures broadly used in substance abuse treatment and research. The first
was the Addiction Severity Index (ASI; McLellan et al., 1985). The ASI is used to
evaluate for examinee functioning across multiple domains, asking lifetime problem
frequency for a total number of years, where the problem was evidenced at least once
during any year, and problem frequency within past 30 days, where the problem was
evidenced at least once. Using a Likert scale design the examinee indicates problem
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severity and need for treatment. The ASI Alcohol/Drugs subscale data was used in this
study. This ASI subscale is scored through weighted summing of individual item results
within each subscale. Index composite score ranges from no problem severity (0.00) to
very high problem severity (1.00) The ASI Alcohol/Drugs subscale data outcomes were
used in this study to measure severity of participant opioid use at three specified testing
intervals.
The Opioid Craving Scale (OCS; McHugh et al., 2014) is used to measure
severity of cravings for illicit opioids. It consists of three visual analogue scale items
measured in 0 (no desire for opioids) to 10 (strong desire for opioids) for item one, and in
severity from 0 (no severity) to 10 (extremely strong severity) for the remaining two
items. The first scale measures the strength of desire to use opioids during the past 24
hours. The second scale measure how strong desire to use opioids has been during the
past week when exposed to an environmental cue associated with opioid use. The third
scale requires recollection of the most recent environment and time of day where the
examinee used opioids and rates the likelihood of opioid use if the examinee were in that
environment at that time today (McHugh et al.). The OCS was used in this study to
measure participant opioid craving severity at three specified testing intervals.
The independent variable (IV) levels in the study were the MBRP manualized
treatment intervention administered for a proscribed 8-week period as an adjunct to
treatment as usual (TAU) in an experimental group of MAT program participants, and
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TAU in the control group of MAT program participants during a concurrent 8-week
period.
A potential mediating variable (MV) in the study was the effect of MBRP
manualized treatment on participant states of mindfulness. This was evaluated by
observing variance between pretest, midtest, and posttest outcome scores measured by
the Toronto Mindfulness Scale (TMS; Lau et al., 2006). The TMS measures two factors
of mindfulness: curiosity and decentering. It consists of 13 questions associated with each
factor. The examinee indicates level of agreement with test item statements using a Likert
scale response from zero (no agreement) to four (very much agreement). Higher scores
indicate increased clinical evidence of mindfulness effects in the test subject.
Statistical covariance data outcomes of TMS scores would likely reveal any
significant mediating associations between changes in participant mindfulness and DV
outcomes. The MV outcomes were used only for observational purposes, and were not
included in the study research questions and hypotheses.
Research Questions and Hypotheses
RQ1: Is exposure to MBRP manualized treatment associated with changes in
frequency of illicit opioid use for individuals with opioid use disorder concurrently
participating in a MAT program?
H01: Exposure to MBRP manualized treatment is not associated with changes in
frequency of illicit opioid use for individuals with opioid use disorder concurrently
participating in a MAT program.
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Ha1: Exposure to MBRP manualized treatment is associated with changes in
frequency of illicit opioid use for individuals with opioid use disorder concurrently
participating in a MAT program.
RQ2: Is exposure to MBRP manualized treatment associated with changes in
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently
participating in a MAT program?
H02: Exposure to MBRP manualized treatment is not associated with changes in
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently
participating in a MAT program.
Ha2: Exposure to MBRP manualized treatment is associated with changes in
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently
participating in a MAT program.
Dependent Variables
The DVs were frequency of illicit opioid use as measured by ASI Alcohol/Drugs
subscale outcomes and severity of participant opioid cravings as measured by Opioid
Craving Scale outcomes.
Independent Variable
The IV for this study consisted of treatment with two distinct levels: the
experimental group level wherein the MBRP manualized treatment intervention was
provided to participants as a treatment adjunct in addition to their TAU at the MAT
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program, and the control group level wherein the participants received only TAU at the
MAT program.
Groups were randomly assigned using a random number table. Each experimental
group participant was exposed to MBRP manualized treatment. Participants not attending
a minimum of six out of eight possible MBRP group sessions while participating in TAU
at the MAT program were classified as study dropouts. The control group level
experienced TAU as it was practiced within the context of the MAT program and did not
receive the MBRP manualized treatment. For the control group condition, participants
discontinuing TAU at the MAT program during the eight-week study period were
classified as study dropouts. The only between groups variable was administration of the
MBRP manualized treatment. This variable was measured by participant completion of
the eight weeks required in the MBRP treatment protocol.
Theoretical and Conceptual Framework for the Study
Theoretical Foundation
Mindfulness practices have been found to be effective in terms of treating
multiple conditions including stress associated conditions, impaired immune system
response, cancer, chronic pain, and substance use disorders (Chang et al., 2004; Jain et
al., 2007; Kabat-Zinn, 2002; 2009; Shapiro & Schwartz, 2000; Witkiewitz et al., 2005;
Zeidan et al., 2011). Their effectiveness is associated with improved treatment outcomes
for multiple psychiatric disorders, including substance use conditions (Brewer et al.,
2010; Davidson, 2010; Farb et al., 2012; Kabat-Zinn, 2002; 2009; Marlatt, 2006;
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Modinos et al., 2010). The area of the brain known as the prefrontal cortex (PFC)
regulates behavior to minimize risk of physical harm and assure optimal chances for
survival. The mesolimbic dopaminergic system regulates behaviors associated with
rewarding activities such as eating, drinking, sexual activity, and mood-altering substance
use. Cognitive deficits in PFC mediation of signals from the mesolimbic dopaminergic
system increase the opioid-dependent individual’s vulnerability to relapse, and reduce
capability to regulate drug craving, seeking, and using behaviors (Childress et al., 2008;
Dennis & Scott, 2007; Kosten & George, 2002). States of mindfulness reflect calm, fully
aware, and optimally balanced cognitive functioning arising from ongoing practice of
nonjudgmental, nonreactive acceptance of experiential phenomena. These mindful states
have been associated with more adaptive PFC regulation of limbic system signaling than
is consistently found in individuals that do not practice mindfulness (Brewer et al., 2010;
Farb et al., 2012; Ostafin & Marlatt, 2008; Modinos et al., 2010). This suggests that
increased attentional control over illicit opioid craving, seeking, and using behaviors
achieved through mindfulness practice may reduce illicit opioid use. Research suggests
opioid use disorder signs and symptoms associated with relapse might be effectively
mediated through clinical applications of mindfulness such as MBRP.
Conceptual Framework
Ostafin and Marlatt (2008) observed that implicit processes regulated in the
limbic system of the brain are strongly associated with substance use disorders. These
findings suggest that mindfulness practices may enhance control of opioid use cravings
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and seeking behaviors, thereby reducing illicit opioid use and resultant health risk
behaviors and offering symptomatic relief and improved quality of life for participants.
Wenk-Sormaz (2005) noted that meditation facilitated cognitive and affective
responsivity. This suggests that engagement in mindfulness-based practices may increase
individual capability for regulating emergence of autonomic substance use cravings via
enhanced PFC functioning.
Continued mindful experiencing of substance use cravings deconditions
associations between substance use behavior and cravings, thereby decreasing
vulnerability to relapse (Marlatt & Chawla, 2007; Ostafin & Marlatt, 2008). Marlatt and
Chawla (2007) said this therapy ultimately reduces substance cravings and counteracts
substance addiction through facilitating awareness and acceptance of present moment
experiences, thereby reducing individual propensities toward using substances to cope
with aversive existential realities.
Mindfulness-based treatment interventions have been found effective in terms of
treating substance use disorders and associated craving, seeking, and using behaviors
(Bowen et al,, 2011; Bowen et al., 2005; Bowen et al., 2006; Bowen et al., 2009;
Witkiewitz et al., 2005). Whereas MBRP has been found effective in reducing illicit
opioid, stimulant, and alcohol relapse frequency in several distinct populations, it has not
been conclusively evaluated for its effectiveness as a treatment adjunct for individuals
participating in a MAT program. The increasing severity and prevalence of national
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opioid use and the chronic relapsing nature of OUD for MAT program participants
suggests a need to evaluate the effectiveness of MBRP as a treatment adjunct.
This study was an attempt to fill identified research gaps through determining the
efficacy of the MBRP protocol as a treatment adjunct for use by MAT programs,
clinicians, and patients. If established as effective in terms of reducing MAT patients’
risk of relapse, MBRP protocol would thus represent an inexpensive, efficient, and costeffective means of reducing potential harms posed to MAT program participants due to
illicit opioid use relapse.
Mindfulness-based treatment interventions that are effective in terms of regulating
illicit opioid use, craving, seeking, and using behaviors in MAT participants merit further
empirical investigation. MAT program treatment effectiveness and quality of life for
MAT participants would likely be enhanced through integration of mindfulness-based
interventions that support them in reducing illicit opioid cravings and use. Aversive
effects involving cooccurring psychiatric conditions, crime, health care overuse and
costs, social alienation, and stigma would be reduced through implementation of
treatment adjuncts that reduce illicit opioid relapse frequency, duration, and severity.
MBRP is a group treatment model, thus reducing staff/patient ratios and associated costs
while still offering enhanced treatment effectiveness. Enhanced MAT outcomes and
reducing associated costs likely would improve public perception of MAT effectiveness
and the need for enhanced treatments for opioid dependence, thereby reducing social
stigma and its negative effects on opioid-dependent persons and others with substance
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use disorders, further facilitating support for and increased participant enrollment in
MAT programs. A more in-depth review follows in Chapter 2.
Nature of the Study
Design Rationale
This study was intended to determine if participant exposure to MBRP
manualized treatment is associated with reductions in frequency of illicit opioid use and
opioid use cravings for individuals concurrently participating in MAT programs for their
opioid use disorder. I addressed the research questions through measurements of DV
frequency outcomes associated with reported opioid use and cravings throughout the 8week study period. A gap in the research addressed by this study is that no research
evaluated the effects of MBRP manualized treatment on illicit opioid use of MAT
program participants.
Key Variables
The two DVs in this study were frequency of participant illicit opioid use as
measured by ASI Alcohol/Drugs subscale (McLellan et al., 1985) and severity of
participant opioid cravings as measured by the Opioid Craving Scale (McHugh et al.,
2014).
The IV for this study consisted of two levels: the experimental group exposed to
MBRP manualized treatment in addition to TAU at the MAT program, and the TAU-only
control group. This IV was considered valid if participants assigned to the experimental
group attends at least six of the eight weekly MBRP group sessions, and if control group
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participants remain in TAU for the concurrent eight-week period of their experimental
group counterparts.
Potential MVs included observed changes in participant mindfulness as measured
by participant TMS outcome scores. Attempts were made to identify mediating variables
and describe their potential effects on the study outcomes.
Methodology
The research design was a quantitative randomized controlled single-site pilot
study design using repeated measures. This is a mixed within-between subjects design
with time as the within-subjects factor and groups as the between-subjects factor.
MANCOVA was used to statistically evaluate relationships between dependent,
independent, and any identified MVs over time..
The study duration was 8 weeks, consistent with established requirements of
MBRP manualized treatment. Data collection occurred during MBRP manualized
treatment administration.
Definitions
Cue Reactivity: A condition where nonvolitional neurobiological responses to
environmental conditions serve as stimuli for opioid craving, seeking, and using
behaviors (Childress et al., 2008; Dennis & Scott, 2007).
Medication Assisted Treatment (MAT) Program: A comprehensive treatment
approach for individuals with opioid use disorder that includes supervised opioid
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pharmacotherapy, counseling and medical and social support services (Parrino et al.,
1993).
Meditation: The contemplative state wherein the individual reflects on
experiential phenomena as they arise into conscious awareness (APA, 2007).
Methadone: A synthetic opioid analgesic medication used to treat opioid
dependence and chronic pain (Parrino et al., 1993).
Mindfulness: A condition wherein an individual’s awareness is focused on
unfolding experience (APA, 2007).
Mindfulness-Based Relapse Prevention: A therapeutic approach to treatment of
substance use disorders involving mindfulness meditation and cognitive behavioral
therapy interventions (Marlatt & Chawla, 2007).
Mindfulness-Based Stress Reduction: A therapeutic approach involving
mindfulness practices to reduce maladaptive stress reactivity and improve quality of life
(Kabat-Zinn, 1982, 2002).
Mindfulness Meditation: A specific contemplative approach in which thoughts,
feelings, and sensations are intentionally and nonjudgmentally experienced as they arise
into conscious awareness (APA, 2007).
Opioids: Drugs with pain relieving and euphoric effects (APA, 2007).
Opioid Dependence: The condition where continued exposure to opioid drugs
results in neurobiological adaptation to opioids (APA, 2013).
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Opioid Relapse: The phenomenon where an individual returns to illicit opioid use
after a sustained period of abstinence (Parrino et al., 1993).
Opioid Tolerance: Condition where increasing amounts of opioids are needed to
experience drug effects (APA, 2013).
Opioid Use Disorder: A persistent maladaptive pattern of illicit opioid use despite
attempts to reduce or eliminate such use, continuing over a sustained period of time, and
presenting with adverse symptoms.
Opioid Withdrawal: The condition where, once dependence has occurred,
discontinuance of the exogenous opioid results in the onset of multiple adverse physical
symptoms (APA, 2013).
Vipassana: A mindfulness meditation practice where intentional focus on
breathing is used to regulate attention and enhance experiential awareness (Fenner,
2002).
Assumptions
DVs for this study were frequency of participant-reported illicit opioid use and
opioid craving. Illicit opioid use was measured using the ASI Alcohol/Drugs subscale
(McLellan et al., 1985), and opioid craving was measured through the OCS (McHugh et
al., 2014). These scales were assumed to be reliable and accurate means of evaluating
frequency of participant illicit opioid use and craving.
This DV was assumed to have normal distribution and homogeneity of variance
between and within the study experimental and control group levels. Both groups were
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randomly assigned from the larger MAT program patient population where the study was
conducted.
It was also assumed that statistical covariance analysis would reveal any
significant mediating associations between changes in participant mindfulness and DV
outcomes.
Scope and Delimitations
Internal Validity
This pilot study involved examining the effects of MBRP group participation on
illicit opioid use and opioid cravings experienced by opioid-dependent individuals
enrolled in MAT programs. Whereas mindfulness practices have been evaluated for their
effectiveness in terms of reducing illicit substance use of participants in multiple program
settings, including substance use treatment facilities, no research has specifically
addressed the use of MBRP manualized treatment in a MAT program setting. By
targeting MBRP in MAT programs, I isolated a narrow segment of individuals with
substance use disorders who were MAT program participants, and further narrowed the
evaluative focus through limiting the approach to MBRP.
External Validity
This study only included participants who were concurrently enrolled in a MAT
program. Thus, individuals experiencing opioid use disorder who were not participating
in the MAT program selected for the study were not eligible for participation. Similarly,
individuals without a primary diagnosis of opioid use disorder were unsuitable for study
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participation. Since the MAT program normally does not admit individuals who are less
than 18 years of age, such individuals were not considered eligible for study
participation. No other study participation restrictions were planned.
The study was not intended to evaluate for other general medical or psychiatric
conditions. The study was not intended to evaluate for psychological practices that
inform psychotherapeutic interventions for MAT program patients, including therapeutic
approaches such as active listening, motivational interviewing, cognitive behavioral
therapy, trauma therapies such as seeking safety, or general addictions counseling
approaches. The study was not intended to evaluate for neurobiological functioning
associated with opioid use disorder.
Potential Generalizability
Generalizability of this study’s outcomes was limited in that it was a pilot study with
a limited number of participants (n = 60). Reduced numbers of participants are associated
with reduced statistical power, which in turn suggests reduced generalizability. Further,
although participants were randomly assigned to either experimental or control group, the
study depended on volunteer participants. It is possible, especially given the limited
number of participants, that those selected did not fully represent normative
characteristics typically present within the larger MAT program participant population.
This study was intended to evaluate MSRP manualized treatment effectiveness in
terms of reducing illicit opioid use within the specific population of MAT program
participants. Given an outcome that suggested effectiveness of MBRP, even limited
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generalizability could be used as a basis for development of studies with larger
populations, greater statistical power, and greater generalizability for the general
population of MAT program patients.
Limitations
A potential limitation of this study was that a sufficient number of participants did not
complete the entire study period. Such dropout cases were noted with reasons for early
discontinuance and addressed in my discussion of data analysis. Additional possible
limitations may have included potential extraneous variable effects such as variance in
participant age, gender, psychiatric status, general medical conditions, and practical
factors limiting participation including scheduling and transportation constraints. The
effects of these potential extraneous variables were not measured and remain unknown. A
further potential limitation was that only one MAT program site was used for study
purposes. It is possible that this site had unique or unknown effects on study participants
that may have resulted in skewing data or otherwise limited generalizability.
At the time of study implementation, I had several years of experience practicing
mindfulness meditation, and thus could be influenced in terms of confirmation bias
involving research outcomes that favored beneficial effects of mindfulness practices on
MAT program patients. To guard against this, the study was structured such that MBRP
group services were not provided at a MAT program location where I worked, and study
participants were not known to me. Statistical analyses were used to address variables.
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Significance
While MAT programs are as a highly effective treatment model for individuals with
opioid use disorder, the potential for relapse among MAT program participants remains
significant. Kreek (2007) said 20% of MAT program patients may relapse at any given
time. Given this, MAT participants, despite the known effectiveness of MAT, remain at
risk for episodic relapse and are likely to benefit from adjunctive treatment interventions
that reduce such risk (Logan & Marlatt, 2010; Parrino et al., 1993).
Mindfulness-based treatment interventions have been demonstrated to be effective at
reducing relapse rates among populations with substance use disorders, specifically in
MAT program populations (Stotts et al., 2009). This study was built to address existing
research gaps by evaluating the effects of MBSR as a treatment adjunct for MAT
program patients. This application of MBSR could be broadly used in MAT programs
throughout the U.S., thereby fostering positive social change through reducing illicit
opioid use relapse rates and its harmful concomitants among thousands of individuals
benefiting from MAT program participation.
Summary
This chapter includes the rationale for and scope of this pilot study. This
discussion includes the study background, problem statement, purpose, research
questions and hypotheses, theoretical and conceptual frameworks, and research methods
along with assumptions and limitations of the study. This pilot study was intended to
evaluate effectiveness of MBRP manualized treatment when used as a treatment adjunct
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for MAT program patients and determine if MBRP is effective in terms of relapse
prevention as evidenced by reduced frequency of illicit opioid use and reduced opioid
craving severity among those participating in the MBRP protocol.
A quantitative experimental design was proposed, comparing two groups: the
experimental group exposed to weekly MBRP procedures, and the TAU group used as a
control. Both groups were composed of randomly selected participants concurrently
participating in a MAT program located in the Bay Area of California. This study
involved testing the hypothesis that use of MBRP as a treatment adjunct within the
context of a MAT program would result in changes in frequency of participant illicit
opioid use as measured by the ASI Alcohol/Drugs subscale (McLellan et al., 1985) and
changes in severity of participant opioid craving as measured by the OCS (McHugh et al.,
2014).
Chapter 2 includes a literature review with information regarding historical and
current social problems associated with opioid use disorders. It continues with
explanations of historical and current treatment approaches used to address opioid use
disorder, the role of MAT programs in treatment for this condition, theoretical concepts
relevant to opioid use disorders, diagnostic formulation, evaluation, and treatment
approaches, and examination of neurobiological substrates of opioid use disorders and
their relevant implications. This chapter continues with an exploration of the historical
antecedents of mindfulness practices, transitioning into contemporary clinical
applications of these practices and examination of research evaluating their effectiveness.
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Neurobiological research evaluating substrates associated with mindfulness practices are
explicated, as well as potential relevance to the neurobiology of opioid use disorders.
Multiple mindfulness-based treatment approaches are discussed, and research evaluating
their effectiveness is critically examined. This leads to an in-depth evaluation of MBSR
and a rationale for its potential use as a treatment adjunct for MAT program patients.
Chapter 3 includes the research design and methodology for the proposed study. Chapter
4 includes study outcomes, including data and statistical analyses, and Chapter 5 includes
a conclusion, summary of relevant results, findings, and recommendations for future
research.
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Chapter 2: Literature Review
Introduction
Opioid use disorder with physiological dependence is characterized as a chronic
relapsing condition where post-remission relapse is highly likely. MAT has been firmly
established as a highly effective treatment for opioid use disorder. Despite comprehensive
pharmacological, psychological, and medical information offered in MAT programs,
participants remain at risk for episodic relapse of illicit opioid use, and are thus likely to
benefit from adjunctive treatment interventions that reduce the likelihood of relapse
(Logan & Marlatt, 2010; Parrino et al., 1993, SAMHSA, 2020b).
Relapse involving illicit opioid use is strongly associated with increased risk of
disease contraction, including HCV and HIV and adverse medical complications, and is
further associated with elevated risk of oversedation, coma, and death due to central
nervous system suppression (Parrino et al., 1993; Volkow, 2007a; 2007b). Further
relapse-associated risks include onset of secondary general medical conditions,
symptomatic exacerbation of cooccurring psychiatric disorders, criminality due to
sustained illicit opioid use, and social dysfunction leading to marginalization by and
alienation from familial and other potential supportive resources (Parrino et al., 1993;
Volkow, 2007a; 2007b). Any therapeutic adjunct reducing relapse risk is likely to benefit
the health and wellbeing of MAT program participants.
The purpose of this pilot study was to evaluate the effectiveness of MBRP
manualized treatment used as a therapeutic adjunct to MAT program participation. This
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pilot study also considered the potential mediating effect of changes in participant
mindfulness as measured by TMS scores associated with concurrent participation in the
manualized MBRP treatment adjunct. In addition, correspondent changes in terms of
participant frequency of illicit opioid use were evaluated.
Examining the effects of MBRP on individuals participating in MAT programs
for opioid dependence necessitates evaluation of the nature of opioid use disorder,
including its neurobiological, psychological, and social concomitants, as well as potential
relationships with mindfulness. This chapter involves investigating etiology, theoretical
perspectives, and empirically-supported treatment options for substance and opioid use
disorders in terms of physiological dependence, including how the condition is evaluated
and treated within the context of MAT programs. The chapter continues with
examinations of individual and social problems associated with illicit opioid use.
Neurobiological structure and functioning of opioid use disorders are explicated. The
chapter includes a brief description of the history and development of MAT programs,
including a synopsis of the current MAT program philosophy and approach to opioid use
disorder treatment.
This chapter continues with an explanation of the historical antecedents of
mindfulness practices. The nature of mindfulness and relevant aspects of mindfulness
practice are discussed, as well as relationships between states of mindfulness and
attentional processes. Neurobiological structure and functioning of the central and
peripheral nervous systems relevant to states of mindful attention are evaluated, and
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implications of these findings in terms of MBRP as an adjunctive treatment for opioid use
disorder are explored. Relevant aspects of contemporary psychological treatment
approaches incorporating mindfulness practices are described.
Literature Search Strategy
The Walden University online library was used to access EBSCOHost in order to
find research related to mindfulness and substance use disorder treatment applications.
Databases used included Academic Search Premiere, PsycArticles, PsycInfo, SocINDEX,
Thoreau, Mental Measurements Yearbook, CALDATA, National Institutes of Health,
American Psychiatric Association, American Psychological Association, American
Medical Association, Substance Abuse and Mental Health Services Administration,
Centers for Substance Abuse Treatment, National Institute on Drug Abuse, Food and
Drug Administration, PubMed, and National Library of Medicine. Google and Google
Scholar were also used.
Key search terms were substance use, substance use disorder, opioid use
disorder, mindfulness, neurobiology, neurobiology of mindfulness, neurobiology of
attention, mindfulness and attention, attentional regulation, attentional dysregulation,
attention regulation, opioid use disorder, neurobiology of opioid use disorder,
neurobiological substrates of opioid use disorder, neurobiological substrates of attention
regulation, neurobiological substrates of mindfulness, mindfulness based stress
reduction, MBSR, mindfulness based cognitive therapy, MBCT, mindfulness and rational
emotive behavior therapy, MBREBT, rational emotive behavior therapy, REBT, cognitive
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behavioral therapy, CBT, cognitive therapy, CT, mindfulness based relapse prevention,
MBRP, acceptance and commitment therapy, ACT, Buddhism, and yoga nidra. Abstracts
were reviewed for relevance to determine applicability of each article. Articles including
only abstracts were not used.
Research journal articles, texts, and treatment manuals published prior to 2017
were used where applicable to denote seminal findings in literature that provide historical
perspectives, or to compare and contrast with more recent findings.
Numerous seminal texts and articles were used as references to describe historical
antecedents of mindfulness practices and psychological functioning associated with
mindfulness practices and measures used to assess mindfulness.
Relevant online research articles were downloaded for further study. Relevant
home and work library journals and texts on neurobiology, theoretical bases and
treatment approaches for substance use disorders, mindfulness theory and practice
research, treatment manuals, and clinical applications were used.
Illicit Opioid Use in America
Recent Epidemiological Trends in Illicit Opioid Use
Illicit opioid use is a severe and pervasive problem in the United States. There
were 669,000 heroin abusers in 2012 (NIDA, 2014b), increasing to an estimated 745,000
in 2019 (SAMHSA, 2020a). The NIDA asserted that some 5.1 million individuals used
opioid medication illicitly in 2012 (NIDA, 2014a), a number that has increased to 10.1
million individuals in 2019 (SAMHSA, 2020a). Epidemiological trends (Johannes et al.,
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2010; NIDA, 2005b; 2014a) indicated that chronic pain affects some 33% of Americans
and is a factor strongly implicated in opioid use disorder. The SAMHSA reported that
Drug Awareness Warning Network (DAWN) data indicated a 183 percent increase in ER
visits associated with illicit opioid use during the period from 2004 to 2011 (SAMHSA,
2013a), with an overall 430% increase observed for the period from 1999 to 2009. The
Office of National Drug Control Policy (ONDCP; 2011) reported a 402 percent increase
in prescription opioids use by Americans from 1997-2007. The NIDA (2011) reported
that in 2010 seven million U.S. individuals used prescription drugs nonmedically
including 5.1 million that abused opioids. This number increased to and the SAMHSA
reported that . The Centers for Disease Control and Prevention (CDC; 2021) asserted that
for the period from 1999 to 2019 close to 500,000 persons died from an opioid overdose,
and that drug overdose deaths have increased by 400% since 1999, including a six
percent increase in opioid-related deaths overall, and a 15% increase in synthetic opioid
associated deaths during the year period ending in 2019.
Opioid misuse has been increasing since 2007 (NIDA, 2011). In 2014, over 2
million individuals experienced the condition of opioid use disorder (National Institute on
Drug Abuse; NIDA, 2014a), a number that increased to 1.6 million in 2019 (SAMHSA,
2029a). The NIDA asserted that in 2013 more than 207 million opioid medication
prescriptions were written. Some 58% of Americans were prescribed opioids in 2017
(CDC, 2019). The National Survey on Drug Use and Health for 2012 report indicated
some 669,000 individuals in the U.S. had used heroin during the past year (SAMHSA,
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2013b). Subsequently, the SAMHSA (2020a) reported that 745,000 persons used heroin
in the year preceding 2019. The NIDA (2011; 2014b) asserted that marked increases in
heroin use have resulted from an estimated near 50 percent of young individuals
transitioning from prescription opioid use to heroin use. Moreover, Johannes et al. (2010)
and NIDA (2014a) estimated that a third of Americans experience some form of chronic
pain and this condition is strongly associated with opioid use disorder. An estimated 41
percent of individuals with chronic pain conditions abuse opioid medication
(Manchikanti et al., 2007).
Of much concern is the increasing number of deaths from opioid overdoses,
which quadrupled over the 10-year period preceding 2014 (NIDA, 2014a). The NIDA
(2014) asserted that more individuals die from prescription opioid overdose than from all
other drugs of abuse combined, and that as of 2019 more than two-thirds of all drug
overdoses were opioid related. The NIDA (2020) reported that as of the end of 2018
opioid overdose was the primary cause of 128 deaths each day in the United States. The
CDC (2021) reported that drug overdose deaths have increased by 400% since 1999,
including a six percent increase in opioid-related deaths overall, and a 15% increase in
synthetic opioid associated deaths during the year period ending in 2019. The CDC
(2020) noted that in the year period ending in May, 2020 there were more than 81,000
drug overdose deaths, a number that included a 98% increase in opioid related deaths
reported by several states in the western U.S., and reflected the highest number of
overdose deaths ever recorded in a 12-month period. Taken together, these data trends
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strongly suggest that illicit opioid use and its harmful effects are continuing to increase at
a very concerning rate.
1,200 MAT programs were in existence as of the end of 2010 providing treatment
services to an estimated 270,000 opioid dependent individuals (SAMHSA, 2011). The
SAMHSA (2020b) reported an estimated 1.2 million individuals enrolled in MAT
programs as of the end of 2019. In MAT programs are a highly effective treatment for
opioid use disorder (Kosten & George, 2002; Parrino et al., 1993; SAMHSA, 2020b;
Volkow, 2007b). Opioid use disorder with physiological dependence is a chronic,
relapsing condition where post-remission relapse is highly likely (APA, 2013; Dennis &
Scott, 2007; Kosten & George, 2002; Leshner, 1989; 2001; Parrino et al., 1993;
SAMHSA, 2020b, Volkow, 2007a; 2007b). MAT participants are at risk for episodic
relapse of illicit opioid use and are likely to benefit from adjunctive treatment
interventions (Logan & Marlatt, 2010; Parrino et al., 1993).
Relapse-Associated Concerns
The medical, psychological, and social risks associated with relapse into illicit
opioid use are of great concern (CSAT, 2005; Chalk et al., 2013). Individuals
experiencing relapse are at high risk for overdose, oversedation effects, and death
(CSAT; Parrino et al., 1993; SAMHSA, 2020b). Overdose death rates associated with
illicit opioid use have tripled since 1990 and continue to increase (Chalk et al., 2013).
The risk of relapse for persons with opioid use disorder is strongly associated with stress
exposure (CSAT, 2005; Kreek, 2000; Kreek & Koob, 1998) and concomitant conditions
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include hepatitis C (HCV) and human immunodeficiency virus (HIV), and their adverse
medical complications. Further associated risks include complications of secondary
general medical conditions, symptomatic exacerbation of concomitant psychiatric
disorders, criminality engaged in to sustain illicit opioid use, and social dysfunction
leading to marginalization by and alienation from familial and other potential supportive
resources (Parrino et al., 1993; SAMHSA, 2020b, Volkow, 2007a; 2007b). Research
findings suggest that as many as 20 percent of MAT program participants experience
relapse into illicit opioid use (Kreek, 2007). Taken together, these considerations strongly
suggest that any therapeutic adjunct associated with reduced relapse risk is likely to
reduce harm potential and benefit the health and well-being of the MAT program
participant.
Theoretical Foundation
Potential for Mindfulness-Based Treatment Adjuncts
Mindfulness-based treatment interventions are effective in treating substance use
disorders and their associated craving, seeking, and using behaviors (Bowen et al., 2005;
Bowen et al., 2009; Chiesa & Serriti, 2013; Garland et al., 2012; Witkiewitz & Bowen,
2010; Witkiewitz et al., 2012; Witkiewitz et al., 2005; Zgierska et al., 2009). In their
evaluation of mindfulness-based treatments for substance use in an incarcerated
population Bowen et al. (2006) found a significant reduction in opioid and other
substance use during treatment and at three-month follow-up. Witkiewitz et al. (2005)
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found that use of mindfulness and CBT practices reduced symptomatic severity of opioid
and other substance abuse disorders in participants.
Mindfulness based relapse prevention (MBRP) uses mindfulness meditation and
cognitive behavioral therapy practices to reduce substance use relapse (Bowen et al.,
2011; Bowen et al., 2006; Bowen et al., 2009; Marlatt & Chawla, 2007). Marlatt and
Chawla and Ostafin and Marlatt (2008) found that continued mindful experiencing of
substance use cravings deconditions the association between substance use behavior and
the craving, thereby decreasing vulnerability to relapse. Marlatt and Chawla observed
that this therapy ultimately reduces substance cravings and counteracts substance
addiction through facilitating awareness and acceptance of the present moment
experience, where such experience is in some way disturbing or uncomfortable, thereby
reducing the individual’s propensity toward using substances to cope with aversive
existential realities.
A relapse liability exists in opioid dependent persons. Cognitive deficits in
prefrontal cortex (PFC) mediation of signals from the mesolimbic dopaminergic system
increase opioid dependent individuals’ vulnerability to environmental substance use cues
and reduce their capability for regulation of drug craving and seeking behaviors
(Childress et al., 2008; Dennis & Scott, 2007; Kosten & George, 2002). Wenk-Sormaz
(2005) showed in a randomized, controlled study that meditation facilitated cognitive
flexibility and affective responsivity and deconditioned maladaptive implicit cognitive
and affective functioning. This suggests that engagement in mindfulness-based practices
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may increase individual capability for regulating emergence of autonomic substance use
cravings through upregulation of PFC functioning.
Role of Neurobiological Research Findings
Ostafin and Marlatt (2008) posited that addiction implies the existence of
automatic processes that are largely nonconscious, unintentional, and difficult to control.
Wenk-Sormaz (2005) observed that mindfulness practices, through their emphasis on
decentered attentiveness toward phenomena and facilitation of volitional states of
selective arousal, deautomatize habitual cognitive processing and facilitate awareness of
cognitive processes that include intentionality, attentiveness, and awareness. Mindfulness
facilitates reregulation of previously habituated substance use-related cognitive and
behavioral patterns into more adaptive and beneficial processes (Ostafin & Marlatt).
States of mindfulness have been empirically associated with stronger PFC structure and
more adaptive regulation of limbic system signaling (Brewer et al., 2010; Ostafin &
Marlatt). Taken together, these neurobiological research findings suggest that
mindfulness practices may enhance control of opioid use cravings and seeking behaviors,
thereby reducing illicit opioid use and resultant health risk behaviors and offering
concomitants of symptomatic relief and improved quality of life for participants.
Examining the effects of MBRP on individuals participating in MAT for opioid
dependence necessitates evaluation of the nature of opioid use disorder, including its
neurobiological, psychological, and social concomitants, and their potential
interrelationship with the constituent experiential elements that together comprise the
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state described as mindfulness. To that end, the etiology, theoretical perspectives, and
empirically supported treatment options for opioid use disorder with physiological
dependence are investigated, together with a description of how the condition is
evaluated and treated within the context of a MAT environment. Neurobiological
structure and functioning relevant to opioid use disorder are explicated. A brief
description of the history and development of MAT programs is offered, along with a
synopsis of the current MAT program philosophy and approach to opioid use disorder
treatment.
Following this, the nature of mindfulness and mindfulness practices are discussed.
Neurobiological structure and functioning relevant to states of mindful attention are
evaluated, and the implications of these findings for use of MBRP as an adjunctive
treatment for opioid use disorder are explored. Finally, relevant aspects of contemporary
psychological treatment approaches incorporating mindfulness practices are described,
the use of treatment interventions based on these models is explicated, and the relevance
of these theoretical constructs and interventions for treatment of opioid use disorder
within the context of MAT programs is offered.
Theoretical Bases for Substance Use Disorders
Three predominant theoretical explanations for the etiology of substance use
disorders exist. Physical dependence theory explains substance use disorders (SUDs) as
arising from neurobiological changes associated with drug exposure and continued use
(Koob & Kreek, 2007). Positive-incentive theory asserts that SUDs occur because of the
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interrelationship between hedonic drug effects and expectations about those effects held
by the substance user (Kolb & Wishaw, 2009). Classical conditioning theory emphasizes
the effects of drug exposure over time on unconscious cognitive functioning (Koob &
Kreek, 2007; Koob & Moal, 1997; Nestler & Aghajanian, 1997).
Physical Dependence Theory
Koob and Kreek (2007) observed that physical dependence theory asserts through
repeated drug administration the individual develops tolerance and dependence.
Tolerance is observed when sensitivity to drug effects decreases. Alteration of the doseresponse curve results in attenuated drug effects given continued dosing at the same level,
with resultant need to increase the drug dosage to regain desired drug effects.
Dependence is observed when the individual maintains optimal levels of the drug within
his or her physiological system in order to prevent the onset of withdrawal syndrome, the
constellation of aversive symptoms uniquely characteristic to each substance when drug
administration is discontinued or reduced.
Koob and Moal (1997; 1998) asserted that dependence arises through hedonic
homeostatic dysregulation, as central nervous system neurotransmitter levels adjust in
response to exogenous drug molecule exposure, a condition referenced as allostasis
(Koob & Moal, 1997; 1998). Thus, in response to continued administration of exogenous
opioids natural opioid (endorphin) production is downregulated. Should the exogenous
opioid supply be reduced, the individual experiences the characteristic aversive signs and
symptoms of opioid withdrawal, including dilated pupils, sweating, tearing, agitation,
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nausea, and diarrhea, among others (Parrino et al., 1993). Initial treatment approaches
suggested that through detoxification a substance dependent individual could gradually
reduce her or his physical dependence on the substance and eventually achieve a state of
drug abstinence without associated withdrawal discomfort (Koob & Kreek). However, as
Koob and Kreek observed, the majority of detoxified individuals relapse into substance
use, leading to considering treatment alternatives to detoxification.
Positive Incentive Theory
Positive-incentive theory attempts explanation of substance use disorders through
suggesting that the euphoria associated with substance use is the primary motivator for
continued substance use, rather than abstinence syndrome avoidance (Kolb & Wishaw,
2009). This theory is based on the hedonic hypothesis (Kolb & Wishaw), suggesting that
pleasure associated with substance use is the primary motivator for continued use. Moal
and Koob (2007) noted that two interrelated functions are central to positive-incentive
substance use theory: the positive incentive value, describing the individual’s anticipated
pleasure of substance effects; and the hedonic value, the actual pleasurable effects of the
drug that the individual experiences.
Kolb and Wishaw (2009) observed that with repeated drug administration, the
positive incentive value increases, thereby explaining the substance user’s transition
along the substance use continuum from initial drug exposure, to regular use, to abuse,
and thence to dependence. This suggests why some individuals do not become addicted
to substances, because their perceptions that attribute positive incentive value to a
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substance are insufficient to motivate them to use the substance repeatedly. A related
explanation in some cases is that positive incentive value for some substance using
individuals does not change with repeated exposure as it does with their substance
dependent counterparts. Moal and Koob (2007) noted that the compulsion to continue
administrating the drug is largely driven by its perceived positive-incentive value, which
facilitates sensitization to anticipated drug effects, whereas the individual will tend to
become increasingly desensitized toward the hedonic effects of the substance. This
suggests why many substance abusers and dependents continue to use, and their
substance use cravings actually increase, despite their experiencing of decreased hedonic
drug effects. A limitation of the positive-incentive theory is that it fails to account for
classical conditioning effects associated with continued substance use and fails to explain
the phenomenon of nonconscious interoceptive and exteroceptive cueing associated with
substance craving and withdrawal states (Childress, 2008; Koob & Kreek, 2007).
Classical Conditioning Theory
Learning theory, as applied to substance use disorders, suggests that repeated
instances of substance using behavior result in classical conditioning effects, thereby
fostering interrelated psychological and neurobiological constituents of substance
dependence (Koob & Kreek, 2007; Koob & Moal, 1997; Nestler & Aghajanian, 1997).
Conscious and nonconscious associations motivate the individual to continue substance
use through repeated contemporaneous pairings of substance administration with hedonic
drug effects (Childress et al., 2008). Koob and Kreek asserted that continued exogenous
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drug administration raises the hedonic reward threshold experienced by the user, thereby
fostering continued increases in drug administration in order to achieve the desired drug
effects.
Koob and Kreek (2007) asserted that this conditioning is similar to that involved in
other intrinsically rewarding behaviors such as eating, drinking, and sexual activity. Such
behaviors are associated with upregulation of the neurotransmitter dopamine throughout
various components of the mesocorticolimbic pathway of the mesotelencephalic
dopamine system of the brain (Koob & Moal, 1997; Kosten & George, 2002).
Neurotransmissions from the ventral tegmental area to the nucleus accumbens are
implicated in dopamine upregulation associated with addictive behavioral conditioning
(Kosten & George). Moal and Koob (2007) posited that addiction develops through
changes in striatal regulation mechanisms; specifically, through increased dorsal striatum
activity along with activation of hypothalamic stress circuits, along with concurrent
reduction in prefrontal cortex mediation of these centers. Koob and Kreek observed that
the prefrontal cortex mediates relapse associated with drug-priming effects, the amygdala
is implicated in cue-activated relapse, and the hypothalamus mediates relapse associated
with stressors.
Moal and Koob (2007) described contingent drug tolerance as that associated with
drug effects experienced by the substance user. The individual tends to experience these
effects within the situational context associated with original conditioning to the drug
effect, thereby creating classically conditioned compensatory response tolerance effects.
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Situational stimuli become predictive of drug effects, such that normative levels of
substance tolerance may not exist in novel situations, thus exacerbating the risk of
overdose, even with previously administered amounts of the same substance the
individual is dependent on. Both interoceptive and exteroceptive situational stimuli are
conditioned with continued substance administration and tend to increase drug
sensitization effects. Situational compensatory conditioning effects likely factor in the
phenomenon experienced by many individuals with opioid use disorder histories, who,
despite years of abstinence and recovery, may experience the onset of opioid withdrawal
symptoms when exposed to an environmental cue associated with prior drug use
experience (Parrino et al., 1993). Situational compensatory conditioning effects suggest
why some individuals with considerable substance use experience situational specific
opioid overdose.
Substance Use Pathology
Substance use occurs along a continuum, ranging from: (a) non-pathological,
experimental or casual use; to (b) escalating drug abuse with resultant harmful effects;
and thence to (c) pathological, compulsive use associated with physical dependence on
the substance (APA, 2013; Moal & Koob, 2007). Dyscontrol of substance use is
evidenced despite adverse consequences (APA; Moal & Koob, 2007). This symptomatic
constellation includes several additional neurobiological and behavioral effects. There is
a marked propensity for relapse despite even years of abstinence. Affective dysregulation
associated with substance using behaviors that fosters continued substance use (e.g.,
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substance use as coping) is frequently evidenced. Also observed is compromised
executive functioning that reduces the individual’s capacity for regulating behavior
appropriately and effectively, leading to dysfunctional behaviors at home, in the
workplace, and in larger social settings. Increased compulsion and preoccupation with
substance craving, seeking, and using is frequently found. Secondary illnesses associated
with substance toxicity effects may occur. Co-occurring medical and psychiatric
conditions that are secondary to, or exacerbated by, continued substance use are also
frequently observed (Moal & Koob, 2007; Leshner, 2001). Leshner (1999; 2000) asserted
that the psychological, social, and physical functional impairments associated with
substance use disorder are highly unlikely to resolve without treatment.
Historically, substance use disorders have been viewed as personal and social
failure. Social perspectives on persons with substance use problems have insistently
regarded such individuals as immoral and amotivated (Volkow, 2007a). These negatively
biased public perceptions continue to persist (Livingston et al., 2012). Substance use
disorders pose a societal challenge to overcome these longstanding negative assumptions
and biases misrepresenting substance use disorders as characterological problems
(Volkow).
Nature of Opioid Use Disorder
This study’s predominant focus is on evaluating the effectiveness of a specific
mindfulness-based manualized treatment for individuals participating in MAT for opioid
use disorder. A review is offered of the nature of opioid use disorder and its effects.
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Understanding the neurobiological substrates of opioid use disorder provides a context
within which the effects of mindfulness practice on neurobiological systems implicated in
the opioid use disorder condition are more clearly apprehended and evaluated. This
discussion now focuses on neurobiological structures and functions associated with
substance use conditions.
Mechanism of Action
Opioid drugs are classified according to their mechanism of action in the CNS.
Agonists, such as heroin, oxycodone, and methadone increase brain cell activity at
specific CNS receptor sites. Antagonists, such as naltrexone, decrease brain cell activity
at specific CNS receptor sites. Partial agonists, such as buprenorphine, both increase and
decrease brain cell activity at specific CNS receptor sites (Koob & Moal, 2007; Parrino et
al., 1993, SAMHSA, 2020).
Agonist Drug Effects
Agonist drugs increase synaptic activity (Stanford, 1988). Synapse references the
microscopic space lying between adjacent neurons, where a predominant number of
receptor sites are located for the purpose of neurotransmission (Koob & Moal, 2006).
Direct acting drug molecules attach to receptor sites; and indirect acting drug molecules
target other synaptic functions, such as neurotransmitter reuptake (Koob & Moal, 2007).
Examples of direct acting drugs include heroin, morphine, methadone, and other opioids
(Koob & Kreek, 2007). Examples of indirect acting drugs are amphetamine,
methamphetamine, and cocaine (Koob & Kreek). Parrino et al. (1993) observed that one
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reason humans may be especially vulnerable to opioid dependence is due to the structural
similarities between endogenous opioid neurotransmitters such as µ-opioids (Zubieta et
al., 2005), and exogenous opioid molecules, such as codeine, oxycodone, heroin, and
morphine.
Homeostasis, Tolerance, and Dependence
Homeostasis references the innate tendency for physiological systems to function
toward balance (Koob & Moal, 1997). The central nervous system (CNS, e.g., brain and
spinal cord) operates on this principle. Use of exogenous drugs disrupts homeostasis,
resulting in CNS attempts to regain neurobiological equilibrium (Koob & Moal). Koob
and Moal asserted that where illicit substance use continues for extended periods,
neurobiological homeostasis is impaired, resulting in a state of disequilibrium that leads
to a state of hedonic homeostatic dysregulation, wherein natural neurotransmitter
functioning re-regulates to maintain the new, artificial neurobiological homeostasis
partially dependent upon the exogenous drug supply.
Koob and Moal (1997) posited that this hedonic homeostatic dysregulation state
results in emotional distress that is frequently associated with further substance use.
Continued disruption of homeostasis through substance use thus results in
neurobiological and thence psychological dependence, the condition of allostasis (Koob
& Moal, 1997). This state is identified in DSM5 (APA, 2013) as substance use disorder
with physiological dependence. Given this condition, the individual is neurobiologically
and physiologically dependent on the exogenous substance.
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Tolerance is the process the body engages in to achieve homeostasis in response
to exogenous substance exposure (Koob & Moal, 2006; 2007). It results in physiological
adaptation to greater drug potency, more frequent drug use, or increased drug exposure
through changes in method of drug administration, such as from oral use to intravenous
use. Increased drug exposure results in increased tolerance, eventually resulting in using
the substance to prevent the onset of abstinence syndrome rather than to obtain euphoric
drug effects initially experienced (Koob & Moal, 2006; 2007; Parrino et al., 1993;
Stimmel & Kreek, 2000).
Dependence and tolerance are interrelated, in that increasing drug use is directly
associated with increased tolerance to the drug effects and the resultant condition of
allostasis (Moal & Koob, 2007). Once allostasis occurs, continued exogenous drug
exposure is necessary to prevent the onset of abstinence syndrome, the constellation of
withdrawal symptoms associated with the specific drug used (Moal & Koob; Parrino et
al., 1993). Thus, hedonic homeostatic dysregulation (Koob et al., 1998) leads to allostasis
and at that point, the individual is physiologically dependent on the exogenous substance.
Koob and Moal (1997) posited that the individual is compelled to respond to
environmental disequilibrium (insufficient substance availability) with substance seeking
and using behaviors in order to maintain allostasis.
Continued allostasis, or drug dependence, is fostered through exposure to hedonic
effects of drug exposure predominantly reinforced through associated increases in
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dopamine levels (Moal & Koob, 2007), and secondarily reinforced through associated
reductions in frequency and severity of aversive abstinence syndrome effects.
Opioid drug molecules have an affinity for mu receptors in the nucleus
accumbens, ventral tegmental area, and locus ceruleus brain areas; all implicated in
opioid use disorder (Kolb & Wishaw, 2009; Kosten & George, 2002). Three CNS
functions are implicated in opioid use disorder. The first is the initial condition of
hedonic homeostatic dysregulation wherein the reward pathway is activated in response
to continued exogenous opioid exposure leading to allostasis and resultant physiological
dependence on exogenous opioids. The second is classical conditioning hedonic effects
of exogenous opioid exposure and avoidance of aversive effects experienced in opioid
withdrawal. The third is cognitive deficits that foster continued opioid use and
dependence (Kosten & George, 2002; Moal & Koob, 2007).
Reward Pathway
The neurobiological system predominantly implicated in opioid use disorder is the
CNS (Kolb & Wishaw, 2009). Kolb and Wishaw observed that CNS functioning
regulates hunger, thirst, and sexual drives, reinforcing behaviors that address these core
survival needs. These brain areas are collectively referenced as the mesolimbic
dopaminergic reward pathway (Kosten & George, 2002; Moal & Koob, 2007). Reward
pathway function and structure fosters conditioned behavioral responses, predominantly
through increases in levels of the neurotransmitter dopamine that are temporally
associated with engagement in the desired behavior (Kosten & George; Moal & Koob).
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In this way, opioids and other drugs of abuse function as dopamine agonists by increasing
the levels of that neurotransmitter in the brain (Koob & Moal, 1997; Koob et al., 1998).
Through operant neuronal cellular conditioning processes, these increases in
dopamine levels associate the cue, which can be the drug exposure itself or any
environmental factor associated with drug use, with euphoric mood (Childress et al.,
2008; Moal & Koob, 2007). Childress et al. noted this neurobiological mechanism
activates in response to the individual’s exposure to drug-associated environmental cues,
resulting in onset of drug craving, and in some cases, abstinence syndrome. Koob and
Kreek (2007) observed that for persons with opioid use disorder exposure to
environmental stressors precipitates the onset of drug cravings and withdrawal
symptoms. Moal and Koob observed that substance use behaviors are reinforced through
this reward pathway functioning such that the compulsion to seek and use drugs becomes
the affected individuals’ predominant focus.
Opioid-Associated Reward Pathway Activation
Given continued exogenous opioid use, mu receptors in the brain become
occupied with the exogenous opioids. Moal and Koob (2007) observed that repeated
ingestion of exogenous opioids activates homeostatic functioning, reducing endogenous
endorphin production that results in the condition of hedonic homeostatic dysregulation.
Continued exposure to exogenous opioids thence fosters the condition of neurobiological
allostasis where the individual is dependent on the exogenous opioid supply in order to
maintain optimal levels of pain control and mood regulation and avoid the onset of opioid
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withdrawal symptoms (Moal & Koob, 2007). The individual is then physiologically
dependent on exogenous opioids, thus meeting diagnostic criteria for opioid use disorder
304.00 according to DSM-5 criteria (APA, 2013); described as either mild (305.50),
moderate (304.00), or severe (304.00), depending on associated symptom prevalence.
Classical conditioning effects reinforce associations between this euphoric mood
and opioid use, fostering continued use of exogenous opioids. The ventral tegmental area
within the brain’s reward pathway increases release of dopamine in the nucleus
accumbens resulting in enhanced sensations of well-being and euphoria (Kosten &
George, 2002; Sun et al., 2011). Any period of exogenous opioid abstinence results in
onset of aversive opioid withdrawal symptoms, further reinforcing continued ingestion of
exogenous opioids (Kosten & George). Most individuals with this condition will engage
in continued illicit opioid use in their attempts to feel a sense of well-being and to avoid
the discomfort of opioid withdrawal.
Individuals with opioid use disorder frequently continue their illicit drug seeking
and using behaviors despite severe socioeconomic consequences (Moal & Koob, 2007).
Such behaviors are often asserted as evidence of the affected individual’s lack of
commitment to recovery from substance use, or as evincing his or her lack of sufficient
willpower or poor character (Volkow, 2007a). Kosten and George (2002) suggested that
the prefrontal cortex (PFC), an integral part of aforementioned neurobiological reward
pathway, regulates cognitions associated with adaptive executive behaviors and thus
normally inhibits engagement in high-risk behaviors. Kosten and George observed that in
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individuals with opioid use disorder these sound judgment and planning capabilities are
compromised, being overridden by bottom-up neurobiological signals from the brain’s
limbic system that support opioid drug craving, seeking, and using despite the likelihood
of aversive consequences.
Moal and Koob (2007) posited that inhibitory top-down messages sent from the
PFC advising against illicit opioid use and its inherent psychosocial, legal, health, and
economic consequences are negated by the bottom-up signals emanating from the limbic
system, regulated in part by contextual drug-associated memories stored in the
hippocampus and the associated withdrawal anxiety and fear associations regulated by
the amygdala. Koob et al. (1998) asserted the existence of a residual deficit state in the
neurobiological reward pathway that leaves the substance dependent individual
vulnerable to and predisposed toward relapse. Nestler and Aghajanian (1997) observed
that chronic opioid use results in genetic adaptations that foster structural and functional
changes in CNS neuronal and synaptic structures, thereby increasing the affected
individual’s liabilities toward opioid use disorder.
Opioid Receptor Sites
The molecular structure of opioid drugs helps them attach to opiate receptor sites
in the brain (Kosten & George, 2002). Parrino et al. (1993) noted that natural opioid
compounds such as codeine and morphine, semisynthetic compounds such as heroin, and
synthetic compounds including oxycodone, hydromorphone, and methadone, readily
occupy these receptor sites. Parrino et al. asserted that whereas there are other opioid
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receptor types in the CNS, the mu receptor is predominantly implicated in the condition
of opioid use disorder.
Endogenous and Exogenous Opioids
Endogenous opioids naturally occupy mu receptor sites within the CNS (Parrino
et al., 1993). These endorphin and enkephalin opioid protein molecules are referenced as
peptides, and under normative conditions, the CNS uses them to help regulate pain and
mood (Parrino et al.). Homeostatic regulation processes cause these natural opiates to
reduce or stop producing in response to exogenous opioid use. Mu opioid receptor sites
are then occupied by exogenous opioid molecules reflecting the condition of allostasis
(Moal & Koob, 2007; Parrino et al.).
Persistent Receptor Disorder
In their seminal research on opioid use disorder and its treatment using
methadone, Dole and Nyswander (1965) observed that replacement of endogenous with
exogenous opioids results in persistent receptor disorder, a process subsequently
identified as hedonic homeostatic dysregulation (Koob & Moal, 1997). Where reduced
levels of the exogenous opioid drug are not replaced by natural opioids, mu receptor sites
are left unoccupied and the individual experiences the resultant discomfort of withdrawal
symptoms (Moal & Koob, 2007). To avoid the aversive experience of opioid withdrawal
individuals engage in opioid drug seeking behavior thereby explaining the chronic
relapsing nature of opioid dependence.
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Opioid Abstinence Syndrome
Opioid abstinence syndrome (OAS), or opioid withdrawal, occurs in individuals
that have physiological dependence on exogenous opioids and experience abrupt
discontinuance of the drug supply. Kosten and George (2002) asserted that in opioid
withdrawal reduced levels of mu receptor site occupation within the locus ceruleus
elevates noradrenaline levels resulting in a constellation of aversive signs and symptoms
(see Table 1). OAS frequently results in opioid craving and seeking behavior because the
affected person seeks immediate relief from the resultant physical discomfort. Simply
ruminating on the possibility of experiencing OAS frequently results in discomfort
anxiety (Ellis et al., 1988) that motivates the opioid dependent person to engage in drug
seeking and using behavior regardless of potential life consequences (Kosten & George).
Frequently used illicit opioids include those with a short half-life of about four
hours, such as hydrocodone and heroin (Parrino et al., 1993). This brief half-life means
that unless the drug is readministered about every four hours, mu receptor site occupation
will decrease resulting in the onset of opioid withdrawal symptoms (Kosten & George,
2002). Further, as opioid tolerance and dependence increase, the individual must either
increase frequency of his or her opioid drug use or use a more potent form of the drug in
order to stave off withdrawal symptoms (Dennis & Scott, 2007). Opioid dependent
individuals seeking MAT program services frequently report increasing opioid use to
avoid the discomfort of OAS rather than to enhance euphoria (Parrino et al.). The
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following table indicates signs and symptoms associated with opioid abstinence
syndrome:
Table 1
Objective and Subjective Opioid Withdrawal Signs and Symptoms
________________________________________________________________________
Objective
Subjective
________________________________________________________________________
Runny nose (rhinorrhea)
Diarrhea
Dilated pupils
Nausea
Tearing eyes (lacrimation)
Insomnia
Sweating (diaphoresis)
Chills
Gooseflesh (piloerection)
Abdominal pain
Yawning
Muscle/joint aches
Sneezing
Anxiety
Coughing
Crawling skin sensation
Salivating
Irritability
Gagging/vomiting
Jitteriness
Restlessness
Opioid craving/seeking/using
________________________________________________________________________
Note: Adapted from “State methadone treatment guidelines (Technical Assistance Publication Series #
7),” by Parrino et al., 1993, pp. 106-113. Published in the public domain by U.S. Department of Health and
Human Services, Substance Abuse and Mental Health Administration, Center for Substance Abuse
Treatment.

Environmental cues can trigger onset of OAS. Cue reactivity in substance use
disorders is strongly associated with substance cravings, urges to use, and onset of
objective and subjective substance withdrawal signs and symptoms (Childress et al.,
2008; Dennis & Scott, 2007). Childress et al. suggested that cue reactivity occurs
nonconsciously in response to environmental triggers prior to conscious awareness of or
volitional control over neurobiological and related physiological responses to the
environment. Parrino et al. observed that individuals with opioid use disorder frequently
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experience onset of OAS from encountering situations similar to those in which prior
opioid use occurred. The inherently aversive nature of opioid withdrawal and the ready
availability of its environmental precipitants suggest the need for effective cognitive
behavioral interventions to regulate these involuntary symptoms.
Considered together, the neurobiological functions of mesolimbic reward pathway
activation, hedonic homeostatic dysregulation, allostasis, cognitive deficits, and opioid
abstinence syndrome strongly suggest that the opioid dependent person, without
treatment intervention, will tend to be increasingly preoccupied with illicit opioid
craving, seeking, and using, regardless of potential adverse consequences (Kosten &
George, 2002; Leshner, 2001; Moal & Koob, 2007). These considerations further suggest
that in order to be effective, any form of treatment for the condition of opioid use
disorder must increase the affected person’s capabilities for mediating these
neurobiological liabilities. This proposal now examines use of methadone medication in
the context of MAT programs, an evidence-based treatment intervention that effectively
addresses the preceding problems and facilitates a return to normal human functioning for
the opioid dependent person.
Methadone Medication Use and Effects
Introduction to Methadone Medication
Parrino et al. (1993) observed that methadone is a synthetic opioid analgesic with
a half-life of 24-36 hours. Medication formulations include 40 mg wafers, 10 mg tablets,
and a 10mg. per ml. oral liquid solution. Parrino et al. suggested that methadone
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medication is effective because of its neuropharmacological mechanisms including mu
opioid receptor binding, neurological blockade, and steady state neurological regulation.
Mu Opioid Receptor Binding
When methadone metabolite molecules bind with mu opioid receptors in the brain
the methadone metabolite molecules cross the blood brain barrier and occupy mu
receptor sites in the brain’s ventral tegmental area and locus ceruleus, both key functional
areas in the mesolimbic reward pathway (Dole & Nyswander, 1965; Kosten & George,
2007). Kosten and George posited that this bonding action within the ventral tegmental
area of the brain’s limbic system structure elevates dopamine levels in the nucleus
accumbens, resulting in nominal feelings of contentment and wellbeing, much as the
average non-opioid dependent individual is likely to experience when engaged in
rewarding behavior. The mu receptor sites remain occupied by methadone metabolite
molecules for up to 36 hours-during which the individual feels normal levels of wellbeing and emotional responsiveness and does not experience OAS (opioid withdrawal
signs and symptoms) or opioid cravings (Dole & Nyswander; Parrino et al., 1993). These
drug effects are essential in facilitating stable mood, preventing onset of opioid
withdrawal distress, and forestalling opioid use cravings that would otherwise precipitate
relapse into illicit opioid use.
Illicit Opioid Blockade Effects
The efficacy of methadone medication is partly due to the affinity for its
molecules demonstrated by mu receptors in the brain. In their early research, Dole and
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Nyswander (1965) posited that methadone molecules would bind to mu receptor sites
even in the presence of competing alternate opioid molecules including heroin. Parrino et
al. (1993) observed that this mu receptor site affinity for methadone molecules resulted in
the therapeutic medication effect identified as euphoric blockade. Parrino et al. noted that
when methadone molecules are bound to the mu receptor sites other competing opioid
molecules are prevented from binding, with resultant reduction or elimination of hedonic
and other drug effects that would otherwise be experienced through exposure to
exogenous (presumably illicit) opioids. Thus, there is a marked reduction in the
classically conditioned effects normally associated with exogenous illicit opioid use.
Because the methadone maintained individual experiences significantly reduced relapse
precipitants he or she is much less likely to continue using illicit opioids.
Steady State
Methadone medication has a lengthy half-life of up to 36 hours (Preston et al.,
2013), markedly different from the typical four-hour half-life of heroin, hydrocodone, or
morphine (Batki et al., 2005; Parrino et al., 1993). Daily ingestion of methadone results
in an adaptive form of allostasis, referenced as steady state, where the methadone blood
levels have reached reasonably optimal consistency and mu receptor sites in the CNS
have fully bound with methadone molecules (Batki et al.; Parrino et al.). Batki et al.
suggested that MAT program patients normally achieve steady state regulation within
five days. An additional pharmacological property of methadone is that once steady state
is achieved the individual can be maintained indefinitely at the same dosage level and
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experience continued beneficial drug effects without increasing either tolerance or
dependence (Batki et al.; Parrino et al.). Thus, individuals participating in MAT programs
utilizing methadone pharmacotherapy avoid the aversive effects of hedonic homeostatic
dysregulation as they benefit from the adaptive allostasis afforded by methadone
medication.
The benefits of methadone maintenance include alleviation of the signs and
symptoms of opioid abstinence syndrome, reduction and eventual elimination of illicit
opioid craving and drug seeking behaviors; and inhibition of euphoria associated with
illicit opioid abuse (Parrino et al., 1993).
Kreek (2000) asserted that MAT program participation using methadone
medication is associated with more adaptive neuronal functioning within the reward
pathway systems and improved stress response capabilities. Kreek and Koob (2007)
suggested that because stress exposure has been determined to be a significant relapse
precursor in opioid dependent individuals, the beneficial stress coping effects of
methadone medication use are likely to prevent relapse or reduce its severity and
duration, thereby enhancing well-being and resilience in the patient with opioid use
disorder. Parrino et al. (1993) asserted that methadone pharmacotherapy within the
context of the MAT program is safe and effective; the medication is prescribed and
administered by licensed medical personnel extensively trained in the treatment of
substance use disorders. Parrino et al. further noted that because daily methadone
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pharmacotherapy reduces or eliminates illicit opioid use in most patients, associated risks
to physiological and psychological health are correspondingly reduced.
Risks Associated with Methadone Medication Use
As with any medication, there are risks associated with the use of methadone.
Within the context of its use at MAT programs, these risks are usually minimal.
Methadone acts as a central nervous system depressant and can cause sedative effects
including drowsiness, respiratory depression, coma, and death (Batki et al., 2005; Parrino
et al., 1993). Although there has been a marked increase in methadone associated
mortality (Fingerhut, 2008), these problems have been predominately associated with
private physician pain treatment administration, whereas MAT program use of
methadone continues to be safe and effective (SAMHSA, 2020). Consistent with using
any drug with potentially sedating effects, methadone-maintained patients must use
caution when operating motor vehicles or dangerous machinery. Parrino et al. suggested
that in some cases methadone medication increases sedative effects of other medications
exerting sedative effects, such as benzodiazepines. Batki et al. advised that methadone
could increase the sedative effects of alcohol, advising against concurrent ingestion. The
Food and Drug Administration (FDA; 2007) warned that ingestion of even a single
methadone dose may be lethal for a person not physically dependent on opioids. In
keeping with this proscription, the SAMHSA (2020) recommended a very low
methadone dosage (5mg to 10 mg daily) when initiating methadone treatment.
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Side Effects of Methadone Medication
All medications have side effects that need to be considered when use is
indicated. Methadone acts as a central nervous system depressant and can cause sedative
effects including drowsiness, respiratory depression, coma, and death (Batki et al., 2005;
Parrino et al., 1993). The FDA (2007) and Parrino et al. (1993) asserted that common
side effects of methadone medication include mild constipation (typical with most
opioids), sweating, changes in libido, and lethargy.
Parrino et al. (1993) posited that severity of these side effects recedes over time.
The MAT program physician plays a key role in assisting the patient with managing these
side effects. The FDA (2007) asserted that individuals maintained on methadone
medication will experience the condition of physiological opioid dependence, thus abrupt
discontinuance of the medication results in rapid onset of opioid abstinence syndrome
with resultant physiological discomfort, psychological distress, and elevated relapse risk.
Benefits of Treatment in MAT Programs
Participation in MAT using methadone is associated with significant reductions in
criminal activity (Parrino et al.), illicit opioid use, alcohol misuse, and other drug use
(Batki et al., 2005). After stabilization on methadone medication, the properly maintained
methadone patient is fully functional (Batki et al.). Positive behavioral changes are
learned or reacquired as treatment continues. The patient gains insight through
participation in ongoing supportive counseling largely based on therapeutic approaches
inclusive of accurate empathy, acceptance, and genuineness (Miller & Rollnick, 2002;
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Rogers, 1957; 1961; 1979; 1980), and through development of the therapeutic alliance
with his or her counselor (McCann et al., 1994). These functional improvements result in
learning or reacquisition of adaptive lifestyle changes. The MAT program patient thence
benefits from substantial improvements in intrapersonal and interpersonal functioning.
MAT treatment is associated with significant reductions in societal costs
associated with opioid use disorder. Overutilization of public health systems associated
with drug misuse, active drug craving, and seeking are lessened, and interaction with the
legal system is significantly reduced, thereby lessening associated costs (Parrino et al.,
1993). Reduction in health risks associated with opioid injection use is significantly
reduced (SAMHSA, 2020). In California, the annual cost for methadone maintenance for
a single individual is approximately $5,000 annually, minimal in comparison to the
yearly prison expenses of up to $60,000 annually (Gerstein et al., 1994). Gerstein et al.
found the cost-benefit ratio for MAT patients maintained on methadone was $1.00/$7.00.
These data suggest multiple societal benefits exist for maintaining individuals with opioid
use disorder in MAT programs.
Clinical Effectiveness of Methadone Medication
Research over the past several decades suggests that participation in MAT
programs using methadone pharmacotherapy is a highly effective treatment approach for
individuals with opioid use disorder (Ball & Ross, 1991; California Society of Addiction
Medicine, 2008; Leshner, 1999; 2001; Rothbard et al., 1999). The combination of daily
methadone medication pharmacotherapy, medical care, and counseling support provided
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for MAT program participants effectively mediates the neurobiological substrates
implicated in the condition of opioid use disorder (Childress et al., 2008; Dennis & Scott,
2007; Kosten & George, 2002). In addition, MAT programs are cost-effective forms of
treatment (Barnett, 1999; Doran et al., 2003). Despite the effectiveness of this
comprehensive treatment approach, relapse risk remains as high as 69 percent for a
significant number of MAT program participants (Rosencrantz et al., 2007); particularly
those who have not yet stabilized in treatment or are exposed to severe environmental
stressors (Kreek, 2002; 2007). This suggests that any additional treatment interventional
approach readily accessible to a majority of MAT program patients that effectively
reduces relapse frequency and severity is likely a clinically useful treatment adjunct. This
proposal evaluated one such treatment adjunct: MBRP (Bowen et al., 2011).
Conceptual Framework
In this section historical antecedents of mindfulness-based practices are explored.
The theoretical and interventional elements of various clinical approaches based on
mindfulness practices will be examined. Given that mindfulness practices reflect a unique
and specific approach to attentional mediation the psychological and neurobiological
factors of attentional regulation are evaluated. Following this, research evaluating the
neurobiological substrates of mindfulness practices is examined, and the implications of
this research for addressing the neurobiological dysfunction associated with the condition
of opioid use disorder are explained.
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Historical Antecedents of Mindfulness Practices
Mindfulness-based practices arose from Vipassana, a term used to connote breathing
or insight meditation (Jain et al., 2007). Vipassana denotes a contemplative approach
utilizing awareness of breathing as a means of focusing attention. Present-day
mindfulness practices evolved from Buddhist teachings originating some 2,500 years ago.
These early philosophical and contemplative learnings were preserved as an oral
tradition, eventually being documented in written form in two disquisitions: the
Anapanasati Sutra and the Satipatha Sutra (Goldstein, 2013; Kabat-Zinn, 1982;
Rosenberg, 1999). Gunaratana (2002) and Kabat-Zinn (1982) observed that individuals
studying mindfulness practices are taught to approach their learning with skepticism and
curiosity.
Mindfulness practices reflect use of a critical, investigative mindset where
experiential phenomena are evaluated with each mindfulness practitioner’s perceptions,
attitudes, and attentional mediation capabilities forming the basis for his or her
experiential evaluation. Empirical investigations of mindfulness approaches for treating
illness were initially conducted to evaluate mindfulness-based stress reduction (MBSR;
Kabat-Zinn, 2003) as a treatment for chronic pain secondary to cancer, and to address
other physical conditions such as dermatitis. Subsequently, multiple mindfulness-based
treatment approaches have been developed and empirically examined.
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Attentional Regulation
Mindfulness practices are predominantly focused on regulating attention. A
background in attentional regulation and its implications for mindfulness and substance
use is explored in the following.
Cowan (1988) said selective attention is composed of an executive regulation
function, attentional orienting function, perceptual filtering capability, and habituation.
Pessoa and Ungerleider (2005) said these functions are limited by maximal processing
capacity, or cognitive loading effects, and by processing motives, where the individual
attends to data based on its salience and valence properties. They further noted that
unattended processing attenuates. These perspectives suggest that humans are capable of
attending volitionally to data in the internal and external environments, and yet retain the
capability for responding automatically to some data percepts, and concurrently
assimilating and responding to new data as well (Yiend et al., 2005). Mirams et al. (2012)
observed that attention data sources subject to selective regulation include interoceptive,
referencing internal somatic sensations, proprioceptive, referencing positional and spatial
sensory data, and exteroceptive, referencing within the external environment detected by
any of the senses.
Mindfulness-based approaches to attentional regulation offer a comprehensive
awareness of these same attentional functions (Kabat-Zinn, 2002; 2009; Stahl &
Goldstein, 2010), achieved through cultivation of metacognitive awareness (Teasdale,
2002; Whitfield, 2006), where the person attends to all experience, regardless of salience
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features. This suggests that individuals tend to respond to perceived negative stimuli
through attributing negative valence, associated with aversion characteristics in
mindfulness nomenclature, whereas they tend to respond to perceived positive stimuli
through attributing positive valence, associated with mindful acceptance.
Cowan (1997) asserted that novel stimuli likely attract attention involuntarily due
to their inherent elevated threat potential. Siegel (2012) asserted that the brain is
structured to be highly sensitive toward novel stimuli, in part because previously
unencountered experience poses potentially greater survival risk. Hanson (2009, 2013)
and Kiken and Shook (2011) observed that the brain tends toward a negative bias, using
this protective sensitivity to over broadly interpret even innocuous stimuli as threatening.
Emotional associations evoked through phenomenological exposure thus direct volitional
attentional processing. In the cases of opioid use urges and cravings, opioid withdrawal,
elevated environmental stressor exposure, and functional cognitive deficits, the person
with opioid use disorder will likely benefit from improved attentional regulation skills
that mediate adverse of effects of negative biasing. Taken together, these assertions
suggest potential for more effective regulation of involuntary attentional phenomena as
the mindfulness practitioner learns to experience novel data as transient phenomena that
can be processed acceptantly and nonjudgmentally, rather than fearfully or anxiously.
Stahl and Goldstein (2010) and Hanson (2009, 2013) asserted that mindfulnessbased approaches offer a more balanced means of voluntary attentional regulation,
through reducing emotional reactivity and increasing adaptive responding to
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environmental stimuli. Ortinski and Meador (2004) posited that through conscious
awareness the individual attends to environmental stimuli and exerts a volitional
behavioral response. This resonates with mindfulness-based attentional regulation
approaches where all elements of internal and external stimuli are apprehended and
processed in accord with the individual’s pre-established intentionality.
Mindfulness and Attentional Regulation
Ives-Deliperi et al. (2011) said downregulation of midline cortical activity during
states of mindfulness meditation, specifically involving the AI, left ventral ACC, right
PFC, and bilateral precuneus. In a controlled MRI investigation, Leung et al. (2013)
found that loving-kindness focused mindfulness meditators had significantly greater gray
matter volume in the right angular and posterior parahippocampal gyri and left temporal
lobe, brain areas implicated in affect regulation and empathy. In a controlled study using
comparative MRI evaluations, Hölzel et al. (2011) found significant increases in brain
gray matter post-MBSR intervention in previously naïve meditators, with marked
increases in structural density found in brain areas associated with improved functioning
of contextual memory, emotional and affective regulation, self-awareness, and situational
and social perceptual and cognitive functioning. Tang (2013) asserted that mindfulness
meditators experience functional connectivity changes within the default mode network
associated with enhanced present-moment awareness and reduced emotional reactivity.
Using MRI neuroimaging, Zeidan et al. (2011) found that mindfulness meditation
significantly reduced participant perceptions of pain intensity associated with functioning
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in the ACC and AI, consistent with the findings of Tops et al. (2014), and pain aversive
effects associated with activation of the orbitofrontal cortex. The Zeidan et al. study is
limited by small number of participants (n = 15). Tang and Posner (2013) noted that
whereas neurobiological imaging is beginning to reveal brain structure and functioning
implicated in mindfulness practices, improved study controls and participant
randomization are needed in order to more clearly identify specific factors of mindfulness
associated with neurobiological substrates.
The neurobiological functioning implicated in mindfulness practices appears to
mediate much of the aforementioned attentional neural functioning. In the treatment of
anxiety and depression, mindfulness practices appear to be effective in promoting
adaptive neurobiological reregulation that supports associated improvements in
psychosocial functioning. In their meta-analysis, Chiesa and Serriti (2010) found that
EEG readings of mindfulness meditators evidenced a connection between predominant
frontal alpha and theta brainwave activity, linking them to the relaxed but attentive
condition typically found in mindfulness meditation practitioners. Theta burst brainwave
activity was more predominant in experienced meditators, suggesting an association
between ongoing meditative practice and the ability to achieve deep relaxed meditative
states of awareness, e.g., bare attention (Epstein, 1995). Moreover, Chiesa and Serriti
observed that some studies suggested that MBSR and MBCT treatment effects produced
increased alpha wave activity in the left-sided anterior region associated with positive
mental states and beneficial immune system effects. Such effects could prove beneficial
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in ameliorating the psychological discomfort associated with depressive and anxious
symptoms. Chiesa and Serriti cautioned that many of these studies lack sufficient controls
and participant randomization, thereby limiting their generalizability.
Enhanced Attentional Mediation Capabilities
Lutz et al. (2008) said focused meditation practice, as found in mindfulness
approaches, fosters increased capability for sustaining selective attentional focus and
redirecting attention when distraction occurs. In their comparative evaluation between
mindfulness meditators and arithmetic calculators, Hölzel et al. (2007) said states of
mindfulness meditation were associated with stronger activations in the bilateral rostral
anterior cingulate cortex and dorsal medial prefrontal cortex. This condition is associated
with enhanced attentional control over distractors (Hölzel et al., 2007). Increased
activation of the medial prefrontal cortex, right anterior insula, and right hippocampus is
thought to be associated with enhanced attention and interoceptive awareness, as well as
more adaptive emotional processing (Chiesa & Serriti, 2010; Hölzel et al., 2007). In their
cross-sectional controlled study of mindfulness meditators vs. non-meditators van den
Hurk et al. (2010) found that attentional orienting, efficiency, and executive functioning
processes were significantly more effective in meditators than in controls. In another
controlled study evaluating the neural correlates of executive performance monitoring,
Teper and Inzlicht (2013) similarly found that mindfulness meditators made fewer
cognitive errors and exhibited greater error-related negativity of briefer duration with
associated reductions in emotional reactivity. Teper and Inzlicht posited that the
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beneficial effects of reduced negative emotional reactivity and enhanced performance
monitoring capabilities were instrumental in achieving these executive regulatory
improvements.
Limitations of Hölzel et al. (2007) include small effect size due to limited
participant sample size (n = 40). There were no controls for extraneous participant
variables such as substance use, duration of meditation experience, or contemplative
methods used. In addition, Hölzel et al. used correlational analyses, leaving open the
possibility that increased amounts of grey brain matter may attract meditators, rather than
result from meditative experience. Limitations of the Teper and Inzlicht (2013) study
include possible extraneous variable confounding from multiple meditative practices
utilized by the experimental group participants, and the lack of an empirical measure for
participant emotional reactivity. Limitations of van den Hurk et al. (2010) include crosssectional design, limited effect size due to small number of participants (n = 40), and
extraneous within experimental group variability through use of two meditational
approaches: Vipassana and concentration.
Mindfulness as Adaptive Attentional Regulation
Garland et al. (2010) said exposure to mindfulness training significantly reduced
the implicit responses of participants with alcohol use disorder to alcohol-associated
environmental cues, supporting the contention that increased mindfulness facilitates
adaptive regulation of autonomic responding to substance use cues. This finding is
consistent with the observations of Lutz et al. (2008) suggesting improved attentional
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regulation is associated with meditative practices. Garland et al. found that implicit
attentional biases orienting and alerting toward alcohol use significantly decreased
through mindfulness practice, suggesting that implicit maladaptive memory and
attentional processes are effectively mediated through regular mindfulness practice.
Further findings included significant reductions in perceived stress levels and marked
reductions in thought suppression associated with more adaptive mediation of alcohol use
cravings. Generalizability from the findings of Garland et al. is limited due to small
participant sample size and lack of a control group.
Chiesa and Serriti (2010) said mindfulness meditation is associated with increased
bilateral activation of the dorsal medial prefrontal cortex and rostral anterior cingulate
cortex, both areas of the brain that mediate attentional regulation. Both Chiesa and
Serreti, and Dakwar and Levin (2009) observed that these adaptive attentional changes
associated with mindfulness meditation reduced cortical atrophy and aging-associated
attentional deficits in long-term practitioners. Davis and Hayes (2011) suggested that
mindfulness practices lead to attenuation of fear responses, more objective appraisal of
experiential phenomena, enhanced coping skills and motivation, and reductions in
maladaptive behavioral responses.
Mindfulness and Neurobiological Regulation Relevant to Substance Use Disorders
Hölzel et al. (2011a) said exposure to 8 weeks of MBSR mindfulness training
facilitated adaptive changes in memory integration, emotional regulation, and regulation
of self, world, and interpersonal schemas. As these elements are essential components of
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executive functioning, this suggests that exposure to mindfulness practices improves
aspects of executive functioning essential for managing substance use effectively.
Blume and Marlatt (2009) asserted that improvement in executive functions
including attentional regulation and concentration is associated with reductions in
harmful substance use. In their fMRI investigation of naïve meditators Westbrook et al.
(2013) found that exposure to mindfulness practices significantly reduced craving in
participants with nicotine use disorder to cigarette smoking cue exposure. Witkiewitz et
al. (2012) asserted that through improved connectivity and functioning of the anterior
cingulate cortex, dorsal lateral prefrontal cortex, insula, and hippocampus associated with
mindfulness practices, enhanced top-down regulation of limbic and basal brain functions
results in improved emotional regulation and inhibition of substance use cravings.
Chiesa and Serriti (2010) asserted a number of studies have suggested that mindfulness
meditation facilitates adaptive attentional control, although they advise caution in
interpreting these data because of extant methodological problems in much of the
research. Generalizability of these studies’ outcomes is limited due to their lack of
randomized controlled designs.
These neurobiological correlates of mindfulness suggest that enhanced PFC
functioning associated with mindfulness practices improves PFC regulation of the limbic
system, particularly the hypothalamus, hippocampus and amygdala, improving mediation
of the hippocampal-amygdalal attentional orienting response. Thus, the mindfulness
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practitioner learns to selectively, and more adaptively, attend to interoceptive,
exteroceptive, and proprioceptive data.
Attentional and Neurobiological Liabilities for the MAT Program Patient
The neurobiological substrates associated with the MAT program patient
maintained on methadone medication include an adaptive allostasis condition supported
through steady state regulation (receptor occupation for extended period closely
mirroring endogenous mu receptor functioning) of the mu opioid receptors located
throughout the CNS. This neurotransmitter function occurs predominantly in the nucleus
accumbens and locus ceruleus (Koob & Moal, 2006; Kosten & George, 2002; Parrino et
al., 1999). Nucleus accumbens mu receptor occupation with methadone molecules results
in upregulation of dopamine in the ventral tegmental area, associated with a perceived
sense of wellbeing and contentment. However, this optimal state is inherently liable to
dysregulation associated with exposure to inter- and intra-personal stressors, effects of
co-occurring conditions including undertreated anxiety, depression, and posttraumatic
stress disorders, and through variant methadone medication dosing patterns. Given the
brain’s inherent predisposition toward negativity bias (Hanson, 2013), the MAT program
patient is thus liable for onset of the neurobiological concomitants and downward
emotional spiraling effects of OAS onset described by Koob and Moal (1997; 2006),
resulting in anxious and depressive affect that foster continued opioid use to avoid
associated mental disturbances. In their meta- analysis, Hofmann et al. (2010) concluded
that mindfulness-based therapies were effective in the treatment of both anxiety and
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depression. Taken together, these findings suggest that mindfulness practices can
effectively address the emotional dysregulation found in depressive and anxiety
disorders.
Mindfulness Effects on Opioid Use Craving and Seeking
Neurobiological substrates associated with opioid craving and seeking behaviors
include nonconscious activation of amygdalal and hypothalamic brain circuits, and
concurrent downregulation of prefrontal cortex mediation of these functions (Moal &
Koob, 2007). Further, selective attentional regulation processes regulated by the brain’s
negativity biasing circuitry (Hanson, 2013) suggest that the MAT program patient
experiencing any destabilizing internal or external environmental stressors will tend to
orient his or her attentional focus toward the distressing phenomena, thereby exacerbating
the downward spiraling of maladaptive allostasis and resultant relapse behaviors. Given
that mindfulness practices are associated with upregulation of the prefrontal cortex and
more effective medication of the limbic system circuits (Chiesa & Serriti, 2010; Hölzel et
al., 2007) it is likely that mindfulness practice can enhance adaptive prefrontal mediation
of conscious and nonconscious opioid craving and seeking neurotransmission signals
from the limbic system. The cognitive deficits outlined by Kosten and George (2002)
suggesting that this prefrontal cortex mediation capability is grossly impaired in opioid
dependent persons underscores the potential utility of mindfulness -based approaches that
strengthen PFC functioning. These theoretical perspectives are supported in general by
the research of Garland et al. (2010), where findings supported associations between
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mindfulness practice and reductions in implicit reactivity, and more specifically in Hayes
et al. (2004) where Acceptance and Commitment Therapy (ACT) based approaches to
mindfulness practices were utilized with a MAT patient population and were associated
with significant reductions in illicit opioid use and treatment dropout.
Having examined the theoretical perspectives on attentional processes and their
relevance to mindfulness practices as evidenced by neurobiological substrates of
attentional regulation and effects of mindfulness practices on attentional regulation, this
proposal now turns to explication of contemporary theoretical and practice models
associated with mindfulness and relevant aspects of mindful attentional regulation
associated with these bodies of theory and clinical practice.
Literature Review of Key Variables and Concepts
Use of Mindfulness Practices for Treatment of Substance Use Disorders
Having considered the historical, philosophical, theoretical, and neurobiological
aspects of mindfulness, this proposal now examines contemporary clinical applications of
mindfulness-based practices and their effectiveness in treatment of substance use
disorders. Primary focus is given to MBRP as it was developed specifically for
intervention with persons having substance use disorders. MBRP is the treatment
approach evaluated in this study.
Mindfulness Based Stress Reduction
MBSR is a therapeutic approach combining mindfulness mediation and hatha
yoga practice (Kabat-Zinn, 2003). Baer (2003) described how MBSR programs include
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an 8- to 10-week participant group-meeting schedule consisting of 2.5 hours of integrated
didactic instruction and mindfulness practice. Participants are further required to practice
individually on a daily basis. MBSR is the first developed and most widely researched
clinical approach to mindfulness practice in the U.S. MBSR has been found effective in
treating fibromyalgia, cancer, multiple sclerosis, eating disorders, chronic pain (KabatZinn, 1982; 2002; 2003; 2009), and anxiety (Miller et al., 1995; Vøllestad et al., 2011).
Shapiro et al. (2008) found that MBSR practice increased mindfulness, reduced
depression and anxiety symptoms, increased positive affect, and reduced negative
ruminations contributing to anger. Ivanovski and Malhi (2007) found that MBSR training
improved emotional regulation and immune system functions. Majumdar et al. (2002)
found MBSR practice significantly reduced psychological distress and increased
perceptions of well-being and quality of life. Jensen et al. (2011) found that MBSR
interventions reduced perceived and physiological stress in participants, and significantly
improved their selective attentional capacity, perceptual threshold, and visual working
memory capacity. Smith et al. (2008) in their study comparing MBSR effects with
cognitive behavioral stress reduction (CBSR) found that MBSR was significantly more
effective than CBSR at increasing mindfulness and reducing adverse effects of stress and
pain. Using fMRI evaluative data, Kilpatrick et al. (2011) found that in comparison to
controls MBSR participants showed changes in brain areas implicated in visual,
attentional, and self-referential processes. Kilpatrick et al. observed that these changes
were associated with enhanced attentional, sensory, and metacognitive awareness. These

73
studies suggest the effectiveness of MBSR in reducing stress and symptomatic severity
associated with multiple medical and psychological conditions. To date MBSR has not
been studied for use with persons having opioid use disorder or persons participating in
MAT programs.
Mindfulness Based Cognitive Therapy
MBCT represents an amalgamation of mindfulness-based and CT treatment
approaches. Building upon existing CT therapies (Beck, 1967; Beck, 1979; Beck, 1995;
Beck et al., 1979; Beck et al., 1993; Butler & Beck, 1995; Clark et al., 1999; Clark et al.,
2004), Teasdale, Segal, and Williams (2000) combined elements of MBSR with CT to
treat refractory depression. Lau and McMain (2005) asserted that the MBCT-based
approach recognizes the chronic, relapsing nature of depressive disorders and is intended
to reduce frequency and severity of depressive relapse episodes. Sherer-Dickson (2004)
asserted that MBCT approaches use interventions intended to foster enhanced
metacognitive awareness, such that the participant attends to emerging cognitions using
an enhanced knowledge base, a non-evaluative processing style, and acquired attentional
monitoring and regulating skills. Lau and McMain (2005) posited that increased
metacognitive awareness reduces depressive relapse through fostering decentering from
maladaptive cognitions. Zoysa (2011) and Williams and Kuyken (2012) found an
approach integrating mindfulness and CBT was effective in treating depressive disorder.
Williams et al. (2012) evaluated MBCT effectiveness for depressive relapse
prevention in a randomized dismantling trial as a treatment adjunct to TAU and
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compared to controls using cognitive psychological education (CPE) and TAU alone. The
Williams et al. (2012) study limitations include that the TAU approach was nonstandardized, thus potentially introducing extraneous variable effects and unmeasured
between-group effects associated with sociocultural variables. Evans et al. (2008) found
that MBCT treatment significantly reduced anxiety and depressive symptoms in patients
with generalized anxiety disorder (GAD) as measured by pre- and posttest reductions in
clinician-administered Beck Anxiety Inventory (BDI; Beck & Steer,1990), Penn State
Worry Questionnaire (PSWQ; Meyer, et al., 1990), Profile of Mood States (POMS;
McNair et al., 1971), and Beck Depression Inventory-II (BDI-II; Beck et al., 1996). The
Evans et al. (2008) study limitations include small participant size (n = 11), thereby
limiting statistical power and generalizability, use of a cross-sectional design without
randomization or controls, and potential extraneous variables associated with unique
participant demographic characteristics (self-selected and highly educated). King et al.
(2013) found significant reductions in PTSD symptoms for the MBCT treatment group
versus the TAU group especially in the avoidance and dissociative symptom clusters.
King et al. (2013) study limitations included lack of randomization, small participant
sample size (n = 37) thereby limiting statistical power and generalizability of results, and
potential confounds from between-group distinctions in treatment duration.
In their meta-analysis of MBCT effectiveness Coelho et al. (2013) found MBCT
as an adjunct to TAU effective for participants with three or more depressive episodes,
though not for those with less than three depressive episodes. Moreover, Coelho et al.
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observed that the evaluated study designs were either non-randomized or failed to
describe their randomization methods, and did not evaluate MBCT as a single treatment,
thereby suggesting potential extraneous variable effects across all studies from the
combined MBCT-TAU modality. Coelho et al. (2013) study limitations include basing
evaluations on study reports rather than original data, and conclusions based on
comparison of studies with inconsistent methodologies.
Investigation of the literature to date did not uncover any studies of MBCT
applied to individuals with opioid use disorder, or as an adjunctive treatment for those
participating in MAT programs. It should be noted that several elements of MBCT,
particularly those focused on facilitating adaptive cognitive restructuring, are utilized in
MBRP (Witkiewitz et al., 2013b).
Mindfulness Based Rational Emotive Behavior Therapy
REBT involves enhancing development of self-acceptance and high frustration
tolerance through fostering formulation of adaptive belief systems, introspective, valuesdriven and reality-based evaluation of cognition, affect, and behavior, and integration of
intrapersonal, interpersonal, and environmental phenomenal acceptance (Ellis et al.,
1998; Ellis & Dryden, 1997; Ellis & MacLaren, 2005). In a seminal paper comparing
REBT to MBSR Ellis (2006) noted many similarities between the two clinical
approaches, including cultivation of non-judgmental attitude, patience, beginner’s mind
(openness to experience), intentionality, awareness of and commitment to values and
related goals, compassion, acceptance, and self-discipline. Ellis took exception to some
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aspects of MBSR, including trust, especially blind trust in one’s intuition, which could
lead to erroneous inferences and associated behaviors, and thence emotional disturbance,
and further disagreed with the MBSR approach to non-striving, asserting that even
participation in mindfulness suggests a desire to strive toward some perceived or needed
change. In a proposal for case-specific treatment approaches integrating elements of
MBCT and REBT Whitfield (2006) proposed an integrated MBREBT approach utilizing
three interventions. The first consisted of using awareness of interoceptive and
metacognitive processes to experientially reinforce apprehension of the associations
between beliefs and consequences. The second consisted of using awareness of
interoceptive processes and acceptance to counter low frustration tolerance. The third
intervention consisted of using awareness of intentions and cultivation of nonjudgmental
attitude to examine and thence counter harmful irrational beliefs.
A search of available literature failed to uncover any empirical research
evaluating the effectiveness of MBREBT-based treatment approaches, and no research
evaluating MBREBT as a treatment for opioid use disorder or as a treatment adjunct for
MAT program participants was found.
Acceptance and Commitment Therapy
Hayes et al. (2012) suggested that Acceptance and Commitment Therapy (ACT) is
based on the perspective that cognition, affect, and behavior are derived within an
interrelated experiential and environmental context. Hayes (2002) asserted that humans
tend to reflect on their experiences and create associations between distinct aspects of
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lived experience using language. Hayes described this predominant tendency as the
capacity to create relational frames. Hayes and Smith (2005) asserted these relational
frames often limit flexibility and adaptive responding to evolving life situations, thereby
resulting in use of maladaptive coping strategies that increase human suffering.
Relational framing often fuses an experience with an evaluative thought about that
experience, resulting in harmful implicit associations that thence regulate cognitive and
affective processes for other similar experiences. Through this cognitive fusion of
relational frames, individuals developed automatized, often maladaptive responding to
their experience. Hayes and Smith further asserted that fused thoughts exacerbate
experiential pain and intrapersonal dysfunction through: (a) evaluation, the recollection
of painful events and their associated attributions; and (b) self-conceptualization, the
integration of maladaptive cognitive fusion processes into one’s perception of and
valuing of the self. Hayes et al. (2002) identified several relational frames commonly
used by most individuals, including temporal and comparative phenomenal associations.
Hayes et al. (2012) described ACT interventions as facilitating multiple aspects of
cognitive functioning including awareness and acceptance of unfolding experience from
moment to moment, cultivating a contextual self-perspective using decentered
observational approach, commitment to behaving in accord with chosen values,
acceptant, and nonjudgmental appraisal of unfolding experience. Hayes et al. further
noted an essential aspect of mental functioning they described as cognitive defusion,
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where behavioral and cognitive therapeutic interventions are used to decenter from
maladaptive cognitions, affective states, and associated behaviors.
ACT has been found effective in treatment of multiple conditions including
seizure disorders, chronic pain, diabetes, depression, anxiety, and posttraumatic stress
disorder (Bach & Hayes, 2002; Gregg et al., 2007; Hayes, & Smith, 2005; McKay et al.,
2012; Varra et al., 2008; Walser & Westrup, 2007). Gratz (2007) found that ACT
interventions effectively enhanced participant awareness and acceptance of emotional
states, reduced impulsive behaviors, facilitated engagement in adaptive emotional
regulation strategies, and reduced frequency of engagement in self-harm. In their
randomized, controlled between-groups comparison study Forman et al. (2007) found
that ACT-based treatments were effectively equivalent to traditional cognitive therapy
interventions in reducing anxiety and depressive symptoms. Bach and Hayes (2002), in
their randomized controlled trial of 80 psychiatric inpatient participants found that
administration of four ACT-based therapy sessions resulted in significantly higher
symptom reporting, significantly lower symptom reification, and a 50% reduction in
participant rehospitalization rates. In his meta-analysis of ACT treatment efficacy Öst
(2014) asserted ACT interventions used for psychiatric, somatic, and distress conditions
exhibited a small mean effect size (d = 0.42) and in comparison to behavioral, CT, and
CBT treatments showed a nonsignificant difference. In their meta-analysis of ACT
treatment effectiveness, Powers et al. (2009) concluded that ACT-based interventions
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were significantly more effective than controls and placebos but were no more effective
than existing traditional treatments such as CT and CBT.
ACT-based treatments are effective in terms of reducing the negative social
stigma and internalized shame often experienced by individuals with substance use
disorders (Luoma et al., 2008; Luoma et al., 2012). Gonzaléz-Menéndez et al. (2013) said
ACT was significantly more effective than CBT at 18-month follow-up in reducing
substance use relapse (ACT 85.7% abstinence at 18 months; CBT 50% abstinent at 18
months).
In a single study, ACT-based treatment approaches were utilized with MAT
program patients (Hayes et al., 2004), where they were combined as an adjunct to TAU
and outcomes compared to a TAU-alone control group and an Intensive Twelve-Step
Facilitation (ITSF) group also combined adjunctively with TAU. The group trials were
run sequentially, using nonduplicated participants who participated in structured
manualized versions of ACT and ITSF individual and group therapies in addition to
TAU, or in TAU alone. Individual and group therapists were of at least Master’s degree
level and had a minimum of 2 years’ experience in substance use disorder treatment. All
therapists were trained prior to implementation of their respective ACT or ITSF models,
whereas TAU utilized the MAT program counselors. ACT and ITSF sessions were
videotaped and evaluated to assure adherence to their respective treatment models.
Effects on drug use were measured by random monthly UDS results obtained pre- and
post-treatment, and at six-month follow-up.
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Hayes et al. found no significant differences (p < .05) between the groups for
illicit opioid use at pre- or posttest, although a significant difference was found at sixmonth follow-up where 42% of the ACT adjunct participants had illicit opioid free UDS
results versus 15% of the MAT-only participants using Pearson x2(1, N = 43) = 7.51, p =
.006. Hayes et al. also found that ACT treatment adjunct group participants were retained
in the MAT program for significantly longer periods than their TAU counterparts were.
Limitations of the Hayes et al. study included a high participant dropout rate (34%), and
potential confounds due to participant funding distinctions. It is unclear why the posttest
UDS results were not significantly different between the groups, as were the six-month
follow-up results. The reasons for the high participant dropout rate are also unknown.
These outcomes suggest that ACT combined with TAU for MAT program patients may
be more effective than TAU alone, but further evaluation is needed using methods that
reduce the impact of participant dropout and evaluate for the posttest effectiveness. No
further studies evaluating ACT as an adjunctive treatment for individuals participating in
MAT programs or those having opioid use disorder were found.
This literature review now focuses on mindfulness-based treatments intended for
reducing and eliminating the harmful effects of substance use conditions.
Mindfulness Oriented Recovery Enhancement
In a randomized controlled pilot study using volunteer participants (n = 53) living
in a therapeutic community, Garland et al. (2010) evaluated the effectiveness of the tenweek Mindfulness-Oriented Recovery Enhancement (MORE; Garland et al.) treatment
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intervention. The control group received standard evidence-based weekly alcohol group
support based on the Matrix model (Rawson & McCann, 2006) of manualized treatment.
Treatment for both groups was provided by Master’s level social worker. Participant
mindfulness was measured using the Five Factor Mindfulness Questionnaire (FFMQ;
Baer et al., 2006). Other measures used by Garland et al. included the Penn Alcohol
Craving Scale measure (PACS; Flannery et al., 1999) for measuring participant alcohol
craving, the Brief Symptom Inventory (BSI; Derogatis & Melisaratos, 1983) for
measuring participant psychological distress, the Impaired Alcohol Response Inhibition
Scale (Guardia et al., 2007), the Perceived Stress Scale (PSS; Cohen et al., 1983)
measuring participant stress levels, and the White Bear Suppression Inventory (WBSI;
Wegner & Zanakos, 1994), measuring participant tendencies toward thought suppression.
Garland et al. measured Alcohol-associated cue reactivity using electrocardiogram
readings taken during participant exposure to visual alcohol associated cues, and
participant alcohol attentional bias was measured using a computerized dot probe task
containing randomized exposure to alcohol associated visual cues.
Using bivariate correlation and repeated measures ANOVA (among other tests),
Garland et al. (2010) found that for the MORE participants, reductions in thought
suppression were significantly correlated with changes in ECG response (r = .49, p =
.042), increased impaired alcohol response inhibition (r = .48, p = .045), and reductions
in post-intervention heart rate variability (HRV) recovery, (r = .49, p = .045). The
findings of Garland et al. suggested that exposure to mindfulness training significantly
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reduced the implicit responses of participants with alcohol use disorder to alcoholassociated environmental cues, supporting the contention that increased mindfulness
facilitates adaptive regulation of autonomic responding to substance use cues. Garland et
al. found that implicit attentional biases orienting and alerting toward alcohol use
significantly decreased through mindfulness practice, suggesting that implicit
maladaptive memory and attentional processes are effectively mediated through regular
mindfulness practice. Further findings included significant reductions in perceived stress
levels and marked reductions in thought suppression associated with more adaptive
mediation of alcohol use cravings. Generalizability from the findings of Garland et al. is
limited due to small participant sample size and lack of a control group. Another
limitation is use of the Matrix (Rawson & McCann, 2006) treatment intervention for
participants with alcohol use disorder, a use for which it has not been normed or
validated. Although suggesting important implications for attentional regulation of
substance use this study did not examine MBRP effects and did not evaluate for
mindfulness effects on attentional regulation of participants with opioid use disorder.
Yoga Nidra
Yoga Nidra references a specific approach toward breathing, originally developed
several thousand years ago in India. It involves mindful focus on the breath where the
rhythm and duration of in- and out-breaths are intentionally manipulated to achieve a
deep level of relaxation (Miller, 2010). Practitioners sit or lie in specific postures, guided
through progressively longer periods of meditation using specific breathing rhythms. An
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example of this unique breathing approach is internally counting to four for the inbreath
and to eight for the duration of the outbreath, over periods of several minutes to an hour
or more (Miller).
Stankovic (2011) reported in a feasibility clinical trial that daily Yoga Nidra
practice for a duration of eight weeks effectively reduced PTSD symptom severity in a
cohort of male war veterans, and that the participants reported increased sense of calm
and self-efficacy. This trial is limited by small participant size (n =16) and lack of a
control group. Temme et al. (2012) found that Yoga Nidra significantly reduced relapse
precursor symptoms and further resulted in improved mood for individuals with
substance use disorders enrolled in residential treatment. Limitations in Temme at al.
included potential variability from reported inconsistent participant understanding of test
measure response items, possible participant expectation bias, and relatively few female
participants. Taken together, these early research efforts suggest that the Yoga Nidra
contemplative approach potentially offers benefit to MAT program patients, particularly
those with trauma exposure history or co-occurring posttraumatic stress disorder, but
further evaluation is needed. Thompson et al. (2011) asserted that mindfulness practices
are effective for persons with traumatic exposure. Further empirical research will more
comprehensively evaluate these preliminary findings. At time of this writing available
research is extremely limited, thus further empirical validation of this mindfulness-based
approach is necessary. No published research to date has evaluated Yoga Nidra as an
adjunctive treatment for MAT program participants.

84
Mindfulness Based Relapse Prevention
The treatment adjunct to be evaluated in this study, MBRP, is a recently
developed manualized treatment approach for substance use disorders that utilizes relapse
prevention strategies integrated with mindfulness meditation (Bowen et al., 2011; Marlatt
& Chawla, 2007). It is based on an amalgamation of CBT approaches and mindfulness
traditions. Bowen et al. (2011) described several core constructs of MBRP. The first is
cultivation of a present-moment focus, wherein the individual with substance use
problems learns to apprehend and accept experience as it unfolds, thereby reducing
preoccupation with substance use as a means of coping with past or future concerns. The
second is development of acceptant, nonjudgmental attitude toward unfolding experience,
where the person learns to skillfully experience and cope with physical and emotional
discomforts rather than attempting to avoid them through substance use. The third is
developing increased understanding of the nature of evolving experience, whereby the
person apprehends the thoughts and cravings for substance use as phenomena whose
frequency and intensity will lessen over time. The fourth is cultivation of metacognitive
awareness, such that the individual perceives his or her substance use in a larger context,
as a conditioned response that can be attenuated or discontinued in accord with personal
values and volition. The fifth is reduction in negative emotional states associated with
stigmatization of substance use, where the individual experiences more effective
regulation of automatized negative self-referents such as guilt, shame, and reduced sense
of self-worth.
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Focus on Experiential Inquiry
Bowen et al. (2011) emphasized that MBRP focuses on supporting participants’
inquiry into the nature of their present moment experience rather than interpreting,
analyzing, or finding solutions for the participants’ unfolding thoughts, emotions, images,
and sensations. Bowen et al. noted that such inquiry eventually results in increased
capability for differentiation between direct experience and reactive responding to that
experience, thereby facilitating increased awareness of internal processes and reducing
reactivity. Further, they asserted that these inquiry processes result in enhanced
awareness of shared experiences, fostering universality, a sense of compassion for self
and others, and a correspondingly reduced sense of the individualized nature of problems
and suffering.
MBRP Program Structure
MBRP treatment is structured as an eight-week course where participants meet
once weekly in a private group setting for two hours with the group facilitator, conduct
daily individual guided meditation practice exercises, and complete daily CBT-oriented
homework assignments (Bowen et al., 2011). The first session consists of an introduction
to the course requirements and two mindfulness meditation exercises (Bowen et al.).
Each subsequent session includes a review of the homework assigned to participants
during the previous session, discussion of participants’ mindfulness meditation practice
experience during the prior week, interactive discussion of mindfulness and relapse
prevention practices and approaches, guided mindfulness meditation exercises, review
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and discussion of the following weeks’ homework assignments, and closing remarks (see
Appendix A).
MBRP Urge Surfing Intervention
Urge surfing is a mindfulness practice designed to decondition the individual’s
identification with substance-associated thoughts, cravings, and urges. The practitioner
envisions the craving or urge as an ocean wave that is cyclical, rising and falling in its
intensity, and ultimately subsiding. Through continued practice, the individual develops
the capability to tolerate the presence of substance-associated cravings and urges without
carrying out the substance seeking and using behaviors, thereby resulting in a classical
deconditioning effect that reduces the frequency and intensity of substance-associated
cravings and urges (Marlatt & Chawla, 2007; Ostafin & Marlatt, 2008). The effectiveness
of the urge surfing intervention has been empirically established with persons dependent
on or abusing a variety of substances including alcohol, opioids, and stimulants (Bowen
et al., 2006; Brewer et al., 2010; Marlatt & Chawla; Ostafin & Marlatt, 2008; Witkiewitz
et al., 2005).
MBRP Sober Breathing Space Intervention
This mindfulness-based approach to relapse prevention utilizes mindful attending to
the breath and to the individual’s unfolding experience to facilitate adaptive responding
in situations where relapse risk is potentially high. The at-risk person learns the acronym,
SOBER, and its associated elements, as follows:
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•

S – Stop, taking a moment to mindfully pause, before proceeding with automatic
reactivity;

•

O – Observe, taking note of emerging thoughts, feelings, sensations, and images;
asking. what is unfolding in awareness at this moment;

•

B – Breathe, focusing attention on the breath; taking a minimum of three to six, or
even more, mindful breaths;

•

E – Expand, fully expanding one’s awareness; examining the thoughts, feelings,
sensations, and images emerging within this augmented awareness of the
situation. Attempting to further explore with openness, acceptance, curiosity,
without judgment; and

•

R – Respond, using the enhanced depth of awareness achieved within the
unfolding moment, responding mindfully, with intentionality, and compassion
(Bowen et al., 2011).

MBRP Perspectives on Substance Use
From an MBRP-based perspective, substance use is a form of experiential
avoidance that is frequently and largely nonconsiously activated in response to
encountering aversive situations, negative thoughts, disturbing emotions, overly intense
affect, physiological pain, and discomfort (Bowen et al., 2012). Bowen et al. asserted that
individuals, when examining their coping behaviors associated with encountering
aversive situations tend to respond reactively, with automatized, usually maladaptive
behaviors. Bowen et al. suggested that mindful exploration of the thoughts, feelings, and
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sensations associated with substance use disorders assists the MBRP practitioner in
uncovering the nature of this automatic responding. Bowen et al. posited that as the
individual explores his or her relationship to the substance of misuse and its effects,
acceptantly, without judgmental distortions, it is likely that more comprehensive
understanding of substance-related thoughts, feelings, cravings, urges, and associated
behaviors is possible. The practitioner thence more objectively evaluates his or her
experience associated with use of substances, earning to cope more adaptively with them
while concurrently reducing and thence eliminating tendencies toward automatized
responding associated with substance use, such as those evoked by environmental cue
reactivity.
This perspective suggests that attempting avoidance generally strengthens the
individual’s identification with the object of the avoidance behavior, whereas mindfully
accepting all aspects of experience with the object fosters disidentification, thereby
reducing its conditioned power. This further suggests that mindfulness practices offer a
means of adaptively changing the individual’s relationship with substance dependence
and other forms of addiction (Smith, 2010).
Evaluation of MBRP Research
Witkiewitz et al. (2005) conducted a preliminary investigation of the effectiveness
of Vipassana meditation, one of the therapeutic elements integral to MBRP, using an
incarcerated population (n = 306) of individuals with alcohol and other substance use
disorders. Volunteer participants were self-assigned to a 10-week Vipassana group or to

89
TAU, consisting of self-help group (Alcoholics Anonymous) participation,
psychoeducation, and social skills training offered at the prison facility. Using ASI
Alcohol/Drugs subscale measures, Witkiewitz et al. found that at three-month follow-up
the Vipassana group reported 29.3% reduction in cutoff alcohol use frequency (defined as
4 drinks per week), a significant difference (p = .08), whereas the TAU group reported a
13.9% reduction. They further found that at three-month follow-up the Vipassana group
reported a 18.1% reduction in cutoff daily alcohol use frequency (defined as seven or
more drinks per day), a trend difference (p = .08) whereas the TAU group reported a
0.2% increase. Witkiewitz et al. reported that limitations of this study included a very
high participant dropout, with 218 participants not completing the study. Further
limitations include lack of randomized participant assignment and possible participant
selection bias stemming from self-selection of groups, and absence of clearly defined
participant control group intervention effects.
Witkiewitz et al. (2013b) conducted a randomized controlled trial of MBRP using
volunteer participants with alcohol use disorder and a mixture of other substance use
disorders (45.2% alcohol, 49.9% stimulants, 7.1% opioids, 5.4% cannabis, 1.9%
undetermined) enrolled at an outpatient Washington treatment facility. They found that
MBRP was significantly more effective at reducing participant alcohol use cravings than
the TAU group receiving psychoeducational, 12-Step (self-help), and relapse prevention
group interventions. MBRP manualized treatment providers were experienced therapists
with graduate degrees who were trained in MBRP, whereas TAU services providers were
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licensed substance use counselors with varying levels of education and experience
(Witkiewitz et al.). Therapist adherence to the MBRP manualized treatment was
evaluated using the Mindfulness-Based Relapse Prevention Adherence and Competence
Scale (Chawla et al., 2010). Study measures used at pre-, posttest, and at two- and fourmonth follow-up included the PACS (Flannery et al., 1999), used to measure alcohol and
other drug use cravings; the FFMQ (Baer et al., 2006), used to measure acting with
awareness and nonjudgmental elements of mindfulness; and the Acceptance and Action
Questionnaire (AAQ; Hayes et al., 2004), used to measure participant acceptance (also an
element of mindfulness). Witkiewitz et al. noted that random group participant
assignment was achieved through use of random number sequencing. Participants were
provided with gift card incentives upon completion of study measures. Witkiewitz et al.
(2013b) found that MBRP participants had significantly lower alcohol use craving scores
measured at midtreatment: t (125) = 2.43, p = 0.02); and posttreatment: t (101) = 2.37, p
= 0.02), whereas at two-month and four-month post-treatment follow-up the MBRP
participants no longer experienced significant differences from their TAU counterparts in
alcohol use cravings. It is important to note that no evidence suggests these findings are
predictive for use of MBRP in the treatment of opioid use disorder.
The Witkiewitz et al. (2013b) study was limited in that no objective measures of
substance use, such as UDS results, were utilized, leading to overreliance on selfadministered participant report measures. Further limitations included lack of an
operational definition of substance craving, the use of a substance craving measure not
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normed or validated for substances other than alcohol use, use of mindfulness measures
that did not specifically target design factors used in MBRP, the lack of a waitlist
comparison or control group, and the between-group distinctions in therapist education
and training. Additionally, the causal association between substance use craving and
actual relapse behavior remains unclear.
In a randomized trial of participants (n = 168) with multiple substance use
disorders (45.2% alcohol, 49.9% stimulants, 7.1% opioids, 5.4% cannabis, 1.9%
undetermined) Witkiewitz and Bowen (2010) evaluated for effectiveness of MBRP in
reducing substance use and cravings associated with depression. This study utilized
therapists with graduate degrees who were trained in MBRP, whereas TAU services
providers were licensed substance use counselors with varying levels of education and
experience (Witkiewitz & Bowen). MBRP sessions were audio recorded and assessed for
fidelity with MBRP criteria using the Mindfulness-Based Relapse Prevention Adherence
and Competence Scale (Chawla et al., 2010). Measures used by Witkiewitz and Bowen
for this study included the PACS (Flannery et al., 1999) for substance use cravings, the
Timeline Followback (TLFB; Sobell & Sobell, 1992) a calendar-based daily log for
substance use reporting, and the BDI-II (Beck et al., 1996) for depression. Measures were
administered at pre- and posttest intervals, and at two- and four-month follow-up.
Witkiewitz and Bowen found that the MBRP group showed significantly reduced
depression-associated substance use cravings compared to TAU during the MBRP
intervention (η2 = .09, p < .05) and up to two months post-intervention (η2 = .04, p <
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.05). Witkiewitz and Bowen noted these effects were maintained at four-month follow-up
(η2 = .02, p < .05) only for those participants that continued their MBRP meditative
exercises. Those continuing participants showed a remarkable zero percent relapse rate at
four-month follow-up.
Limitations of the Witkiewitz and Bowen (2010) study included a relatively short
duration of follow-up measurement and undetermined potential extraneous variable
effects arising from reliance on participant self-report, unmeasured differences in
therapist skill level, and high participant attrition rates (27%). Further limitations include
that multiple participants (62.7% of TAU group, 52.8% of MBRP group) were court
mandated to participate in treatment and to abstain from illicit substance use, a possible
confounding variable. Finally, no objective data confirming participant substance use was
obtained.
Hsu, Collins, and Marlatt (2013) evaluated effectiveness of MBRP manualized
treatment moderation effects on distress tolerance for participants (n = 168) with
substance use disorders including alcohol, cocaine, methamphetamine, opioids, cannabis,
and undefined other substance use who were enrolled in outpatient treatment for their
substance use conditions. Participants were randomly assigned to the MBRP or TAU
group, with TAU consisting of 12-step group participation, psychosocial education, and
process-based intervention. Measures used included the Distress Tolerance Scale (DTS;
Simons & Gaher, 2005) to evaluate participant capacity for adaptive responding to
stressors, and the TLFB (Sobell & Sobell, 1992) for participant reporting about alcohol
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and other drug use. Mindfulness was measured using the FFMQ (Baer et al., 2004) and
convergent validity between the DTS and FFMQ was assessed.
Hsu et al. found that MBRP participant DTS results showed a significant positive
correlation with all five FFMQ subscales (r =. 28; r =.41; r =.4; r =.41; r=.47; p = .001),
suggesting strong convergent validity of the measures and an association between higher
distress tolerance and mindfulness. They further found a significant positive association
between MBRP intervention and reduction of substance use at posttest and two-month
intervals, Wald χ2 (13, N =162) = 3595.33, p =.001. Hsu et al. found that MBRP
participants with lower distress tolerance who received MBRP showed significant
reductions in alcohol and other drug use over time compared to their TAU counterparts
with lower distress tolerance through two-month follow-up.
Limitations of the Hsu et al. (2013) study include lack of objective substance use
data collection, resulting in overreliance on participant retrospective self-reporting of
substance use, a brief follow-up period, potential between-group variability arising from
distinctions in MBRP and TAU group content and procedures, lack of waitlist control
group, distinctions in education, training, and clinical approach between the MBRP
therapists and the program counselors, and uncontrolled participant demographic
variables.
Bowen and Kurz (2011) evaluated post-MBRP intervention moderating effects on
therapeutic alliance and between-session meditative practice on mindfulness in a
randomized trial of outpatient substance use program participants (n = 168) with multiple
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substance use disorders (45.2% alcohol, 49.9% stimulants, 7.1% opioids, 5.4% cannabis,
1.9% undetermined). Their study utilized therapists with graduate degrees who were
trained in MBRP (Bowen & Kurz). MBRP sessions were audio recorded and assessed for
fidelity with MBRP criteria using the Mindfulness-Based Relapse Prevention Adherence
and Competence Scale (Chawla et al., 2010). Bowen and Kurz found that participation in
MBRP was significantly associated with increases in mindfulness at post-intervention.
Bowen and Kurz noted that paired sample t-testing revealed a significant increase in
levels of mindfulness between baseline and posttest, t(33) = - 2.43, p = 5.02, and through
four-month follow-up t(33) = -2.57, p = 5.014. Using regression analysis, Bowen and
Kurz found that increased levels of participant mindfulness were significantly associated
with an effective therapeutic alliance as measured by the Working Alliance InventoryShort Form (WAI-S; Tracey & Kokotovic, 1989) post-treatment and at two-month
follow-up, β =.479, t(31) = 3.51, p = .001 although results were not significant at fourmonth follow-up. Their results suggested that the strength of the therapeutic alliance is
associated with increased levels of participant mindfulness and may be enhanced through
MBSR practice. Implications include that an effective therapeutic alliance, enhanced
through MBSR participation, may foster improved treatment outcomes for substance
users, although this association was not studied.
The Bowen and Kurz (2011) study limitations include a reliance on participant
self-report measures and correspondent lack of objective participant substance use data,
use of a nonvalidated measure to evaluate participant between-session meditative
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practice, lack of a control group, and high participant attrition rates (57%) that reduced
statistical power and generalizability.
Lee et al. (2011) conducted a randomized controlled trial evaluating MBRP
effectiveness for an incarcerated Taiwan population of individuals with currently
asymptomatic substance use disorders for “cannabis, amphetamine, cocaine, MDMA,
heroin, Ketamine, glue, and LSD” (p.479) use. The MBRP intervention was provided by
licensed psychologists trained for two years in mindfulness meditation and relapse
prevention. TAU consisted of substance use education. Measures used by Lee et al.
include drug use Identification Disorders Test-Extended (DUDIT; Berman et al., 2007) to
measure positive and negative perspectives on and frequency of illicit substance use, the
Drugs Avoidance Self-Efficacy Scale (DASE; Martin et al., 1995) to evaluate for selfefficacy of substance refusal skills, and the BDI-II (Beck et al., 1996) to measure
depressive affect. Participants (n = 24) were randomly assigned to either the MBRP or
TAU groups, and Lee et al. used MANOVA to evaluate between group differences and
repeated measures ANOVA to evaluate for MBRP within group changes over the 10week duration of the study. Lee et al. found that MBRP participants experienced
significantly higher negative perspectives toward drug use (t = 2.46, p < 0.05),
significantly higher negative expectancies toward potential substance use (t = −5.22, p <
0.01), and significantly less depressive affect (F (1, 9) = 110.40, p < 0.05) than their TAU
counterparts. The findings of Lee et al. suggest a significant association between
participation in MBRP, reduced depressive affect, and increased negative perspectives
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and expectancies toward substance use. These results are consistent with Hendershot et
al. (2011), whose review findings asserted the importance of enhanced self-efficacy and
adaptive outcome expectancies resultant from MBRP participation.
Limitations of the Lee et al. (2011) study include use of male-only participant
selection, lack of measurement for depressive affect in the TAU group, lack of objective
and subjective substance use measures, no long-term follow-up, and small participant
size (n = 24), thereby reducing statistical power and generalizability.
Bowen et al. (2014) conducted a randomized clinical trial comparing the effects
of MBRP, RP, and TAU as an aftercare treatment for a population (n = 286) of volunteer
participants who had previously completed either a 28 day or 90-day inpatient
rehabilitative treatment for alcohol, stimulants, opioids, cannabis, and other undetermined
substance use disorders. TAU consisted of eight weeks of process-oriented support
groups based on 12-Step principles. RP consisted of an eight-week intervention focused
on relapse risk assessment, improving cognitive and behavioral skills, increasing selfefficacy, establishing goals, and using social support systems. The eight-week MBRP
intervention was used in place of TAU, rather than as an adjunctive treatment. TAU
therapists were certified counselors, whereas the RP and MBRP therapists were graduate
students at the Master’s degree level or higher and were extensively trained in either RP
or MBRP administration. Study measures included the TLFB (Sobell & Sobell, 1992) for
alcohol and other substance use, UDS results data for a percentage (0.695) of the
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participants, and monitoring of recorded intervention sessions to evaluate for adherence
to manualized treatment guidelines.
Bowen et al. (2014) used Cox proportional hazards regression models to estimate
hazard ratios for number of days prior to participant relapse into alcohol or drug use.
They found that MBRP and RP groups showed a 54% decreased risk of relapse to drug
use (β = −0.77, HR = .06, p = .05) and a 59% decreased risk of relapse (β = −0.89, HR =
.41, p = .05) to heavy drinking in comparison to the TAU group, and the MBRP group
showed a 21% increase in relapse risk to first drug use (β = .19, p = .05) compared to RP.
Using negative binomial hurdle statistical models to determine incidence rate ratio (IRR),
at six-month follow-up Bowen et al. found no significant differences between RP and
MBRP effects on drug or alcohol use, whereas RP and MBRP participants reported a
significant 31% fewer days of alcohol use than their TAU counterparts (β = 0.33, IRR =
.69, p < .05). Finally, Bowen et al. noted that at twelve-month follow-up there was
significant difference between MBRP and RP in drug use (β = −0.37, IRR = 0.69, p < .05)
and in likelihood of participant alcohol use using odds ratio (OR) measure for likelihood
of drinking (β = 0.43, OR = 1.51, p < .05). These results suggest that both RP and MBRP
are significantly more effective interventions for alcohol and drug use than TAU up
through 12 months posttreatment, with MBRP exerting stronger inhibiting effects on
substance use.
Limitations of Bowen et al. (2014) included inconsistent objective data collection
on participant substance use, reliance on participant self-report measures, between-group
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distinctions in levels of therapist training and education, subjective evaluation of therapist
adherence to RP and MBRP models, and large differences between TAU group and the
RP/MBRP groups in participant therapeutic assignment and intervention time
requirements.
In general, limitations of MBRP research include a small number of randomized,
controlled study designs (Bowen et al., 2011; Bowen et al., 2014). An additional concern
raised by Levin, Dalrymple and Zimmerman (2014) in their randomized, controlled study
comparing mindfulness factors between persons with substance use disorders and an
abstinent control group is that capabilities for fostering states of mindfulness are limited
in persons with SUD history. Hendershot et al. (2011) noted that further research
evaluating the theoretical constructs and clinical applications of MBRP are needed,
especially those incorporating study designs using randomized controlled trials.
An important consideration here is that many of the preceding MBRP studies
(Bowen & Kurz, 2011; Hsu et al. 2013; Witkiewitz & Bowen, 2010; Witkiewitz et al.,
2013b) were conducted using the same participant population. This suggests the
possibility that unique, albeit unidentified characteristics of that population could exert
unknown effects on these multiple study outcomes. Other concerning limitations of the
preceding studies include the lack of objective measures for participant substance use
data and that the participants were predominantly individuals with alcohol use disorder,
as only 7.1% reported opioid use. Although Bowen et al. (2014) collected objective
participant substance use data using UDS results, these data were not collected
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consistently from all participants. A further consideration here is that these studies mostly
focused on MBRP’s subjective effects on substance use cravings rather than objectively
measuring substance use behaviors. Two other MBRP studies (Witkiewitz et al., 2005;
Lee et al., 2011) were conducted using incarcerated populations, suggesting an important
limitation on generalizability of results, and the majority of these participants were
presenting with alcohol use disorder histories. Of even greater importance, none of the
preceding studies used MAT program patient populations to evaluate the effectiveness of
MBRP for opioid use disordered populations.
Bowen et al. (2017) conducted a study of 15 participants with OUD that were
enrolled in a MAT program, maintained on methadone medication, and exposed to the
eight-week MBRP group manualized treatment protocol. Bowen et al. found a significant
reduction in opioid cravings at p£ .05 for participants at study conclusion. They further
noted significant changes in reduction of depression and trauma symptoms reported by
the seven participants completing the MBRP group. Limitations of this study included the
small sample size (n=15) thereby limiting statistical power, insufficient attendance at the
MBRP group (59% over the course of the study), and a marked reduction in number of
participants enrolled at study completion compared to initial enrollment (from n=15 to
n=7). An important limitation was that this study design did not include a control group
or randomized participant assignment. A further limitation included the use of the
Acceptance and Action Questionnaire (AAQ; Hayes et al., 2004), an instrument that
evaluates for the global psychological functional factors of experiential avoidance and
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psychological flexibility, but does not specifically evaluate for more direct aspects of
mindfulness including curiosity and decentering as evaluated for in the TMS (Lau et al.,
2006). Overall the Bowen et al. study represents an important initial feasibility evaluation
for use of MBRP with methadone-maintained patients.
Lyons et al. (2019) undertook a randomized controlled study of incarcerated
males with varied substance use disorders. Lyons et al. utilized a randomized cohort
assignment design including an MBRP participant cohort and a control cohort using a
six-week version of the Mapping-Enhanced Counseling Manuals for Adaptive Treatment
(MECMAT; Joe et al., 2012). Lyons et al. used a revised version of the MBRP protocol
that reduced the eight-week group period to six weeks through elimination of the
mountain meditation exercise and amendment of other exercises integral to the original
MBRP manualized treatment protocol. The potential effects of this revision remain
unknown as Lyon’s et al. did not undertake a comparative analysis between the original
and revised versions. Lyons et al. found that drug cravings were significantly reduced
(p=.05) for the MBRP intervention group at completion of an abbreviated (six-week)
MBRP intervention in comparison to the MECMAT participant control group. To
evaluate for levels of participant mindfulness they used multiple measures including the
Five Factor Mindfulness Questionnaire (FFMQ; Bohlmeijer et al., 2011) and the Freiburg
Mindfulness Inventory (FMI; Walach et al., 2006). Lyons et al. observed a significant
increase (p=.05) in participant mindfulness for the experimental condition as measured by
comparing pretest and posttest FMI results, while noting no significant change in
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mindfulness in the control group. Limitations of the Lyons et al. study include the
undetermined empirical efficacy of their abbreviated MBRP protocol and any resultant
potential covariability, a participant attrition rate of 31% with its attendant reduction in
statistical power, and potential, albeit unmeasured, covariability between the MBRP
exposure experimental condition and extant jail therapeutic community effects.
Imani et al. (2015) in their randomized , controlled study evaluated effectiveness
of MBRP as a treatment adjunct for 30 participants enrolled in an opioid treatment
program (OTP) and maintained on either methadone or buprenorphine medication. Both
the experimental and control groups included maintenance treatment as usual (TAU).
Randomized participant assignment was used to determine group selection. Imani et al.
used the ASI Alcohol/Drugs subscale (Leonhard et al., 2000; McLellan et al., 1985) to
measure participant opioid use and the FFMQ (Bohlmeijer et al., 2011) to measure
participant mindfulness. Imani et al. observed a reduction in opioid use as measured by
ASI Alcohol/Drugs subscale outcomes and concurrent increase in mindfulness as
measured by FFMQ outcomes but neither of these findings proved statistically significant
(p=.05). Limitations of the Imani et al. study included a lack of distinction between
participants prescribed methadone versus those prescribed buprenorphine, which could
exert unmeasured covariability into the MANCOVA statistical analysis they used.
Another limitation was a potential, albeit undetermined MBRP manual fidelity problem
resultant from its translation into Farsi to facilitate communicating in the participants’
native language. The effects of this translation were not measured (Imani et al.). An
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additional limitation was the small number of enrolled participants (n=30) that limited
statistical power and generalizability of the results. Notably, participant attrition was
small, with 29 participants completing the study (Imani et al.).
In a random controlled study evaluating the effectiveness of MBRP in the
treatment of individuals with stimulant use disorder Glasner-Edwards et al. (2017) found
no significant post-treatment difference (p=.05) in stimulant use between the MBRP
group and the control group. They noted some posttest improvement for MBRP
participants that reported reductions in stimulant use and reduced symptoms of
depression and anxiety, but these changes did not rise to the level of significance. The
control group received eight weeks of health education group meetings run concurrently
with the experimental group receiving the MBRP manualized treatment (GlasnerEdwards et al.). The FFMQ (Baer et al., 2004) was used for pretest and posttest
measurement of participant mindfulness. A twelve-week contingency management
protocol was run with the initial four weeks preceding the experimental and control
groups implementation (Glasner-Edwards et al.). A feasibility strength of the study was
the demonstrated strong MBRP protocol fidelity adherence as measured by MBRP
Adherence and Competence Scale (Chawla et al., 2010) outcomes. Study limitations
noted by Glasner-Edwards et al. included a 59% study participant attrition rate, with an
initial 63 participants reduced to 26 remaining at study conclusion, and the unmeasured
potential for covariability resultant from combining the experimental and control
conditions with contingency management.
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Hayes et al. (2004) evaluated the effectiveness of mindfulness-based approaches
for MAT program patients, and this study, while demonstrating significant effects of the
ACT-based intervention, did not evaluate for the effectiveness of MBRP. Whereas ACT
and MBRP can both be regarded as mindfulness-based treatment approaches, ACT is
strongly dissimilar to MBRP in its theoretical constructs, treatment approach, and
interventional design. ACT is conceptually based on the theoretical constructs of
relational framing (Hayes, 2002) and cognitive fusion (Hayes et al., 2012), with
interventions focused toward achieving cognitive defusion with maladaptive relational
frames using mindfulness-based decentering exercises. MBRP, in contrast, is based on
principles of cognitive therapy, relapse prevention, and mindfulness (Bowen et al., 2011),
using interventions amalgamated from these disciplines to increase participant
metacognitive awareness, self-efficacy, and affect regulation, and improve coping skills,
which together improve participant capabilities for effectively managing substance use
cravings and reducing harmful behaviors associated with substance use.
Grant et al. (2017) found in their meta-analysis of MBRP efficacy that MBRP did
not show significant reductions in substance use relapse prevention, or increased levels of
mindfulness in comparison to relapse prevention, CBT interventions, or TAU. They
suggested the need for larger participant sample sizes, and to find methods for reducing
participant attrition, which appeared to be a common confounding factor across multiple
studies they reviewed. A significant limitation in their study was that they did not
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differentiate between distinct drugs of abuse, an essential consideration in the present
study as it focused on persons with OUD enrolled in MAT.
Considered together, research outcomes suggest the MBRP treatment approach is
likely an effective treatment for many substance use disorders and that volitional
attention, when adaptively directed, appears to reduce the compelling nature of the
association between substance use-associated cognitions and cravings. Despite these
efforts, important MBRP research gaps remain in that as of the development of this study
there has been thus far only a single study (Imani et al., 2015) using a random controlled
participant assignment design to evaluate MBRP effectiveness with individuals that have
opioid use disorder, are enrolled in a MAT program and are being maintained on
methadone. This study was limited by a potential fidelity concern due to unevaluated
translation of the MBRP manualized treatment document and undefined number of
methadone-maintained participants. The only other study evaluating MBRP effectiveness
for methadone-maintained individuals with OUD lacked a control group and randomized
participant assignment, and was limited by a severe participant attrition rate (Bowen et
al., 2017).
Rationale for Study Variables
Two measures for of illicit drug use in MAT program patients have been
consistently utilized at MAT programs and in the associated substance use disorder
research: random monthly urine drug screen outcomes and the ASI Alcohol/Drugs
subscale outcomes (Batki et al., 2005; Parrino et al., 1993). Consistent with historical
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treatment and investigative methodology, one measurement for DV utilized in this
proposal to evaluate for frequency of participant illicit opioid use is the ASI
Alcohol/Drugs subscale (Leonhard et al., 2000; McLellan et al., 1985). Given the strong
association between opioid use cravings and opioid use behaviors (Batki et al., 2005;
Parrino et al., 1993; Wasan et al., 2012), an additional DV measurement for this proposal
was the OCS (McHugh et al., 2014).
A potential MV was the level of participant mindfulness as measured by
participant TMS (Lau et al., 2006) outcome scores at pretest, midtest, and posttest
intervals. Statistical covariance data outcomes were to be used for determining any
significant mediating association between changes in participant mindfulness and
changes in dependent variables outcomes.
MBRP (Bowen et al., 2011; Bowen et al., 2014; Bowen & Enkema, 2014) is a
manualized treatment specifically researched and designed to address and reduce
substance use-related thoughts, cravings, and reactive responding to environmental cues
and stressors exposure (substance use as maladaptive coping). Given the impaired stress
response of individuals with opioid use disorder (Kreek, 2000) and its associated elevated
relapse risk, MBRP likely offers an effective strategy for reducing MAT program patient
illicit opioid use and the onset of its harmful concomitants. Moreover, MBRP has not yet
been effectively evaluated as a treatment adjunct for MAT program patients. Thus, the
MBRP manualized treatment protocol was selected in order to evaluate its effectiveness
as a treatment adjunct used within the context of a MAT program, and to address the
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previously described research gap. The independent variable (IV) in the study was
defined as two treatment levels: level one being administration of the MBRP (Bowen et
al., 2012) manualized treatment intervention to the experimental group of MAT program
participants concurrently participating in TAU for the proscribed eight-week period, and
level two being the control group of MAT program participants participating only in
TAU for the proscribed eight-week period.
Review and Synthesis
The research literature clearly indicates that opioid use disorder is a chronic,
relapsing condition. Whereas MAT programs offer viable and effective treatment for this
disorder, relapse for MAT program participants remains a serious concern, occurring in
up to 20 percent of the treated population at any given time (Kreek, 2007). The risk of
relapse is strongly associated with stress exposure in persons with opioid use disorder
(CSAT, 2005; Kreek, 2000; Kreek & Koob, 1998; 2007). The medical, psychological,
and social risks associated with relapse into illicit opioid use are of great concern
(CSAT). Individuals experiencing relapse are at high risk for overdose, oversedation
effects, and death (CSAT; Parrino et al., 1993, SAMHSA, 2020). Overdose death rates
associated with illicit opioid use have tripled since 1990, and continue to increase (Chalk
et al., 2013). Other associated risks include initiation or exacerbation of psychological
conditions including anxiety and depression, alienation from friends and family, loss of
beneficial functionality such as employment, and mounting legal problems with their
associated expenses (CSAT). The social costs associated with illicit opioid use in the U.S.
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are accrued mostly through overutilization of public healthcare, social support services,
and criminal justice and court systems, and are estimated to amount to more than $500
billion annually (Manchikanti et al., 2012). Moreover, the annual U.S. healthcare costs
associated with illicit opioid use are estimated to be greater than $ 72.5 billion (Rinaldo
& Rinaldo, 2013). Taken together, the preceding considerations strongly suggest that any
treatment adjunct that can potentially reduce the frequency of illicit opioid use in the
MAT program patient population is thus of considerable benefit to both MAT program
patients and society.
The research evaluating neurobiological substrates of opioid use disorder suggests
several key functional aspects of brain function that contribute to the condition. The first
is hedonic homeostatic dysregulation, where activation of the ventral tegmental area
(VTA), nucleus accumbens (NAc), and locus ceruleus (LC) located within the brain’s
mesolimbic dopaminergic reward pathway occurs in response to repeated ingestion of
exogenous (illicit) opioids through reduction in endogenous mu opioid receptor site
occupation (Koob & Moal, 2006; Moal & Koob, 2007; Kosten and George, 2002).
Continued hedonic homeostatic dysregulation results in allostasis, the neurobiologically
conditioned phenomena of increased tolerance of and physiological dependence on illicit
opioid use (Koob & Moal, 1997; 2006; 2007). The use of exogenous opioids is reinforced
through classical conditioning hedonic effects that include sensations of well-being and
euphoria arising from VTA mu receptor site occupation and resultant transmission of
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increased dopamine levels from the VTA into the NAc and LC (Koob & Moal; Kosten &
George).
Neurobiological functioning further contributing to OUD includes the
phenomenon of opioid abstinence syndrome (OAS), or the state of opioid withdrawal,
wherein the individual with opioid use disorder experiences a protracted constellation of
increasingly severe and aversive physiological symptoms in response to discontinuance
of or marked reduction in exogenous illicit opioid use (Chalk et al., 2013; CSAT, 2005;
Parrino et al., 1993). OAS symptoms are precipitated by reduction in mu receptor site
occupation in the LC, which thence results in upregulation of noradrenaline levels in the
endocrine system that cause the marked discomfort of OAS symptoms (CSAT; Koob &
Moal, 2006; Parrino et al.). Further, reduction of mu receptor site occupation in the VTA
results in correspondent reduction of dopamine levels in the NAc with attendant
dysphoric effects (Koob & Moal). Moreover, these aversive symptoms are immediately
relieved through again ingesting illicit opioids, reducing noradrenaline levels and
increasing dopamine levels, and thereby further reinforcing and perpetuating continued
illicit opioid use (Kosten & George, 2002).
A third contribution factor in OUD is that of cognitive deficits, where the
neurotransmitter signals from prefrontal cortex (PFC) of the brain, normally implicated in
sound judgment and planning, are overridden by competing neurotransmission signals
from the more primitive brain functions of the VTA, NAc, and LC. This action results in
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the impaired decisional and behavioral control leading to continued illicit opioid craving,
seeking, and use (Kosten & George, 2002).
Considering MBRP as a MAT Program Adjunct
The research evaluating neurobiological substrates of mindfulness suggests that
recurrent use of mindfulness practices results in enhanced PFC regulation of the more
primitive limbic system functioning, neurobiologically evidenced in measurable increases
in adaptive PFC functioning and structural mass (Chiesa & Serriti, 2010; Hölzel et al.,
2007; Hölzel et al., 2011b; Sperduti, Martinelli, & Piolino, 2011). Witkiewitz et al.
(2013b), Kashdan et al. (2011), and Williams (2010) posited that these structural and
functional effects result in enhanced awareness and attentional control, reduced reactivity
to stress and environmental cues, and increased acceptance and management of
discomfort. Witkiewitz et al. asserted the existence of several neurobiological substrates
implicated in MBRP practice. Improved metacognitive awareness fosters Dorsolateral
PFC, anterior cingulate cortex (ACC), ventral striatum (VS), insula, and amygdala
bottom-up processing of substance use-associated stimuli without reactivity. The PFC
and ACC upregulate adaptive attentional monitoring and control of cognitive, affective,
and somatic functions associated with substance use cravings. Resultant improved selfregulation is reflected in adaptive inhibitory control of substance use sustained through
the medial PFC, orbitofrontal cortex (OFC), and ACC; and tolerance for discomfort
previously associated with substance use is improved through adaptive functioning of the
ACC and VS.
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Through these increased structural and adaptive functional capabilities individuals
are able to more adaptively regulate their conditioned responses to internal mental and
physiological conditions and to external environmental cues (Farb et al., 2012; Hölzel et
al., 2011b); stimuli that would otherwise likely result in illicit substance use (Bowen &
Enkema, 2014; Dickenson et al., 2013; Witkiewitz et al., 2013a; Witkiewitz et al.,
2013b). Thus, the maladaptive neurobiological responses associated with hedonic
homeostatic dysregulation and allostasis, as well as the neurobiological responses
associated with OAS, likely could be more effectively mediated through the enhanced
PFC control capabilities achieved through engagement in mindfulness practices. Zgierska
and Markus (2010), in their review of the empirical literature, asserted that mindfulness
practices have been found effective for addressing multiple concomitant conditions
experienced by persons with substance use disorders that exacerbate relapse risk. Shorey
et al. (2014) found that reduced levels of participant mindfulness were significantly
associated with increased illicit substance use. Further, Shorey et al. (2013) found that
individuals with substance use disorders have significantly reduced levels of mindfulness
compared to healthy adults, suggesting that interventions increasing mindfulness in
substance users would likely reduce tendencies toward illicit drug use as a maladaptive
avoidance or coping strategy. Considered together, the concepts of neurobiological
functioning, maladaptive functioning of the brain’s reward pathway associated with
impaired PFC regulation of lower order circuits, and the adaptive structural and
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functional regulation of the PFC arising through mindfulness-based practices, underlie
the research questions and hypotheses central to this pilot study.
Empirical research strongly suggests that mindfulness practices are effective in
reducing substance use associated thoughts, cravings, and relapse (Blume & Marlatt,
2009; Bowen et al., 2006; Bowen et al., 2007; Bowen et al., 2009; Bowen et al., 2011;
Bowen et al., 2014; Bowen & Enkema, 2014; Brewer et al. 2012; Brewer et al., 2009;
Zgierska and Markus, 2010); and in reducing harmful effects of stress exposure (Baer,
Carmody, & Hunsinger, 2012; Kabat-Zinn, 2002; 2003; 2009; Zgierska and Markus).
Substance use-related cues, thoughts, and cravings are effectively mediated through use
of mindfulness based attentional regulation (Witkiewitz et al., 2013; Hölzel et al, 2011b),
suggesting that through engagement in mindfulness practices individuals with opioid use
disorder likely can reduce their harmful substance use cognitions and behaviors, while
concurrently improving their capabilities for adaptive stressor response.
Kabat-Zinn (2002; 2009) asserted that mindfulness approaches include
intentional, decentered, acceptant attentional regulation of percepts, cognitions, and
affective phenomena. Use of decentered selective attention is exemplified in MBRP by
mediating substance use associated thoughts and cravings through multiple cognitive
strategies. The first is conceptualization of such cognitions as impermanent mental events
that need not be intrusive or compelling (Bowen et al., 2011). The second is enhancing
adaptive coping with them via use of the ocean wave meditative exercise and other
meditative exercises. The third occurs through use of CBT-based interventions that
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together, strengthen PFC regulation of the more primitive conditioned limbic system
responses (Bowen et al.).
Thus, as Witkiewitz et al. observed, MBRP interventions target brain functioning
that is strongly associated with substance use and relapse. In their controlled study of
MAT program patients Nejati et al. (2012) found that daily use of methadone medication
fostered improved selective attentional capabilities through associated reductions in
automatized illicit opioid use biases and maladaptive responding to environmental
stressors. This suggests that methadone medication is unlikely to impair the selective
attentional functions inherent in mindfulness practices. Taken together, these
considerations suggest MBRP is potentially a viable treatment adjunct for use with
individuals participating in MAT for opioid use disorder and thus its evaluation as a
treatment adjunct for MAT program participants is relevant, likely addressing a key gap
in the research.
Summary and Conclusion
A considerable body of research suggests mindfulness-based treatment
approaches offer effective interventions for a number of conditions including anxiety,
depression, chronic pain, substance use disorders, and multiple general medical
conditions. Further, research evaluating mindfulness practices appear to enhance
neurobiological, cognitive, and affective protective functioning. Mindfulness meditation
has demonstrated effectiveness in reducing maladaptive responses to multiple aversive
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conditions and enhancing adaptive responding, thereby markedly reducing human
distress and suffering.
Neurobiological research evaluating mindfulness has found strong correlations
between use of mindfulness-based practices and adaptive modifications to
neurobiological structure and functioning. Research shows that impaired connectivity
between the PFC and limbic system secondary to stress exposure, general medical illness,
psychiatric illness, and substance use disorders has been implicated in symptomatic
exacerbation of these conditions. Mindfulness research shows that even in naïve
meditators, neurobiological changes have been observed including increases in neuronal
mass within and blood flow from areas of the PFC to the limbic system, suggesting
improved PFC regulation of more primitive central nervous system functions. An
important area of investigation into mindfulness practices remaining unexplored to date is
how such adaptive reregulation capacity could affect the neurobiological dysfunction
associated with psychiatric illness, especially that specific to substance use disorders.
This pilot study attempted to address this research gap through evaluating the
effects of a specific mindfulness-based intervention, MBRP, on the illicit opioid use
behaviors of individuals concurrently participating in MAT. This study continues with
Chapter 3, focused on specific research design, methods, and implementation strategies.
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Chapter 3: Research Methods
Study Purpose
Opioid use disorder is a chronic, relapsing condition where post-remission relapse
is likely (APA, 2006; 2013; Dennis & Scott, 2007; Kosten & George, 2002; Leshner,
1989; 2001; Parrino et al., 1993; Volkow, 2007a; 2007b). MAT is an effective treatment
for addressing opioid use disorder (Kosten & George, 2002; Parrino et al., 1993; Volkow,
2007b). Nevertheless, given the chronic and relapsing nature of this condition, MAT
program participants remain at risk for illicit opioid use relapse and are thus likely to
benefit from adjunctive treatment interventions that reduce this risk (Logan & Marlatt,
2010; Parrino et al., 1993).
MBRP treatment interventions are effective in terms of treating substance use
disorders and their associated craving behaviors, have not yet been investigated for their
effectiveness as a MAT program treatment adjunct. This study involves addressing this
gap in the research through evaluating the effects of illicit opioid use among MAT
program participants.
Overview of This Chapter
This chapter includes an outline of the research design and its rationale, including
research questions addressed by the study, study design, types of variables , time
constraints imposed by the design, how the design addressed existing gaps in the
research, and the rationale for the study intervention. Characteristics of the target
population are described. Sampling strategies and procedures are identified. Procedures
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for participant recruitment and data collection are identified and described. The rationale
for conducting this pilot study is explicated. The MBRP manualized treatment
intervention is described, and associated procedures for implementation are discussed.
Measures used to evaluate DV outcomes are discussed, as well as their relevance for use
in this study and reliability and validity characteristics. Study variables are operationally
defined, and measurement, scoring, and interpretational methodologies are discussed.
The data analysis plan is outlined, including software, research questions and hypotheses,
explanation of statistical tests, evaluative methods for inclusion of covariates and
controlling for confounding variables, and interpretational factors including confidence
intervals. Validity threats are evaluated, including external and internal factors, as well as
construct and statistical validity concerns. Ethical considerations are identified and
discussed, including procedures used to assure consistency with Walden University IRB
and APA ethical standards for participant research, institutional permissions, adherence
to MAT program ethical standards, ethical treatment for all study participants regardless
of nature or duration of their participation, and concerns regarding potential conflicts of
interest. This chapter concludes with a summary of the experimental design and method
of inquiry in this study.
Research Design and Rationale
This pilot study was intended to evaluate the effects of administration of a MAT
program intended to develop and enhance mindfulness skills in participants concurrently
enrolled in treatment for opioid use disorder with methadone maintenance
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pharmacotherapy. Mindfulness-based interventions are associated with significant
reductions in frequency and severity of substance use behaviors and cravings associated
with substance use relapse (Bowen et al., 2006; Brewer et al., 2010; Ostafin & Marlatt,
2008; Marlatt & Chawla, 2007; Witkiewitz et al., 2005). These outcomes suggest that a
mindfulness-based treatment intervention administered to participants concurrently
enrolled in MAT programs using methadone pharmacotherapy may result in reductions in
terms of frequency of illicit opioid use behaviors and severity of opioid cravings. This
provides a context for evaluating the potential utility of conducting subsequent larger
studies involving MBRP groups at multiple MAT programs, thereby evaluating MBRP
manualized treatment effects in terms of statistical power associated with larger groups of
study participants.
Research Questions and Hypotheses
RQ1: Is exposure to MBRP manualized treatment associated with changes in
frequency of illicit opioid use for individuals with opioid use disorder concurrently
participating in a MAT program?
H01: Exposure to MBRP manualized treatment is not associated with changes in
frequency of illicit opioid use for individuals with opioid use disorder concurrently
participating in a MAT program.
Ha1: Exposure to MBRP manualized treatment is associated with changes in
frequency of illicit opioid use for individuals with opioid use disorder concurrently
participating in a MAT program.
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RQ2: Is exposure to MBRP manualized treatment associated with changes in
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently
participating in a MAT program?
H02: Exposure to MBRP manualized treatment is not associated with changes in
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently
participating in a MAT program.
Ha2: Exposure to MBRP manualized treatment is associated with changes in
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently
participating in a MAT program.
Study Variables
The study was a quantitative design utilizing mixed within-between subjects
design with time as the within-subjects factor and groups as the between-subjects factor.
MANCOVA was to be used to evaluate relationships between the dependent and
independent variables over time (Cohen et al., 2003, p. 608).
The DVs in the study were: (a) participant illicit opioid use during the eight- week
study period as measured by the ASI Alcohol/Drugs subscale (McLellan et al., 1985)
outcomes positive for illicit opioids and participant illicit opioid craving severity as
measured by the OCS (McHugh et al., 2014).
The IV consisted of two levels: the first being provision of the MBRP (Bowen et
al., 2011) manualized treatment intervention as an adjunct to TAU in the experimental
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group of MAT program participants for eight-weeks, and the second consisting of TAU
in the control group of MAT program participants for the concurrent eight-week period.
A potential MV was level of participant mindfulness as measured by the TMS
(Lau et al., 2006) outcome scores. Investigation to determine the significance of this MV
was not included in the study design, although it was the subject of limited commentary.
The TMS was administered at pretest, midtest, and posttest intervals. Statistical
covariance data outcomes would likely reveal any significant mediating association
between changes in participant mindfulness and changes in dependent variables
outcomes. A positive significant scoring difference at posttest would suggest that the
participant increased his or her level of mindfulness in association with MBRP exposure,
whereas the absence of a significant difference in pre- and posttest scores would suggest
that there was not a change in participant mindfulness resultant from MBRP exposure. A
negative significant scoring difference would suggest that the participant decreased his or
her level of mindfulness in association with MBRP exposure.
The first research question for this study asked if participant exposure to the
MBRP manualized treatment is associated with reductions in percentage of illicit opioid
use for individuals concurrently participating in MAT for their opioid use disorder. The
research design addressed this research question through its measurement of this DV
associated with two levels of IV administration throughout the eight-week study period.
The second research question for this study asked if participant exposure to the
MBRP manualized treatment was associated with reductions in severity of illicit opioid
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craving for individuals concurrently participating in MAT for their opioid use disorder.
The research design addressed this research question through its measurement of this DV
associated with two levels of IV administration throughout the eight-week study period.
The study duration was 14 weeks, including phases for study participant
enrollment, pre-treatment data collection, administration of the MBRP manualized
treatment, posttreatment data collection, and participant debriefing. Participant
enrollment procedures were to begin at the MAT program site three weeks prior to
beginning the study.
Research regarding effects of mindfulness-based adjunctive interventions for
MAT program participants maintained on methadone pharmacotherapy is severely
limited, and thus far has not consistently included randomized, controlled designs. This
study addressed these concerns through its empirical methodology utilizing a minimal
number of group participants and relatively brief study period to minimize potential
adverse effects on study integrity such as time and fiscal constraints.
Study Population Characteristics
The target population was individuals in the U.S. with opioid use disorder who
are enrolled in MAT programs and who are maintained on methadone pharmacotherapy.
At the inception of study design, there were an estimated 270,000 patients serviced by
some 1,200 MAT program located throughout the US (SAMHSA, 2011). At the
conclusion of study implementation there were an estimated 350,000 methadonemaintained individuals enrolled in MAT programs (Alderks, 2017). Given changes in
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U.S. healthcare rules and associated increases in multiple states reflecting support for
treatment of opioid use disorder, the number of individuals enrolled in MAT programs
for treatment of opioid use disorder will likely continue to increase.
Sampling Procedures
Larger sample sizes reduce standard error and larger effect sizes increase
statistical power (Gravetter & Wallnau, 2007). Gravetter and Wallnau observed that a
type I error, where a treatment effect is falsely reported, can be reduced by decreasing
alpha level, whereas a type II error, where an extant treatment effect is not detected, can
be addressed through increasing effect size. They further noted that reducing standard
deviation reduces variance, thereby reducing standard error and increasing power and
effect size. A sufficient sample size thus must address these considerations.
Julious (2005) asserted that criteria for pilot study sample size include
considerations about feasibility, precision of mean and variance, and regulatory
requirements, where applicable. Julious observed that whereas larger studies have
specific recommendations in the literature to assure optimal levels of standard error and
statistical power at the chosen significance level, such standards have not been
consistently applied to pilot studies.
Mean and variance precision characteristics include consideration that whereas
increased sample size is associated with reduced standard error, sample size increases
beyond 12 participants are likely to yield decreasing reductions in standard error given
confidence interval of 0.95 (Julious, 2005). This suggests that for this study a sample size
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of 30 participants per group (n = 60) was likely to minimize standard error of the mean at
significance p ≤ 0.05. To assure optimal variance precision characteristics in a pilot study
Julious asserted that the sample size contain sufficient degrees of freedom such that a
future study would have sufficient statistical power at chosen significance (p ≤ 0.05) if
based on the prior pilot study. As recommended by Julious, a sample size assuring 20
degrees of freedom is sufficiently large to assure 50% statistical power given p ≤ 0.05. At
n = 45, this study would have assured greater than 20 degrees of freedom. This study
design reflected the preceding recommendations, thereby assuring equivalence between
the control group and experimental group. To account for possible participant dropout,
which could not be predicted, this study design was planned for number of participants n
= 60, including group n TAU = 30 and MBRP = 30.
Participant Inclusion and Exclusion Criteria
Study participants were individuals aged 18 years or more who are concurrently
enrolled in a medication assisted treatment (MAT) program located in California. Each
participant had a primary DSM-5 diagnosis of 304.00 opioid use disorder, severe, on
maintenance therapy (American Psychiatric Association, 2013). Federal guidelines
(SAMHSA, 2015) and California State regulations (Title 9, Section 4, Part 4) require that
patients meet these primary diagnostic criteria as a condition of MAT program
admission, unless an infrequently utilized regulatory exception process is initiated by the
program and approved by state and federal authorities. MAT program policies and
procedures (BAART Programs, 2015) specify that patients cannot be admitted into MAT
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unless they are minimally 18 years of age and able to provide informed consent to opioid
treatment. No participants were excluded provided they completed study informed
consent, maintained study participation, and maintained their concurrent MAT program
participation at the study site for the duration of the study. Study enrollment will not be
limited by sex, age (above adult status), ethnicity, race, educational level, or the presence
(or absence) of any co-occurring psychiatric or medical conditions.
A private room at the MAT program site was used for implementing study
interventions and data collection. Study materials were provided and study procedures
conducted in a manner sensitive to the strengths, needs, abilities, limitations, and
preferences of the participants (Commission on Accreditation of Rehabilitation Facilities
[CARF], 2012).
Study participation was voluntary, and post enrollment, participants were able to
withdraw at any time. Participants that did not complete the requisite informed consent
process were excluded from study participation.
Continued MAT program enrollment was required in order for an individual to
receive program services, including the MBRP group services (BAART Programs, 2015).
Thus, participants were required to maintain enrollment in the MAT program throughout
the duration of the study. In cases where a participant discontinued MAT program
enrollment during the eight-week study period his or her study enrollment was
discontinued.
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Each participant was required to maintain adherence with MAT program
participation standards for the duration of the study implementation period. For study
purposes, such adherence was defined in accordance with MAT program policy
requirements requiring that patients attend individual counseling sessions in accord with
the schedule identified on their respective individualized treatment plan, typically once
weekly for 50 minutes, and that patients ingest their methadone medication on a daily
basis as ordered by the program physician (BAART Programs, 2015). MAT program
requirements may additionally include patient participation in group therapy services,
including but not limited to MBRP, relapse prevention, and groups for support of
individuals experiencing he effects of trauma, grief, and loss (BAART Programs). Any
participant that demonstrated substantial MAT program requirement nonadherence
during the course of the study was discontinued from study participation and debriefed.
Examples of such nonadherence would include missing more than one scheduled
individual or group counseling session or more than two scheduled dosing appointments
during the eight-week MBRP intervention period. The principal investigator was
provided access to OTP program computer data systems to verify participant adherence
with MAT program requirements.
Participant Recruitment
Participant recruitment occurred at the MAT program site selected for study
implementation. For a three-week period prior to implementation phase of the study, an
informational flyer (Appendix B) was distributed to all MAT program patients by
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program front desk staff persons as they check in to the program for TAU services. This
flyer described the study purpose and procedures, outlined participatory requirements,
and provided principal investigator phone contact information to address any additional
questions or concerns participants may have prior to participant enrollment and study
implementation. The principal investigator was available at the program site during
normal operation hours to answer questions and implement study enrollment process for
interested MAT program patients. Participants were informed that a $ 25.00 debit card
would be provided to all those completing the study as required. Participants were
informed that discontinuing study participation prior to completion would result in
ineligibility for this compensation. A private room at the MAT program site was used for
study enrollment.
Participant Informed Consent Procedures
The study principal investigator facilitated the provision of informed consent for
each participant, though review, discussion, and signing of the study informed consent
document provided to each participant (See Appendix C). Participants were informed of
the study purpose, treatment methods to be used, how they will be provided with relevant
study outcome data, their right to discontinue the study at any time, and study personnel
identifying information, qualifications, and contact information. The meetings with
participants for purposes of effecting informed consent took place in a private office
located at the program site. Informed consent participant meetings occurred during the
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three weeks period prior to implementation of the eight-week MBRP manualized
treatment study phase.
Informed consent procedures were carried out in a manner consistent with all
Walden University IRB requirements and institutional approval letter stipulations.
Additionally, this study was conducted such that all state and federal laws regulating
MAT program patient privacy (HIPAA rule) and confidentiality (42CFR rule) are fully
adhered to for all study participants.
Types and Sources of Information or Data
Data sources included study participant reporting of the above-described testing
instrument outcomes. In order to assure privacy and confidentiality of the participants,
data outcomes for each participant were associated with a unique four-digit number
assigned by the principal investigator. Deidentified study participant record information
collected from the MAT program computerized patient record included participant MAT
program attendance records to assure participant continued in concurrent treatment for
the duration of the study. Deidentified participant record information collected from the
MBRP group services provider (the principal investigator) included dates of participant
attendance at each MBRP group meeting group session and records of participant weekly
MBRP homework assignment completion. Deidentified participant record information
collected by the principal investigator from all participants included pretest, midtest, and
posttest scores for the TMS (Lau et al., 2006), ASI Alcohol/Drugs subscale (McLellan et
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al., 1985), and OCS (McHugh et al., 2014). Participant report of an adverse event (see
Appendices E and F), if any, would also have been collected, however there was none.
Data Collection Procedures
Participants were randomly assigned to either the treatment group (n = 30) or
control (TAU) group (n = 30). Random participant (n = 60) assignment to either
treatment or control group was achieved through use of a randomization table. After
selection, each participant was assigned a unique four-digit identifier that was associated
with all study data collected about that participant. A key tying the randomized
participant assignment identifying numbers to the participant names was securely
maintained by the principal investigator in an encrypted file format stored on secure
computer system with the encryption key known only by the principal investigator. Raw
test data was retained in secure, private storage using a locked file cabinet by the
principal investigator for subsequent scoring and recording data outcomes in the study
database. All study data was retained in a manner that ensures adherence with participant
privacy and confidentiality rules. Only participant ID numbers were noted on any study
test materials. No participant names were used on any study data other than the
aforementioned encrypted key log. The study database consisted of outcomes for all
measures previously identified in participant recruitment and data collection procedures.
A private room at the MAT program site was used for implementing study data
collection. Study materials were provided and study procedures conducted in a manner
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sensitive to the strengths, needs, abilities, limitations, and preferences of the participants
(Commission on Accreditation of Rehabilitation Facilities [CARF], 2012).
Pretest Data Collection
The pretest data collection phase occurred during weeks three and four, prior to
the first MBRP group meeting. The principal investigator met with each study participant
(in both study groups) individually in a confidential, private setting at the MAT program
site, and administered the pretest ASI Alcohol/Drugs subscale (McLellan et al., 1985),
OCS (McHugh et al., 2014), and TMS (Lau et al., 2006) measures.
Midtest Data Collection
For Midtest data collection the principle investigator met with each study
participant (in both groups) individually in a confidential, private setting at the MAT
program site, and administered the midtest ASI Alcohol/Drugs subscale (McLellan et al.,
1985), OCS (McHugh et al., 2014), and TMS (Lau et al., 2006) measures.
The principal investigator met with the MAT program MBRP group participants after the
fourth group meeting (end of study implementation week 8) to collect data on MBRP
group participation. This data collection consisted of several elements for each MBRP
participant, including the dates of participant MBRP group attendance, participant
completion of weekly MBRP assignments, a review of MAT program adherence data for
all participants, a review of MBRP group facilitator adherence with MBRP group
administration manualized procedures, and a review of any adverse event reporting. The
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preceding data was recorded in a computer spreadsheet securely retained by the principal
investigator for subsequent discussion.
Posttest Data Collection
Weeks 13-14 comprised the study posttest data collection phase wherein the
principle investigator met with each study participant (in both groups) individually in a
confidential, private setting at the MAT program site, and administered the posttest ASI
Alcohol/Drugs subscale (McLellan et al., 1985), OCS (McHugh et al., 2014), and TMS
(Lau et al., 2006) measures.
This data collection for each MBRP participant included the dates of participant
MBRP group attendance, tracking the completion of weekly MBRP assignments, review
of MAT program dosing and counseling requirements adherence, review of MBRP group
facilitator adherence with MBRP group administration manualized procedures; and
review of any participant adverse event reporting.
Management of Potential Adverse Effects
The principal investigator was responsible for meeting with study participants
reporting adverse events. Adverse event data would have been immediately reported to
the Walden IRB, however, no adverse events were reported. Documentation of adverse
event data would be securely retained in a locking file cabinet accessible only to the
principal investigator. Participants were informed that should they experience such events
they may inform the principal investigator of their concerns and will then be immediately
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excused from further MBRP group participation until the concerns can be satisfactorily
resolved, if possible, or their study participation discontinued.
Although any adverse effects from study participation were considered unlikely,
during the course of the study all participants reporting any unanticipated adverse effects
would be assessed and appropriately referred by the principal investigator. Such
assessment proved unnecessary, as no such adverse events were reported. This
assessment would have included the following elements: (a) eliciting participant
reporting of adverse effects thought to be associated with study participation; (b)
documentation of reported adverse effects; (c) discussion of and documentation of
participant consent to disclose in accord with provisions and restrictions of Federal
Confidentiality Rule for Alcohol and Drug Treatment programs (42CFR); (d) report of
adverse effects and referral to the MAT program physician for further evaluation and
development of recommended course of treatment, if any; (e) an explanation to
participant that given the reported adverse effect he or she may discontinue study
participation immediately; (f) an explanation to participant that his or her MAT program
enrollment status will not be affected by any reporting of adverse effects; and (g)
reporting of the adverse event and its outcome to the Walden IRB. Because no adverse
events were reported, implications of adverse event data were not analyzed by the me.
Participant Post-Study Debriefing
All active participants were debriefed at the conclusion of the study
implementation phase by the principal investigator. No further follow-up requirements
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were required of study participants, and at the debriefing meeting each participant
completing the study received the participation compensation as explained during the
study informed consent process. Participants that discontinued the study prior to
completion of all data collection phases were offered debriefing services by the principal
investigator, regardless of the reason for study discontinuance. Upon completion of the
study data analyses all participants were offered a summary of the study outcomes and
findings without charge. Participants in the control group were offered MBRP
manualized treatment adjunct services after the conclusion of study debriefing.
Summary of Study Procedures
Table 2 depicts a summary outline of previously described study operational
procedural elements:
Table 2
Outline of Study Procedures
________________________________________________________________________
Study Phase and Description
Period
_______________________________________________________________________
Study information provided to potential participants
Informed consent obtained from participants
Pre–test data collection
MAT Program staff provides MBRP to participants
Posttest data collection and participant debriefing

Weeks 1 and 2 (before MBRP starts)
Weeks 1-3 (before MBRP starts)
Weeks 3-4 (before MBRP starts)
Weeks 5-12 (MBRP administered)
Weeks 13-14 (after MBRP ends)
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Nature of MBRP Manualized Treatment Intervention
The MBRP manualized treatment is an eight-week structured clinical intervention
course where participants meet once weekly in a private setting at the MAT program site
for up to two hours (as needed to complete proscribed MBRP treatment activities) with a
MAT program staff person designated by the MAT program, who will function as group
facilitator; conducting daily individual guided meditation practice exercises, participating
in conceptual discussion of relevant manualized treatment topics, and reviewing and
completing CBT-oriented treatment assignments (Bowen et al., 2011). The first session
consists of an introduction to the course requirements and two mindfulness meditation
exercises (Bowen et al.). Each subsequent session includes a review of the homework
assigned to study participants during the previous session, discussion of participants’
mindfulness meditation practice experience during the prior week, interactive discussion
of mindfulness and relapse prevention practices and approaches, guided mindfulness
meditation exercises, review and discussion of the following weeks’ homework
assignments, and closing remarks. The MBRP manualized treatment (Bowen et al.)
structure is described in detail in Chapter 2 and Appendix A of this proposal.
Study Instrumentation and Construct Operationalization
This experimental design attempted to evaluate whether there is an association
between participant exposure to the MBRP manualized treatment adjunct and percentage
of participant illicit opioid use. This was achieved through between groups comparison of
the dependent variables for illicit opioid use, and levels of participant mindfulness. Data
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outcomes evaluation using repeated measures MANCOVA were planned to be conducted
at significance (p < .05).
The ASI Alcohol/Drugs subscale (McLellan et al., 1985) was administered at
pretest, midtest, and posttest intervals by the principal investigator. ASI Alcohol/Drugs
subscale scoring outcomes were reviewed by the principal investigator to assure data
collection and interpretive accuracy. The OCS (McHugh et al., 2014) was administered at
pretest, midtest, and posttest intervals by the principal investigator. OCS scoring
outcomes were reviewed by the principal investigator to assure data collection and
interpretive accuracy. The TMS (Lau et al., 2006) was administered at pretest, midtest,
and posttest intervals by the principal investigator. TMS scoring outcomes were
evaluated for possible mediating effects on ASI and OCS outcomes. TMS scoring
outcomes were reviewed by the principal investigator to assure data collection and
interpretive accuracy.
Quantitative analysis of the multiple independent and dependent study variables
was planned using MANCOVA. If an inverse covariability were to be found between
experimental group participant exposure to MBRP and illicit opioid substance use as
predicted by the first alternative hypothesis, then the first null hypothesis would be
rejected in favor of the first alternative hypothesis. This outcome would suggest that
administration of MBRP manualized treatment to concurrently enrolled MAT program
patients is associated with significant reductions in illicit opioid use. If an inverse
covariability were to be found between experimental group participant exposure to
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MBRP and illicit opioid craving as predicted by the second alternative hypothesis, then
the second null hypothesis would be rejected in favor of the second alternative
hypothesis. This outcome would suggest that administration of MBRP to concurrently
enrolled MAT program patients manualized treatment is associated with significant
reductions in illicit opioid craving.
Materials required for the administration of all test measures included printed
versions of each measure, pens for indicating line item responses, and a comfortable
private setting where the participants can be interviewed. These were readily available at
the MAT program site. Substance use scoring outcomes were reviewed by the principal
investigator to assure data collection and scoring accuracy. Finally, the strength of this
study’s quantitative methodology was enhanced through minimization of extraneous
variable effects achieved by conducting the experiment in the MAT program
environment known to the study participants.
Addiction Severity Index
The fifth edition of the ASI (McLellan et al., 1985) evaluates for examinee
functioning across multiple domains, asking lifetime problem frequency for a total
number of years, where the problem was evidenced at least once during any year, and
problem frequency within past 30 days, where the problem was evidenced at least once.
Using a Likert scale design the examinee indicates problem severity and need for
treatment: not at all, slightly, moderately, considerably, or extremely (McLellan et al.).
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Using a Likert scale design from 0 to 4, the examiner then indicates three
evaluative items for each ASI functional domain: Problem severity ratings; The
examinee’s ability to understand the test questions; and the examinee’s ability to answer
test items honestly and accurately (McLellan et al., 1985).
The ASI demonstrates strong concurrent reliability (α = .89) and consistent
validity and reliability scores for widely diverse substance use disordered populations
(Leonhard et al., 2000; McLellan et al., 1985). Butler et al. (2001) found that one-month
test-retest reliability of the ASI drug use domain index is strong (α = .77), as is criterion
reliability for the drug use domain index (r = .67).
Mäkelä (2004) found inconsistent reliability in non-English version ASI
interviewer severity ratings and composite scoring, attributed to insufficient interviewer
training and combined composite scoring methodologies that may artificially reduce
index score levels. McLellan, Cacciola, and Alterman (2004) asserted the ASI is in
revision with the intention of improving reliability. The standard English version of the
ASI will be used in this study, and will be administered by the principal investigator, who
has extensive experience in ASI administration and interpretation.
This study used the ASI Alcohol/Drugs subscale data pertaining to illicit opioid
use. This ASI subscale is scored through weighted summing of individual item results
within each subscale. Index composite score ranges from no problem severity (0.00) to
very high problem severity 1.00 (Cacciola et al., 1997). Scoring methodology includes
dividing each test item response by 30 (reporting period in days), summing the results,
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and dividing by the total number of test items (McGahan et al. 1986). The final two test
items asking for examinee reporting of problem disturbance level and desire for treatment
are divided by 4, then by 13 (McGahan et al.). A composite subscale score for the drug
use domain at or near 1.00 thus indicates severe substance use. The ASI Alcohol/Drugs
subscale is in the public domain.
Opioid Craving Scale
This study used the OCS to measure severity of participant cravings for illicit
opioids. The OCS consists of three visual analogue scale items measured in 0 (no desire
for opioids) to 10 (strong desire for opioids) for item one, and in severity from 0 (no
severity) to 10 (extremely strong severity) for the remaining two items. The first scale
asks the participant to evaluate the strength of desire to use opioids during the past 24
hours. The second scale asks the participant to rate how strong desire to use opioids has
been during the past week when exposed to an environmental cue associated with opioid
use. The third scale asks the participant to recall the most recent environment and time of
day where he or she used opioids and rate the likelihood of opioid use if the participant
were in that environment at that time today (McHugh et al., 2014). The scoring
methodology for this scale consists of averaging the three individual scale outcomes
together for a composite craving severity score (McHugh et al.).
The OCS appears to demonstrate strong reliability and validity. Using Spearman’s
rho, Mann-Whitney U, and Kruskal-Wallis testing, McHugh et al. (2014) found that the
OCS demonstrated strong internal consistency and reliability (.85 to .92, p < .001), and
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strong concurrent and predictive validity for illicit opioid use (OR = 1.17, 95% CI = 1.11,
1.22 , p < .54). For the OCS, a composite score close to 0 would suggest little to no
craving, whereas a composite score close to 10 would suggest severe craving likely
predictive of illicit opioid use. The OCS is in the public domain.
Toroto Mindfulness Scale
The TMS measures two factors considered essential components of mindfulness:
curiosity and decentering. In psychometric evaluations by Lau et al. (2006), the TMS
evinced high internal consistency (α = .95), with statistically significant factor loadings
for curiosity (α = .56) and decentering (α = .82), and internal consistency of the two
scales were (α = .86) and (α = .87). Lau et al. noted that composite reliability scores were
robust for curiosity (CR = .93) and decentering (CR = .93). Criterion validity is supported
by significantly higher scores evidenced on both factors for post versus pre MBSR
training groups, as well as for mindfulness meditators with greater than one-year
experience versus those with less than one year of meditation experience (Lau et al.).
Lau et al. (2006) described how the measure consists of 13 questions associated
with factors contributing to mindfulness, requiring approximately three minutes for
administration. The examinee indicates level of agreement with the test item statement
using the Likert scale design: 0 - not at all, 1 - a little, 2 – moderately, 3 - quite a bit, or 4
- very much.
Curiosity index scores are derived from individual test item scores for 3, 5, 6, 10,
12, and 13; while decentering scores are obtained from individual test item scores for 1,
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2, 4, 7, 8, 9, and 11 (Lau et al., 2006). Higher scores indicate increased clinical evidence
of mindfulness effects in the test subject (Lau et al.). The TMS appears psychometrically
sound and will require little administration time. The TMS is in the public domain.
Operationalization of DVs and IVs
Only data collected during the study implementation period was used. This period
was defined as two weeks prior to start of MBRP group services to participants,
concluding two weeks after conclusion of same. No archival data was used. For the first
research question, the DV was frequency of illicit opioid use as measured by ASI
Alcohol/Drugs subscale scoring outcomes. For the second research question, the DV was
participant OCS scoring outcomes.
Each ASI Alcohol/Drugs subscale outcome score greater than zero for opioids
indicates the participant used illicit opioids for one or more days during the past month
and will be considered as an illicit opioid positive result. An example of an ASI
Alcohol/Drugs subscale result positive for illicit opioids is where any illicit opioid use is
reported for five of the past 30 days. Each Opioid Craving Scale composite scale score
of five (moderately severe craving) or greater is considered as representative of
participant illicit opioid craving.
The IV consisted of two treatment levels: provision of the MBRP (Bowen et al.,
2011) manualized treatment intervention to the experimental group of MAT program
participants (in addition to TAU) for the proscribed eight-week period, and the control
group of MAT program participants (TAU only) for the proscribed eight-week period.
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Any experimental group participant not attending at least six of the eight MBRP
group sessions while consistently participating in TAU at the MAT program was
considered as not meeting the IV requirement, identified as a study dropout, and this
outcome so noted in the study data analysis. Where possible, dropout participants were
debriefed and their data was not used for the quantitative analysis of the study.
The control group experienced TAU as it is consistently practiced within the
context of the MAT program, excluding MBRP group participation. For the control group
any participant not consistently participating in TAU for the eight-week study period was
considered as not meeting this IV requirement, identified as a study dropout, and this
outcome so noted. Study dropout participant data was not be utilized for purposes of
study quantitative data analysis. The only between groups variable was administration of
the MBRP manualized treatment.
Data Analysis Plan
Statistical Software and Data Validation
Software planned for use in data analysis in this study was the Statistical Package
for the Social Science (SPSS; International Business Machines, 2009), with the alpha
value set at .05 for all statistical procedures used. All outcomes data were planned to be
uploaded into a computer running SPSS software and results that will be calculated by
the SPSS program. Each participant data entry record was to be reviewed against the
original documentation provided by the study site coordinator to assure data entry
integrity. A complete descriptive data analysis procedure was to be run on all study
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variables using the SPSS program, thereby crosschecking to assure that data outliers or
entry errors are not significantly skewing data outcomes. Finally, the SPSS Data
Validation procedure was to be run to assure that missing or erroneous data entries are
not influencing data analyses outcomes. The principal investigator was responsible to
assure that all outcomes data were accurately transcribed, that appropriate statistical tests
were run, and that inferences made from these results would be interpreted accurately in
accord with the statistical model used (MANCOVA) and experimental design utilized.
Despite the data analysis plan described above the principal investigator was
unable to carry out as planned due to unforeseen high levels of participant dropout. This
confound led to an insufficient number of participants remaining in the MBRP group
(n=3), thereby invalidating data analysis due to inability to achieve sufficient statistical
power.
Research Questions and Hypotheses
RQ1: Is exposure to MBRP manualized treatment associated with changes in
frequency of illicit opioid use for individuals with opioid use disorder concurrently
participating in a MAT program?
H01: Exposure to MBRP manualized treatment is not associated with changes in
frequency of illicit opioid use for individuals with opioid use disorder concurrently
participating in a MAT program.
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Ha1: Exposure to MBRP manualized treatment is associated with changes in
frequency of illicit opioid use for individuals with opioid use disorder concurrently
participating in a MAT program.
RQ2: Is exposure to MBRP manualized treatment associated with changes in
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently
participating in a MAT program?
H02: Exposure to MBRP manualized treatment is not associated with changes in
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently
participating in a MAT program.
Ha2: Exposure to MBRP manualized treatment is associated with changes in
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently
participating in a MAT program.
Data Analysis Methods
This study planned for use of a quantitative, randomized, controlled design
utilizing repeated measures of dependent variables and a single measure of a between
groups independent variable. It reflected a mixed within-between subjects design with
time as the within-subjects factor and groups as the between-subjects factor.
Quantitative Methodologies
Cohen et al. (2003) said MANCOVA is used for statistical evaluation research
designs where there are multiple DVs and IVs. This supports a study design and
correspondent statistical model for evaluation of relationships between multiple, distinct
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IVs and DVs over time. Cohen et al. further suggested that requisite properties for the
MANCOVA test include utility when examining non-nominal multivariate factors,
calculating partial variance, determining multivariate significance, and calculating
“measures of association, parameter estimation, hypothesis testing, and statistical
analysis” (p. 609) within a unified conceptual statistical approach. Given the complexity
of multivariate data gathered over distinct periods in this study, MANCOVA testing was
considered the most effective method of statistical analysis.
Gravetter and Wallnau (2007) and Cohen et al. (2003) suggested that when an
experiment consists of three or more treatment conditions use of t-tests would result in
accumulation of type I errors from each test, collectively known as the experiment-wise
alpha level. A single MANCOVA test can simultaneously test all means using one alpha
level, thereby avoiding the inflated alpha error effect. Real world participant sampling
suggests the possibility that unequal sample sizes must be compared due to unanticipated
phenomena such as participant drop out. MANCOVA provides a valid test with sufficient
sample size where groups are sufficiently large: n ≥ 12 for pilot studies (Julious, 2005),
and sample size differences are not too great.
The preceding MANCOVA methodology assumed that a minimum of number of
participants (n ≥ 12) would complete the entire study, would consistently attend study
MBRP group meetings, and would participate in and complete study measures as
scheduled for the pretest, midtest, and posttest measure administration. The most direct
and comprehensive way to assure these assumptions were made was to enroll a sufficient
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number of participants such that even with participant dropout the minim number of
participants would remain.
Threats to Validity
External Validity Threats
An important consideration here is that of extraneous variables caused by TAU
effects. Generally, TAU for the MAT program patient includes daily methadone
pharmacotherapy administered by a program nurse, weekly individual counseling
sessions, and appointments with program medical staff where indicated (Batki et al.,
2005). Inconsistencies in TAU services frequency or quality may exert unknown effects
on participants, possibly influencing substance use behavior, study participation, or test
item response data. This study was designed to control for these potential extraneous
variables through use of random participant assignment and a control group.
Other validity threats could arise through distinctions in MAT program
counseling styles and therapeutic approaches used, or from differences in counselor
education, training, and experience. Batki et al. (2005) and McCann et al. (1994) asserted
there is considerable variability in therapeutic approaches and counselor education and
training at MAT programs. At the MAT program site used for the study clinical
approaches attempts were made to support consistency in clinical approach through use
of mandatory organizational training and work implementation standards based on
implementation of standardized policy and procedure (BAART Programs, 2013). All
counselors at the site were trained in a central approach based on acceptance, empathy,
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genuineness, and unconditional positive regard (Miller et al., 1999; Rogers, 1961; 1980),
and in use of motivational interviewing practices (Miller & Rollnick, 2002). Whereas the
preceding TAU variables argue for caution in interpretation of experimental results, the
inclusion of randomized participant assignment and a control group was intended to
protect study outcomes from these potential validity threats.
Distinctions in participant lived experience, personality, and behavior may have
exerted unknown confounding effects. Extraneous variability could arise from varied
levels of participant knowledge and skill level relevant to mindfulness practices, or from
naïve participant mindfulness states and traits. These distinctions could result in
differences in participant conceptual and experiential levels of mindfulness, thereby
exerting effects on individual participant meditation practice and efficacy of mindfulness
practices integration. Random participant assignment and use of a control group in this
study design were planned to reduce such potential effects.
Lau and McMain (2004) asserted that key to effective mindfulness research is the
use of research personnel experienced in mindfulness practices prior to teaching others.
This study addressed this potential source of variability through use of the principal
investigator, who held the requisite training and experience in use of the MBRP
manualized treatment; as the MBRP group facilitator.
Internal Validity Threats
Nastasi and Schensul (2005) observed that confirmation bias may occur in
quantitative research approaches when the observer is focused on hypothesis testing such
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that extraneous, relevant data is overlooked and illusory correlations are formulated.
Johnson and Onwuegbuzie (2004) cited multiple internal validity threats, including
foreclosure effects, where relevant data is erroneously ruled out, and discounting error,
where an expected association is found and other potentially relevant associations are not
considered. The study attempted to address confirmation bias potential through use of
randomized participant assignment, use of a control group, use of data crosschecking
methods, and critical exploration of study limitations.
In this study selection, bias could arise through reliance on voluntary participant
enrollment, where individuals with certain, potentially confounding characteristics seek
study participation. Participants could be predisposed toward an interest in mindfulness
practices or have historical experience with such practices that confounds study
outcomes. These potential participant-biasing effects were controlled through pretest,
midtest, and posttest measures administration, and through use of a control group.
Quantitative investigational approaches may be limited in that their
operationalization methods fail to accurately or sufficiently reflect participant
understandings of the treatments and measures offered during the course of the study
(Johnson & Onwuegbuzie, 2004). This issue was addressed through use of clearly
established quantitative interventional and evaluative methods and procedures
implemented within the experiential context of the MAT program familiar to study
participants, thereby likely facilitating participant comprehension of and accurate
responding to the measures and procedures used in this investigative effort.
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Regression and correlation analyses must be interpreted with caution. Linear
correlations cannot be used to determine causal relationships or the reason for them
(Gravetter & Wallnau, 2007). Correlational evaluations are vulnerable to limitations
posed through unintended effects of data range limitations, outliers, regression toward the
mean, and insufficient sample size. In this study, correlations between measured pretest,
midtest, and posttest outcomes were intended for use in asserting a causal relationship
exists between MBRP manualized treatment effects and any observed correspondent
reduction in illicit opioid use.
Ethical Procedures
Agreement for Participant and Data Access
This study was conducted at a MAT program site located in the California
Bay Area. The agency that operates the MAT program at this site is BAART Programs,
Inc. This study was implemented in accordance with specific permissions allowing MAT
program site and patient access and use of patient data as delineated by the BAART
Programs (See Appendix D). All such access and use was conditional upon strict
adherence by all study investigative personnel to regulatory standards regarding MAT
program patient privacy and confidentiality restrictions and provisions and delineated in
the Health Insurance Portability and Accountability Act (HIPAA; U.S. Department of
Health and Human Services, 2003); the confidentiality regulations for drug and alcohol
patient treatment programs (Confidentiality of Alcohol and Drug Abuse Patient Records
Rule, 1987); the standards for research as promulgated by the NIH Office of Extramural
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Research (2008); and existing BAART Programs policy and procures pertaining to
research conducted at a program site delineated in the BAART Programs Policy and
Procedures Manual (2015). Individual participant data gathered during the course of this
study was private and confidential, and was not shared with the MAT program personnel.
Institutional Permissions
Ethical considerations for this study included assuring advance Walden
Institutional Review Board approval and obtaining consent of the sponsoring program’s
senior management team and board of directors (APA, 2010). Institutional permission for
participant and data access and usage were obtained from BAART and BayMark
Programs (See Appendices D, H). Walden University IRB Approval was obtained and
the approval number was 05-11-18-0067220.
The study participants were informed of the study purpose, methods to be used,
and data outcomes and conclusions. Participants were informed of their right to
discontinue the study at any time and were provided needed qualifications and contact
information for study personnel. All participants were debriefed after study intervention
and data collection was ended. Although not anticipated, unintended effects on
participants, including any identified adverse effects, would have been evaluated by the
principal investigator and referrals made if indicated. All participants were to receive a
copy of the final research report without charge. The study was conducted in accord with
established research guidelines (NIH Office of Extramural Research, 2008) and MAT
program privacy and confidentiality regulations relevant to research conducted on site
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(Confidentiality of Alcohol and Drug Abuse Patient Records Rule, 1987; NIH Office of
Extramural Research; U.S. Department of Health and Human Services, 2003).
Considerations in Participant Recruitment
Assurance of participant confidentiality and privacy is essential to protect
participants from unauthorized disclosure, to ensure requisite trust for complete and
accurate participant data reporting, to assure adherence to American Psychological
Association ethical standards (APA, 2010), and to protect study personnel and the MAT
program organization from undesirable legal consequences (Creswell, 2003;
Confidentiality of Alcohol and Drug Abuse Patient Records Rule, 1987; U.S. Department
of Health and Human Services, 2003). All participants in this study were recruited based
on provision of informed consent, and all discussion pertaining to the informed consent
process was carried out in a confidential, private setting at the MAT program site.
Participants were provided with principal investigator contact information in order to
facilitate timely responses to any emerging participant questions or concerns. All such
queries were to be responded to as soon as possible, at the most within seven calendar
days, although no adverse events were reported.
Intervention Considerations
To the fullest extent possible, the principal investigator assured that biases were
not allowed to affect the study, and the research plan included fully discussing any biasbased limitations in the research report (APA, 2010; Creswell, 2003; NIH Office of
Extramural Research, 2008). An extensive body of mindfulness research suggests that
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mindfulness-based practices and research are beneficial to participants, and have not
resulted in any harm (Brantley, 2007; Brewer et al., 2010; Chang et al., 2004; Davidson
et al., 2003; Farb, Anderson, and Segal, 2012; Jain et al., 2007; Kabat-Zinn, 2002; 2009;
Modinos et al., 2010; Shapiro & Schwartz, 2000; Witkiewitz et al., 2005; Zeidan et al.,
2013). Multiple studies using the MBRP manualized treatment have been implemented
and concluded without any observed or reported harm to participants (Bowen et. al.,
2006; Bowen et al., 2009; Bowen et al., 2011; Marlatt, 2006; Marlatt & Chawla, 2007;
Witkiewitz et al., 2005). In their systematic review of multiple meditation studies Arias et
al. (2006) found some case reports of practitioners participating in extended mindfulness
retreats experiencing the onset of recurrent dissociative effects. They found other case
reports where practitioners experienced a sense of detachment or affective flattening, or
of increased awareness of uncomfortable personal or life situations. However, overall
Arias et al. found that most mindfulness practice participants perceived overall benefit
from their meditative experiences. Considered altogether, these studies suggest that the
risk to mindfulness practice participants is minimal. Given that the MBRP group services
were provided by the principal investigator, and that this study evaluated data collected
concurrently from both TAU without the group and including the group, risk to study
participants was considered minimal. In the unlikely event that an adverse condition had
arisen from participation in this study, clinical evaluation and referral would have been
provided to the affected participant without charge.
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Data Collection, Use, and Storage
The principal investigator was responsible for assuring privacy and security of all
participant test documentation in accord with confidentiality and privacy rules pertaining
to MAT programs. All documentation of participant informed consent, and study raw
data and outcomes was stored in a private, locking file cabinet accessible only to the
study principal investigator. All study data relevant to each participant was associated
with a unique participant ID number assigned by the principal investigator. A data key
was securely retained in a separate password protected computer file retained by the
principal investigator that linked participant names to their unique ID numbers. Aside
from this procedure, no participant names, birthdates, social security numbers, addresses,
phone numbers, email addresses, or other information that could potentially be used by
unauthorized persons to identify any participant was collected, stored, or used as part of
the study implementation procedures. Study outcome data was planned to be summarized
and made available without charge to interested study participants and to the BAART
Programs administrative staff with oversight responsibility for the study. Study materials,
including all testing data and outcome measures and SPSS database information were,
and will continue to be, securely retained for a period of five years as required by Walden
University standards. Once that time period has elapsed all study data will be securely
destroyed.
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Assuring Participant Privacy and Confidentiality
Information in the MAT program patient record is referred to as Protected Health
Information (PHI), and conditions for collection and use of PHI are set forth in the body
of federal rules known as the Health Insurance Portability and Accountability Act
(HIPAA; U.S. Department of Health and Human Services, 2003). MAT program patients
have specific rights pertaining to how their PHI is used by the program and disclosed to
others. PHI encompasses any health record information that is under the control of the
program, and any personal information known about the patient that could be used to
identify the patient. Generally, MAT programs use PHI to assist them in providing
treatment services, sharing patient information with other agencies or individuals given
that a written consent to disclose is in effect, and for disclosure to the patient.
PHI data is subject to the minimum disclosure necessary principle, suggesting that
only the minimum information required for achieving the authorized disclosure may be
communicated, and to the need to know principle, meaning that only individuals with a
need to know in order to carry out indicated patient services are informed of PHI (U.S.
Department of Health and Human Services, 2003; BAART Programs). All patients must
receive a notice about how the program will use and disclose their PHI (U.S. Department
of Health and Human Services).
The federal rules also provide for unique MAT program patient confidentiality
protections under the body of rules commonly identified as 42 CFR (Confidentiality of
Alcohol and Drug Abuse Patient Records Rule, 1987). Alcohol and drug treatment
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programs are prohibited from disclosure of any patient information without the written
consent of the patient, and any further or subsequent disclosure of such authorized
information is prohibited without additional specific written consent. The 42 CFR
delineates the specific elements required for a patient’s consent to disclose and describes
circumstances and procedures for legal proceedings where such disclosure may be
requested with and without patient consent. Through utilization of unique participant
identifying numbers throughout data collection and analyses the research procedures used
in this study did not involve collection or disclosure of any patient identifying data, and
thus did not violate any privacy or confidentiality rules.
The NIH Office of Extramural Research specifies a number of conditions that
human participant research must satisfy, including protections against participant harm,
right to participant discontinuance at any time, and assurance of informed consent
processes for each participant (NIH Office of Extramural Research, 2008). This study
rigorously adhered to all such NIH research requirements.
Additional Ethical Considerations
The principal investigator had oversight of all aspects of participant study
involvement. The principal investigator is trained, experienced in, and responsible for
evaluating administration of the MBRP treatment protocol (Bowen et al., 2006; Bowen et
al., 2009; Bowen et al., 2011) to study participants during the eight-week study period.
Upon completion of the study, participants who remained in the study for the full
implementation period received a $ 25.00 gift card as compensation for their participation
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efforts. This was intended to foster consistency in study participation throughout the
implementation period.
Summary of Study Design and Methodology
This was a quantitative randomized controlled single-site pilot study design using
repeated measures of DVs and IVs. It reflected a mixed within-between subjects design
with time as the within-subjects factor and groups as the between-subjects factor.
MANCOVA was planned for use to statistically evaluate relationships between multiple,
distinct IVs and DVs over time (Cohen et al., 2003).
The study principal investigator provided the MBRP manualized treatment
adjunct. Study participants met individually with the principal investigator in a private
setting at the study site for pretest, midtest, and posttest administration of the TMS to the
experimental and control groups.
All treatment groups participated in TAU correspondence with that of the typical
MAT program participant, which included planned daily program attendance, daily
administration of the medication(s) prescribed by the MAT program physician, and once
weekly individual counseling sessions of 50 minutes duration.
The IV for the quantitative methodology used in this study consisted of two
adjunctive treatment levels: the first being administration of the MBRP manualized
treatment intervention to the experimental group of MAT program participants for the
proscribed eight-week period; and the second consisting of the control group of MAT
program participants for the proscribed eight-week period. The DVs were ASI
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Alcohol/Drugs subscale outcomes collected at pretest, midtest, and posttest intervals and
OCS outcomes collected at pretest, midtest, and posttest intervals.
Testing for existence of a significant experimental effect was planned through use
of quantitative analyses of within- and between-groups effects on pretest, midtest, and
posttest outcome scores of the ASI Alcohol/Drugs subscale (McLellan et al., 1985) and
the OCS (McHugh et al., 2014). Comparative data evaluation using repeated measures
MANCOVA was planned to be conducted (p < .05), although as previously mentioned
could not be carried out due to very high participant dropout rate.
Temporal association of MBRP manualized treatment participation with
significant reductions in illicit opioid use would have suggested that the first null
hypothesis was not supported and the first alternative hypothesis was supported.
Temporal association of MBRP manualized treatment participation with significant
reductions in illicit opioid cravings would have suggested that the second null hypothesis
was not supported and the second alternative hypothesis was supported. No significant
increases in mindfulness within the experimental group over time as measured by TMS
(Lau et al., 2006) outcomes would have suggested the absence of mindfulness effects as a
MV. In general, the presence of a significant negative (inverse) correlation between
increased levels of mindfulness and decreased frequency of illicit opioid use and/or
cravings would have suggested that mindful states are a factor influencing participant
mediation of illicit opioid use and cravings.
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This study documentation now proceeds to Chapter 4 wherein data outcomes,
statistical analyses, and implications of results and findings are discussed.
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Chapter 4: Results
Introduction
In Chapter 4, data collection outcomes are reported, including a discussion of
implementation discrepancies in the study design resulting from feasibility impediments.
Statistical analyses considerations are offered, and implications of study implementation
and data collection results and findings are discussed.
Summary of Study Design and Methodology
This study involved using a quantitative randomized controlled single-site pilot
study design with repeated measures of dependent and independent variables. I used a
mixed within-between subjects design with time as the within-subjects factor and groups
as the between-subjects factor. MANCOVA was used to statistically evaluate
relationships between multiple distinct IVs and DVs over time.
Research regarding the effects of mindfulness-based adjunctive interventions on
MAT program participants is severely limited, and thus far has not involved randomized
controlled designs. The study involved using a minimal number (n=54) of group
participants and a brief study period minimizing potential adverse effects on study
integrity involving time and fiscal constraints.
Research Questions and Hypotheses
RQ1: Is exposure to MBRP manualized treatment associated with changes in
frequency of illicit opioid use for individuals with opioid use disorder concurrently
participating in a MAT program?
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H01: Exposure to MBRP manualized treatment is not associated with changes in
frequency of illicit opioid use for individuals with opioid use disorder concurrently
participating in a MAT program.
Ha1: Exposure to MBRP manualized treatment is associated with changes in
frequency of illicit opioid use for individuals with opioid use disorder concurrently
participating in a MAT program.
RQ2: Is exposure to MBRP manualized treatment associated with changes in
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently
participating in a MAT program?
H02: Exposure to MBRP manualized treatment is not associated with changes in
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently
participating in a MAT program.
Ha2: Exposure to MBRP manualized treatment is associated with changes in
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently
participating in a MAT program.
Study Variables
The study involved use of a quantitative mixed within-between subjects design
with time as the within-subjects factor and groups as the between-subjects factor.
MANCOVA was used to evaluate relationships between DVs and IVs over time.
The DVs in the study were participant illicit opioid use during the 8-week study
period (concurrent with MBRP group participation) as measured using the ASI
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Alcohol/Drugs subscale (McLellan et al., 1985) and participant illicit opioid craving
severity as measured by the OCS (McHugh et al., 2014).
The IV in the study consisted of two levels: the first being the MBRP manualized
treatment intervention as an adjunct to TAU for the experimental group of MAT program
participants for the requisite eight week period, and the second being TAU in the control
group of MAT program participants for the concurrent eight week period.
A potential MV in the study was the prestudy level of participant mindfulness as
measured using the TMS (Lau et al., 2006). Positive significant differences between
pretest and midtest or posttest scores would suggest that the participants’ level of
mindfulness as measured by the TMS increased in association with MBRP exposure,
whereas the absence of significant differences in pretest, midtest, and posttest scores
would suggest no significant changes in terms of participant mindfulness were associated
with engagement in MBRP treatment. A negative significant scoring difference would
suggest that participant level of mindfulness as measured by the TMS was inversely
associated with MBRP group exposure. Although not the focus of this study, the effects
of this potential mediating variable were observed through TMS administration during
the pretest, midtest, and posttests.
RQ1 was about participant exposure to MBRP manualized treatment and
associations with reductions in terms of percentage of illicit opioid use for individuals
concurrently participating in a MAT program for their opioid use disorder. I addressed
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this research question by measuring DVs associated with two levels of IV throughout the
8-week study period.
RQ2 was about whether participant exposure to MBRP manualized treatment is
associated with reductions in severity of illicit opioid craving for individuals concurrently
participating in a MAT program for their opioid use disorder. I addressed this research
question by measuring this DV associated with two levels of IV throughout the 8-week
study period.
Data Collection
The study included phases for study participant enrollment, pre-treatment data
collection, administration of the MBRP manualized treatment, posttreatment data
collection, and participant debriefing. Participant enrollment procedures began at the
MAT program site three weeks prior to beginning the study. Participant enrollment and
data collection procedures were conducted by the principal investigator.
The MBRP manualized treatment adjunct was administered to study participants
by the principal investigator. The principal investigator provided pretest, midtest, and
posttest administration to all participants with ASI Alcohol/Drugs subscale (McLellan et
al., 1985), the OCS (McHugh et al., 2014), and the TMS (Lau et al., 2006).
All treatment groups participated in TAU as typically provided to MAT program
participants. This included daily program attendance, daily administration of the
medication prescribed by the MAT program physician; and once weekly individual
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counseling sessions of 50 minutes duration. Exceptions to TAU participation were noted
where they occurred.
The IV for the quantitative methodology used in this study consisted of two
treatment levels, the first being administration of the MBRP (Bowen et al., 2011)
manualized treatment adjunct (in addition to TAU) as an intervention to the experimental
group of MAT program participants for the proscribed eight-week period, and the second
consisting of the control group of MAT program participants experiencing TAU only for
the proscribed eight-week period.
The DVs included the ASI Alcohol/Drugs use subscale (McLellan et al., 1985)
outcomes collected at pretest, midtest, and posttest intervals and the OCS (McHugh et al.,
2014) outcomes collected at pretest, midtest and posttest intervals. TMS (Lau et al.,
2006) pretest, midtest, and posttest scores were also collected to monitor for any potential
MV effects, but were not included in the study RQs and hypotheses.
Study Implementation and Data Collection
The study duration was planned for 14 weeks, including phases for study
participant enrollment, pre-treatment data collection, administration of the MBRP
manualized treatment, posttreatment data collection, and participant debriefing.
Phases of the study implementation at the MAT program site are outlined in the
following table:
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Table 3
Outline of Study Implementation at MAT Site
________________________________________________________________________
Planned Study Phase and Description
Period of Implementation
________________________________________________________________________
1.
2.
3.
4.
5.
6.

Study information provided to potential participants
Informed consent obtained from participants
Pretest data collection
MBRP treatment provided to selected participants
Midtest data collection
Posttest data collection and participant debriefing

Weeks 1 and 2(before MBRP starts)
Weeks 1-3 (before MBRP starts)
Weeks 3-5 (before MBRP starts)
Weeks 6-9 (MBRP begins)
Weeks 10-16 (MBRP concludes)
Weeks 17-20

After discussion with the MAT clinic director at the program site it was agreed
that the most effective weekday of study implementation was Wednesday, as this day
typically had the highest rate of MAT patient attendance. Given the full-time
employment requirements of the principal investigator, only one day per week could be
designated for study implementation purposes. Participant recruitment took place over a
three consecutive week period prior to the implementation of pretest data collection.
Study information was provided and informed consent obtained during this period. At the
conclusion of the participant recruitment phase 52 participants were enrolled in the study.
Random participant group assignment for both participant groups, Treatment as Usual
(TAU only) and Experimental (TAU plus MBRP), was completed by the principal
investigator based on statistical random number table selections prior to the end of week
three.
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Pretest data collection began in week three and continued through week five. This
phase took a week longer than planned in study design because of the time required to
contact individual participants, many of whom no-showed for scheduled pretest
administration appointments. At the conclusion of this study phase participant dropout
left 16 participants available (see table four below). These and subsequent participant
attendance influences on study participation and outcomes are discussed in in further
detail in the forthcoming section of this chapter evaluating treatment fidelity.
Phase four of study implementation (weeks 1-4 of MBRP group) began on week
six of study implementation. The principal investigator administered weeks one through
four of the MBRP manualized treatment protocol to the selected group participants
during this period. During this phase marked inconsistency of participant group
attendance was observed. By the conclusion of this study phase a severe frequency of
participant dropout for the MBRP group was observed (see table four).
Implementation of phase five of the study (weeks 5-8 of MBRP group, and
midtest data collection for all participants) began in week ten, continuing through week
sixteen. Midtest data collection began during the first week of this period, with all
measures administered by the principal investigator. The fifth through eighth week of
MBRP group administration was not completed until the fourteenth week of study
implementation. Midtest measures were administered to MBRP group participants prior
to group meetings to reduce potential for confounding between group participation
effects and data collection.
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The additional weeks of study implementation during phase five were required
due to only one MBRP group participant presenting on week 13 for the final group
session, and subsequent no-show of all group participants during week 14 of study
implementation. Following this, during implementation week 15 the final MBRP group
was again re-scheduled due to an unexpected staffing crisis occurring at the clinic facility
overseen by the study principal investigator, that precluded his attendance. Thus, the final
administration of the MBRP group intervention occurred on week 16 of study
implementation. Inconsistent participant attendance at this final MBRP group was noted
by the principal investigator.
The above described factors influencing inconsistent MBRP group attendance
during implementation of this study phase are discussed in further detail in the treatment
fidelity section of this study description. As previously noted during the above
description of phase four, overlap between measures administration and administration of
the MBRP group protocol occurred to the competing needs of timely measures data
collection for both groups and continuance of MBRP treatment group participation.
Phase six (posttest administration and participant debriefing) began in week 17,
continuing through week 20 of study implementation. One additional week of measures
administration was required due to no-show of some participants in both study groups.
Some participants were unavailable during this study period. Review and scoring of study
measures, evaluation of study outcomes, and participant debriefings were subsequently
completed. Only three participants were available for debriefings during the conclusion
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of this study phase. As previously noted, factors influencing the attendance of study
participants are discussed in further depth in the following treatment fidelity evaluation
section.
Participant Descriptive and Demographic Characteristics
Study volunteer participants were randomly selected from and thus representative
of the population of the larger group of individuals participating in MAT programs. The
study participant characteristics include a current diagnosis of OUD (304.00) (APA,
2013) participation in the BAART MAT program used for the study, being maintained on
methadone medication as a treatment for OUD, and exhibiting no signs or symptoms
contraindicating study participation. All participants were at least 18 years of age.
Analysis of Fidelity in Study Implementation
Following is an analysis of the preceding factors influencing study
implementation and outcomes, and thereby impacting fidelity to study design. Their
ultimate effects led to irregularity of participation in study measures administration, data
collection, and attendance at scheduled MBRP group meetings. These observed factors
are described and evaluated in the following discussion.
Participant dropout and no-show were feasibility factors anticipated to some
extent in study design. A much higher than anticipated frequency of participant dropout
was observed throughout study implementation (see table four below). This effect can be
seen throughout all phases of data collection, notably in the MBRP Group intervention
level, where number of active participants reduced from an initially enrolled 26 to seven
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in pretest phase, to three in midtest phase, and then two participants remaining in posttest
phase, a 92% reduction (See table four). More globally, at conclusion of study data
collection, only nine participants remained from the initial enrollment of 52, representing
an 83% attrition rate in study participation. These marked reductions in participant
attendance throughout the study implementation resulted in an insufficient number of
participants remaining to meet the minimum necessary (n=60) for achieving sufficient
statistical power.
Table 4
Participant Dropout Frequency - Both Intervention levels
________________________________________________________________________
Study Phase

Group

# Assigned

# Remaining

Freq. Difference % Difference

________________________________________________________________________
1.
2.
3.
4.
5.
6.

Study information
Informed consent
Pre–test data
collection
MBRP treatment
begins
Midtest data MBRP
collection
Posttest dataMBRP
collection
Study conclusion

NA
NA
MBRP
TAU
**

0
0
26
26
**

26
26
26
TAU
26
(BOTH) 52
TAU

52*
52*
7
9
**

0
0
-19
-17
**

0
0
-73
-65
**

3
5
2
7
9

-23
-21
-24
-19
-43

-88
-80
-92
-73
-83

*Total participant enrollment. **No participant dropout measured, reported, or observed during this
phase. Source: Deidentified study participant data.

During phase four (pretest) of study implementation 19 MBRP Group and 17
TAU participants discontinued study participation (see Table 4). Attempts to contact
participants to assess reasons for their study discontinuance, and for encouraging possible
study reengagement, were unsuccessful. Methodology for these contact attempts included
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developing a list of participants not presenting as scheduled, and then flagging them in
the study site computer system. This attempt to control for missed participant
appointments proved ineffective.
During phase five of study implementation a total of 23 MBRP Group participants
dropped out, and a total of 21 Control group participants had dropped out. This
represented a dropout rate of 88% of MBRP Group participants, and 80% of control
participants. As noted during the above discussion of phase four, attempts to contact
participants in order to assess their reasons for study discontinuance were unsuccessful.
Thus, reasons for study participant dropout remain undetermined.
During phase six of study implementation a total of 24 MBRP Group participants
had dropped out, and a total of 19 Control group participants had dropped out. This
represented a dropout rate of 92% of MBRP Group participants, and 73% of control
participants (see table 5). As noted during the above discussion of phase five, attempts to
contact participants in order to assess their reasons for study discontinuance were
unsuccessful.
Interventions to facilitate participant attendance were utilized, including
developing a list for tracking nonadherent participants and flagging them in the study site
computer system. These attempts to contact participants for study reengagement were
unsuccessful. Thus, reasons for study participant dropout remain undetermined.
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Table 5
MBRP Group Participant Attendance
________________________________________________________________________
Week Number* No. Scheduled

Attendance Freq.

% Attending Freq. Difference % Non-Attending

________________________________________________________________________
1
2
3
4
5

26
26
26
26
26

2
4
6
2
3

07.69
15.38
23.08
07.69
11.54

-24
-22
-18
-24
-23

92.31
84.62
69.23
92.31
88.46

6
7
8

26
26
26

3
3
2

11.54
11.54
07.69

-23
-23
-24

88.46
88.46
92.32

Avg.

26

3.13

12.04

-22.63

86.75

Note. Excludes weeks where no group was conducted. Source: Deidentified study participant data.

Treatment dropout from MAT programs has been frequently observed by this
writer in his role as clinic director at two different MAT program sites over the past three
decades, thus some study participant dropout was unsurprising, albeit not at the frequency
encountered in this study.
Although the severity of participant dropout was not anticipated in the study
design, it is understandable that some dropout would occur as enrolled participants may
not have been sufficiently motivated to initially or recurrently provide information
regarding their opioid use, cravings, and level of mindfulness. Further, some of these
participants may have discontinued due to being inhibited about providing sensitive
substance use information, despite the assurance provided by the principal investigator
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during implementation of informed consent procedures. Assessment of these potential
contributing causes to participant dropout from the participants’ perspective could not be
completed due to participant unavailability. Discussion with the clinic director at the
program site revealed there were multiple potential causes that so many participants
dropped out. These confounding factors included participant discontinuance of the MAT
program, participant incarceration, participant no-show on study implementation days,.
participant transportation impediments, and participant arrival at program outside of time
periods that study group and data collection procedures were available.
An additional feasibility factor that may have impacted study data collection was
the recurrent difficulty several participants had with comprehending some questions
included in the TMS (Lau et al., 2006). Many participants reported not understanding
TMS questions. Examples of this included participant commentary during TMS
administration: (a) “I was curious about what I might learn about myself by taking notice
of how I react to certain thoughts, feelings, or sensations.” (from TMS test item 3);
(b) “I experienced my thoughts more as events in my mind than as a necessarily accurate
reflection of the way things really are.” (from TMS test item 4); (c) “I was receptive to
observing unpleasant thoughts and feelings without interfering with them” (from TMS
test item 7); (d) “I was more invested in just watching my experiences as they arose, than
in figuring out what they could mean.” (from TMS test item 8); (e) “I was aware of my
thoughts and feelings without overidentifying with them” (from TMS test item11); and
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(f) “I was curious about what I might learn about myself by just taking notice of what my
attention gets drawn to” (from TMS test item 13). In such instances the principal
investigator attempted to clarify the meaning of the problematic test questions but the
effects of these efforts on TMS scoring are unknown. This unanticipated problem likely
interfered with accuracy of TMS scoring, thereby invalidating fidelity to data collection
implementation of the study.
In summary, there were multiple unanticipated feasibility confounds that
impacted study implementation such that efficacy of data collection procedures and
MBRP group services were invalidated by very high frequency of participant dropout,
inconsistent participant attendance, MBRP group scheduling inconsistencies, and
inconsistent participant comprehension of several test items included in the Toronto
Mindfulness Survey.
There were no adverse effects on study participants observed by or reported to the
study principal investigator throughout all phases of study implementation. This
discussion of study outcomes continues with reporting on the descriptive and
demographic characteristics of the study participants.
Study Fidelity Considerations and Impact on Results
This writer now takes up discussion of the outcome of pretest, midtest, and
posttest results. Throughout this discussion of study results please refer to tables that
follow where indicated.
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In comparatively evaluating the MBRP group intervention level outcomes vs. the
Control level outcomes, data in the tables below suggests that participants in the control
group tended to have higher severity of substance use than their counterparts in the
MBRP Group intervention level. On average, the MBRP group participants tended to
have 0.11 or greater positive scoring difference than those in the Control group
throughout the study data collection period. Given the comparative elevated participant
attrition in the MBRP group a statistically significant between-groups comparison cannot
be made. In general, the data suggest a higher level of drug use in the Control group, but
attributional etiology regarding this outcome must remain speculative.
Table 6
MBRP Group Intervention Level Addiction Severity Index Drug Scale Test Results
________________________________________________________________________
Pretest Score

Midtest Score

Posttest Score

________________________________________________________________________

Average

0.22
0.36
0.20
0.11
0.29
0.31
0.12

0.24
0.21
0.25
*
*
*
*

0.23
0.12
*
*
*
*
*

0.23

0.23

0.18

Scoring Range: 0.00 – 1.00

Higher Numbers indicate increased substance use severity

*= no test data collected. Source: Deidentified study participant data.
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The MBRP experimental group level within-group ASI Alcohol/Drugs subscale
scores reflected several scoring trends (Refer to Table 6). There was no change in
average scoring from pretest to midtest. A reduction (-0.05) in average scoring from
midtest to posttest was observed. These scoring changes suggest a small, likely
nonsignificant, decrease (-0.50) of MBRP participation on reported opioid use from
pretest to posttest. There were four less administrations at midtest compared with pretest.
There were five less administrations at posttest compared with pretest. The variance in
test administration frequency exerted strong effects on scoring variance such that no
statistical significance can be determined in these scoring outcomes.
Table 7
Control Intervention Level ASI Drug Scale Test Results
________________________________________________________________________
Pretest Score

Midtest Score

Posttest Score

________________________________________________________________________

Average:

0.54
0.42
0.39
0.58
0.27
0.29
0.38
0.08
0.08

0.46
0.38
0.39
0.29
0.21
*
*
*
*

0.50
0.46
0.33
0.25
0.30
0.48
0.23
*
*

0.34

0.35

0.36

Scoring Range: 0.00 – 1.00 Higher Numbers indicate increased substance use severity *=no test data
collected. Source: Deidentified study participant data.
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The TAU control group level within-group ASI Alcohol/Drugs subscale scores
reflected several scoring trends (Refer to Table 7). There was a slight increase (+0.01) in
average scoring from pretest to midtest. There was a further slight increase (+0.01) in
average scoring from midtest to posttest. These scoring changes suggest a small, likely
nonsignificant, increase (+0.02) in reported opioid use over time from pretest to posttest.
There were four less administrations at midtest compared with pretest. There were two
less administrations at posttest compared with pretest. The variance in test administration
frequency likely exerted strong effects on scoring variance such that no statistical
significance can be determined for these scoring outcomes.
Comparative evaluation (Refer to Tables 6 & 7) of the ASI Alcohol/Drugs
subscale between-group outcomes suggests that participants in the TAU control group
level tended to have higher severity of substance use than their counterparts in the MBRP
group experimental level. On average, the MBRP group participants tended to have 0.11
or greater positive scoring difference than those in the Control group. In general, the data
suggest a higher level of drug use in the TAU group but this remains a speculative
observation. The cause for these differences cannot be objectively determined at this
time, and comparative analysis of these test results is problematic given the disparate
rates of participant dropout between the groups, as evidenced by two MBRP group
participants remaining at posttest data collection, as compared to seven control group
participants. Given the comparative elevated participant attrition in the MBRP group a
statistically significant between-groups comparison cannot be made.
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Table 8
MBRP Group Intervention Level Opioid Craving Scale Test Results
________________________________________________________________________
Pretest Score

Midtest Score

Posttest Score

________________________________________________________________________

Average:

0
8
8
4
0
13
9

3
9
1
*
*
*
*

5
12
*
*
*
*
*

6

4.33

8.5

Scoring Range: 0 – 30

Higher Numbers indicate increased craving severity *= no test data

collected. Source: Deidentified study participant data.

The MBRP experimental group level within-group OCS scores reflected several
scoring trends (Refer to Table 8). There was a slight decrease (-1.67) in average scoring
from pretest to midtest. There was a marked increase (+4.17) in average scoring from
midtest to posttest. These scoring changes suggest a marked, likely significant, increase
(+2.50) in reported opioid cravings over time from pretest to posttest. There were four
less administrations at midtest compared with pretest. There were five less
administrations at posttest compared with pretest. The variance in test administration
frequency likely exerted strong effects on scoring variance such that no statistical
significance can be determined for these scoring outcomes.
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Table 9
Control Intervention Level OCS Test Results
________________________________________________________________________
Pretest Score

Midtest Score

Posttest Score

________________________________________________________________________

Average:

4
19
13
0
0
6
10
0
0
0

11
15
16
6
20
*
*
*
*
*

15
13
10
0
2
15
21
*
*
*

5.2

13.6

10.86

Scoring Range: 0 - 30

Higher Numbers indicate increased craving severity

Source: Deidentified study participant data.

The TAU control group level within-group OCS scores reflected several scoring
trends (Refer to Table 9). There was a marked increase (+8.40) in average scoring from
pretest to midtest. There was a noted decrease (-2.74) in average scoring from midtest to
posttest. These scoring changes suggest a strong, likely significant, increase (+5.66) in
reported opioid cravings from pretest to posttest. There were four less administrations at
midtest compared with pretest. There were five less administrations at posttest compared
with pretest. The variance in test administration frequency likely exerted strong effects on
scoring variance, such that no statistical significance can be determined for these scoring
outcomes.
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Comparative evaluation (Refer to Tables 8 & 9) of the OCS between-group
outcomes suggests that the TAU control group participants experienced higher levels of
opioid craving (10.89) than participants in the MBRP experimental group (8.5). There
were two MBRP participants remaining at posttest, and seven control group participants
remaining at posttest. The causes for these differences cannot be objectively determined
at this time, and comparative analysis of these test results is problematic given the
disparate rates of participant dropout between the groups. Given the comparative elevated
participant attrition in the MBRP group a statistically significant between-groups
comparison cannot be made.
Table 10
MBRP Group Intervention Level TMS Results
________________________________________________________________________
Curiosity

Pretest Score
Decentering

Curiosity

Midtest Score
Decentering

Curiosity

Posttest Score
Decentering

________________________________________________________________________
14
10
17
24
20
20
14
14

14
13
9
17
10
15
11
12

18
19
9
*
*
*
*
*

14
13
13
*
*
*
*
*

22
15
*
*
*
*
*
*

14
12
*
*
*
*
*
*

16.63

12.63

15.33

13.33

18.5

13.00

(Avg.)

Scoring Ranges: 0 – 24 (Curiosity); 0- 28 (Decentering). Higher Numbers indicate increased level of
mindfulness. *= no test data collected. Source: Deidentified study participant data.
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The MBRP experimental group level within-group TMS scores reflected several
scoring trends (Refer to Table 10). For the Curiosity scale there was a small decrease (1.30) in average scoring from pretest to midtest. For the Decentering scale there was a
very small increase (+0.07) in average scoring from pretest to midtest. For the Curiosity
scale there was a notable increase (+3.17) in average scoring from midtest to posttest. For
the Decentering scale there was a very small decrease (+0.33) in average scoring from
midtest to posttest. For the Curiosity scale there was a notable increase (+1.87) in average
scoring from pretest to posttest. For the Decentering scale there was a very small increase
(+0.37) in average scoring from pretest to posttest. There were five less administrations at
midtest compared with pretest and six less administrations at posttest compared with
pretest. The variance in test administration frequency likely exerted strong effects on
scoring variance such that no statistical significance can be determined for these scoring
outcomes.
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Table 11
Control Intervention Level TMS Results
________________________________________________________________________
Curiosity

Pretest Score
Decentering

Curiosity

Midtest Score
Decentering

Curiosity

Posttest Score
Decentering

________________________________________________________________________
24
20
17
3
13
18
13
18
9

12
16
12
4
2
21
12
17
11

13
11
4
15
9
*
*
*
*

17
15
3
14
6
*
*
*
*

22
17
17
14
20
11
24
*
*

16
11
13
11
18
15
19
*
*

15.00

11.89

10.40

11.00

17.86

14.71

(Avg.)

Scoring Ranges: 0 – 24 (Curiosity); 0- 28 (Decentering). Higher = increased level of mindfulness *=no data
collected. Source: Deidentified study participant data.

The TAU control group level within-group TMS scores reflected several scoring
trends (Refer to Table 11). For the Curiosity scale there was a notable decrease (-4.60) in
average scoring from pretest to midtest. For the Decentering scale there was a very small
decrease (-0.89) in average scoring from pretest to midtest. For the Curiosity scale there
was a marked increase (+7.46) in average scoring from midtest to posttest. For the
Decentering scale there was a marked increase (+4.71) in average scoring from midtest to
posttest. For the Curiosity scale there was a notable increase (+2.86) in average scoring
from pretest to posttest. For the Decentering scale there was a notable increase (+2.82) in
average scoring from pretest to posttest. There were four less administrations at midtest
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compared with pretest, and two less administrations at posttest compared with pretest.
The variance in test administration frequency likely exerted strong effects on scoring
variance such that no statistical significance can be determined for these scoring
outcomes.
Comparative evaluation of the between-group levels average test scores for the
TMS (Refer to Tables 10 & 11) measure outcomes suggests that whereas the MBRP
group scored marginally higher for posttest curiosity subscale (+0.64) the TAU group
scored somewhat higher for posttest decentering subscale (+1.71). Scoring for both group
levels was invalidated by the lowered (and diminishing over time) number of MBRP
Group participants. There were two MBRP group participants remaining at posttest and
seven TAU control group participants remaining at posttest. These disparate rates of
participant dropout between the groups limited between-groups analysis. These outcomes
may suggest that there is a general trend for individuals predisposed toward mindfulness
to score higher on the TMS than those that are less inclined toward mindfulness,
regardless of MBRP Group participation. However, given the confound of MBRP patient
dropout, which is much more severe than that of the control group, this effect could not
be statistically evaluated.
As a result of the impact of the multiple feasibility factors described in the
preceding discussion, an insufficient number of participants remained in the MBRP
Group at the conclusion of the study, thereby impeding implementation of any valid
statistical analysis procedure. Thus, valid testing of the hypotheses as proposed in the
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study design could not be carried out. The preceding data strongly suggest that in order to
objectively determine whether MBRP group participation can reduce opioid craving and
increase participant mindfulness further evaluative attempts must be made. Such attempts
must address feasibility factors, in particular, patient dropout effects, and methodologies
for ameliorating such effects.
Temporal association of MBRP (Bowen et al., 2011) manualized treatment
participation with significant reductions in illicit opioid craving and use would suggest
that the first and second null hypotheses are not supported and the first and second
alternative hypotheses are supported. Due to participant attrition no significant changes in
mindfulness as measured by TMS (Lau et al., 2006) outcomes were observed.
Resultantly, the presence of a significant negative (inverse) correlation between increased
levels of mindfulness and frequency of illicit opioid use and cravings was not established
in this study. Given these findings, study outcomes cannot suggest that changes in
measured levels of mindfulness arising are a MV factor influencing participant illicit
opioid use and cravings.
Due to the feasibility confounds posed by high and progressively higher
participant dropout, testing for existence of a significant experimental effect using
quantitative analyses could not be accomplished through evaluation of within- and
between-groups effects on pretest, midtest, and posttest outcomes of the ASI
Alcohol/Drugs subscale (McLellan et al., 1985) and the OCS (McHugh et al., 2014).
Similarly, the TMS (Lau et al., 2006) outcomes could not be used to observe any
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potential MV effects. Comparative data evaluation using repeated measures MANCOVA
(p < .05) was not conducted given these experimental confounds.
As a result of the preceding implementation problems, the first research question
that asks if exposure to MBRP manualized treatment associated with changes in
frequency of illicit opioid use for individuals with opioid use disorder concurrently
participating in a MAT program could not be answered. Further, for the same reasons
previously described, the second research question that asks is exposure to MBRP
manualized treatment associated with changes in severity of illicit opioid use cravings for
individuals with opioid use disorder concurrently participating in a MAT program could
not be conclusively answered.
The preceding data strongly suggest that in order to objectively determine
whether MBRP group participation can reduce opioid craving and opioid use further
evaluative attempts must be made. Such attempts must address feasibility factors, in
particular, patient dropout effects, and methodologies for ameliorating such effects. This
writer recommends that future studies consider methodologies that reduce participant
dropout in order to foster statistically significant analyses of within and between group
outcomes.
Chapter 5 includes interpretations of research findings, study limitations, and
recommendations for future research. Implications for social change are explored, and
methodological implications are discussed, followed by a conclusion.
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Chapter 5: Discussion, Recommendations, and Conclusions
Introduction
The purpose of this study was to examine the relationship between participant
exposure to MBRP manualized treatment protocol as a treatment adjunct and participant
opioid use and cravings. All participants were diagnosed with OUD, enrolled in the MAT
program offered at the study site, and maintained methadone medication throughout the
course of the study. After completing the informed consent process, participants were
randomly assigned to either the experimental group using MBRP and TAU or the control
group using TAU only. All measures were completed by me. The MBRP group was
provided to onsite participants by me over the course of eight weeks.
The study design included two experimental group levels, one combining MBRP
exposure with TAU, and the other using only TAU. The study DVs were changes in
participant opioid use and opioid cravings as measured through pretest, midtest, and
posttest administrations of the ASI Alcohol/Drug use subscale (McLellan et al., 1985)
and the OCS (McHugh et al., 2014). The study involved using a quantitative mixed
within-between subjects design with time as the within-subjects factor and groups as the
between-subjects factor. Use of MANCOVA (p < .05) was planned to evaluate for
significant relationships between DVs and the IV. The comparative data evaluation
involving repeated measures MANCOVA was not conducted due to unexpected
experimental confounds including a 83% participant attrition rate and highly inconsistent
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participant attendance at MBRP group meetings. The study research questions and
hypotheses were as follows:
RQ1: Is exposure to MBRP manualized treatment associated with changes in
frequency of illicit opioid use for individuals with opioid use disorder concurrently
participating in a MAT program?
H01: Exposure to MBRP manualized treatment is not associated with changes in
frequency of illicit opioid use for individuals with opioid use disorder concurrently
participating in a MAT program.
Ha1: Exposure to MBRP manualized treatment is associated with changes in
frequency of illicit opioid use for individuals with opioid use disorder concurrently
participating in a MAT program.
RQ2: Is exposure to MBRP manualized treatment associated with changes in
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently
participating in a MAT program?
H02: Exposure to MBRP manualized treatment is not associated with changes in
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently
participating in a MAT program.
Ha2: Exposure to MBRP manualized treatment is associated with changes in
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently
participating in a MAT program.
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The research gap addressed in this study was identified via an extensive review of
literature regarding effectiveness of MBRP manualized treatment as an intervention for
individuals with OUD. The aforementioned research review effort yielded two studies
that evaluated the effects of MBRP manualized treatment adjunct on individuals with
OUD who were currently enrolled in a medication MAT program and prescribed
methadone medication as a treatment for their condition.
This study represented a first effort to evaluate and increase understanding of the
relationship, if any, between participation in MBRP manualized treatment and changes in
opioid use cravings and using behaviors for methadone-maintained individuals
participating in a MAT program.
If findings in the present study indicated the MBRP treatment adjunct was
effective in terms of reducing participant opioid use and cravings, individuals with OUD
would likely benefit from MBRP participation in terms of how to more effectively
manage their opioid craving and using behaviors, thereby significantly improving their
quality of life.
Interpretation of Findings
Findings of this study include that the study design, while carefully considered,
did not account for multiple implementation feasibility factors that served as significant
confounds in study data collection an analysis. The largest single such factor was
participant dropout, which by the conclusion of the study was greater than 90% of the
originally enrolled participants. Attempting to determine what may have contributed to
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such a high dropout rate provided difficult because of limited participant contact with the
primary investigator. The high participant dropout rate resulted in such a small number of
participants (two posttest MBRP group participants remaining) that statistical analysis of
participant pretest, midtest, and posttest data using MANCOVA methodology could not
be conducted with validity at significance p <= 0.05.
Limitations of the Study
This study outcome evidenced the critical importance of fully anticipating
feasibility factors potentially affecting consistency of participant retention when
conducting a study at an opioid treatment program site. Limitations included the
predominant confounding effect of participant dropout on study outcome. The high rate
of participant dropout experienced in this study severely limited the ability to conduct a
valid statistical analysis of the testing outcomes because the number of MBRP group
participants was reduced to two at time of posttest data collection, thereby preventing
data collection for the minimum number of participants required to complete a valid
MANCOVA data outcome analysis. In addition, the inability to develop a valid statistical
analysis of data resulted in being unable to offer associated analyses of theoretical
research associated with mindfulness, opioid use, and neurobiological functioning.
Participant Attendance Confounds
Participant attendance inconsistencies were repeatedly encountered throughout
study implementation. These included: (a) no-shows, referencing nonappearance to the
program site as scheduled, on days the MBRP group was being conducted; (b) no-shows
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on study data collection days; (c) discontinuance of the MAT program and thus no longer
eligible for study participation. (In these cases, the patients never returned to the program
during the study implementation period, so it was impossible to attempt their
reengagement in the OTP or the study); (d) incarceration and resultant nonattendance at
the OTP; (e) hospitalization and resultant nonattendance at the MAT program; (f) transfer
to another MAT program and thus no longer presenting for services at the study site; (g)
encountering difficulties obtaining transportation to the MAT program; (h) instances
where patients arrived too late to receive MAT program services or participate in study
activities on a given day; (i) reported inability to stay for study participation as scheduled,
despite receiving MAT program services on such days; (j) reported symptoms of a
general medical illness that precluded such patients from staying for study activities after
receiving their MAT medication as scheduled; (k) instances where a participant
experienced childcare needs that precluded them from participating in study activities; (l)
instances where participants reported an intention to return for MBRP group services
after receiving MAT program services but did not do so for undetermined reasons; (m)
instances of conflicting time schedule between study participation requirements and
MAT program services, such as cases where a patient was required to participate in a
counseling session or meet with the program physician. (In such instances, the OTP
requirements took precedence over the study participation); and (o) instances where a
study participant had a conflicting responsibility offsite, such as a medical, social
services, or legal appointment.
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The central limitation relative to all the above situations was that the principal
investigator could only be at the study site once weekly. This meant that study
participants had only the once weekly opportunity to attend the scheduled study activity.
Whereas the data collection could be rescheduled for the following week, the group
meetings proceeded once weekly in accord with the MBRP manualized treatment
protocol. Ideally, there would have been alternate weekdays for offering MBRP group
services to address this contingency, but due to time constraints the principal investigator
could only be at the study site once weekly. Therefore, for example, if a participant
missed the MBRP group there was no opportunity to reschedule. Additionally, any of the
above factors, singly or in combination, may have influenced participant dropout.
Program Operational Confounds
Another feasibility confound involved program operational considerations,
including but not limited to an unanticipated program dispensing nurse staffing crisis that
interfered with MBRP group administration for one week. The effects of the resultant
MBRP group meeting schedule change on study outcomes were not measurable but may
nevertheless have been significant.
An unexpected confound arose through the occurrence of errors in flagging
participant alerts in the MAT program computer system. Although a list for participant
appointments was provided by the principal investigator to program administrative staff
the morning of each study implementation day, for unknown reasons some participants
were not flagged. These oversights likely caused missed data collection and interfered
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with MBRP group session attendance. It is also possible that in some instances
participants simply ignored the study flags and left the MAT program without completing
their assigned study activities. The effects of this confound on overall study participation
could not be evaluated and thus remain undetermined.
In addition, a potential study design confound was experienced by the principal
investigator during administration of the TMS (Lau et al., 2006) to study participants.
Multiple participants in both IV group levels reported a lack of understanding regarding
some TMS test items, especially those that were more abstractly worded. These test line
items and related participant reporting are discussed in the following:
TMS test item three states: “I was curious about what I might learn about myself
by taking notice of how I react to certain thoughts, feelings, or sensations.” (Lau et al.,
2006). For this test item, many participants reported not understanding what it meant to
learn about themselves through noticing their reactions to the various aspects involved in
apprehending their life experience. The principal investigator attempted to explain this
line item through use of verbiage such as “understand yourself more fully through
becoming aware of your emotions, thoughts, feelings, and sensations in your body.”
TMS test item four states: “I experienced my thoughts more as events in my mind
than as a necessarily accurate reflection of the way things really are” (Lau et al., 2006).
For this test item, many participants reported not understanding what it meant to
experience their thoughts as “events in the mind.” The principal investigator attempted to
explain this line item using verbiage such as “do you think you are accurately
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understanding what happens around you, or might you be seeing things differently than
what is actually occurring?”
TMS test item seven states: “I was receptive to observing unpleasant thoughts and
feelings without interfering with them” (Lau et al., 2006). For this test item, many
participants reported not understanding what it meant to “observe their unpleasant
thoughts and feelings without interfering.” The principal investigator attempted to
explain this line item excerpt using verbiage such as “do you think you are really
understanding what happens around you, or might you be seeing things differently than
what is actually occurring?”
TMS test item eight states: “I was more invested in just watching my experiences
as they arose, than in figuring out what they could mean.” (Lau et al., 2006). For this test
item, many participants reported not understanding what was meant by “watching my
experiences as they arose.” The principal investigator attempted to explain this line item
excerpt as “are you able to step back from an experience and just allow it to happen,
rather than getting caught up in what it means for you?”
TMS test item eleven states: “I was aware of my thoughts and feelings without
overidentifying with them” (Lau et al., 2006). For this test item, many participants
reported not understanding what “overidentifying” with their thoughts and feelings
meant. The principal investigator attempted to explain this line item excerpt as “getting
caught up in thoughts and feelings such that a person sees them as part of their identity

188
rather than simply as experienced events;” e.g., discerning the difference between “I am
angry” versus “I am experiencing some anger.”
TMS test item thirteen states: “I was curious about what I might learn about
myself by just taking notice of what my attention gets drawn to” (Lau et al., 2006). For
this test item, many participants reported not understanding what was meant by “taking
notice of what my attention gets drawn to.” The principal investigator attempted to
explain this line item meant to “see what stands out most strongly in a situation or
experience.”
As seen in the above described cases the principal investigator was left to
determine an ad hoc explanation conveying the relevant concepts inherent in the test line
items to the study participant, but the effects of such an interpretive process were
impossible to measure, and thus the effects for TMS instrument scoring remain
undetermined. There was no means of evaluating whether the alternative line item
explanations offered by the principal investigator were sufficiently consistent with their
meaning as delineated in the original test instrument. Further, there was no means of
determining the efficacy of these explanatory alternatives in facilitating participant
comprehension. At times, several such explanatory attempts using varied descriptive
language were made in order to better facilitate participant understanding. After each
explanatory attempt the principal investigator asked the involved participants if they felt
that they now understood the line item in question, but there was no means of assessing
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whether affirmative participant responses to that query in these instances reflected an
understanding sufficient to support valid line item responses.
Anecdotal participant reporting suggested that the majority of study participants
were educated at a twelfth grade or lower level. Further, the majority of study participants
were of African American race. These two cultural aspects may have been contributing
factors associated with the above described difficulties reported by some participants in
understanding the language used in some TMS line items. These considerations suggest
the TMS measure may have been developed with limitations posed by inherent cultural
and educational biases. Further, there may exist some inherent difficulties in participant
understanding posed by unknown limitations associated with concurrent MAT program
enrollment. These feasibility confounds likely interfered with accuracy of TMS scoring,
thereby invalidating fidelity to TMS data collection and scoring procedures. They suggest
the need for a revised mindfulness measure sensitive to various participant educational,
cultural, and MAT setting associated needs and limitations that facilitates development of
test line items readily and consistently understandable to participants in the MAT
program setting.
MBRP Group Participation Confounds
Group protocol adherence by participants was a feasibility confound observed by
the principal investigator. In addition to exhibiting markedly inconsistent meeting
attendance, most participants reported that they either misplaced their meditation practice
CDs or were not able to use them to facilitate meditation practice exercises due to
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unavailability of a CD player for their use. Another observed feasibility confound was
that most participants reported that they had either lost their assigned worksheets or
forgot to bring them to the group meeting for discussion purposes. These feasibility
problems impaired study validity through exerting unknown but potentially significant
effects on the efficacy of the MBRP group treatment adjunct. Chawla et al. (2010)
developed a fidelity measure for use in implementation of the MBRP manualized
treatment. They created a scale that evaluates for the adherence and competence factors
affecting MBRP treatment fidelity. Zgierska et al. (2017) identified multiple elements for
evaluating fidelity of MBSR group treatment provided to persons with alcohol use
disorder. Zgierska et al. found that study design best assured fidelity to the MBRP
manualized treatment when therapists facilitating the MBRP groups were sufficiently
trained in and had clinical experience with the MBRP treatment. Further identified
elements supporting MBRP treatment fidelity included participant adherence with
weekly MBRP group attendance, assignment completion, and daily meditation practice
(Zgierska et al.). An additional intervention reported by Zgierska at al. that enhanced
MBRP treatment fidelity was research staff monitoring of participant adherence with the
protocol and phoning participants who were not completing assignments, meditations, or
group attendance as scheduled. A final identified feasibility element was reported
participant satisfaction with the group (Zgierska et al.).
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MBRP Group Participant Perspectives
A critical feasibility factor in this study involved participant perception regarding
the MBRP treatment adjunct. It is likely that participants would continue for the full
duration of study implementation if they perceived their participatory experience as
useful or beneficial for them. In accord with the MBRP protocol administration
participants in this study, the MBRP group participants were asked to complete a form
provided to them by the principal investigator that asked for their views on the group
procedures and how participation affected them. This form, entitled “Reflections on the
Course Worksheet” (Bowen et al., 2011, p. 170) is outlined below and includes
deidentified participant responses to the worksheet line items as collected from
participants by the principal investigator during the final MBRP group session. There are
three sets of participant responses despite only two group participant attendees in the
final MBRP session. One nonattending participant turned in his responses at another
time. The line item responses are delineated here.
Line item one asks “What did you find most valuable about this course? What, if
anything, did you learn?” (Bowen et. al., 2011, p. 170). Participant responses to this line
item included: (a) “I learned to stop, and observe in my curious mind,”; (b) “Being able
to be in the moment. Time for self.,”; and (c) “Thinking in a more enlightened way.
[That] others can learn about meditation.” (From deidentified study participant data).
Line item two asks “What, if anything, has changed for you over the past eight
weeks as a result of your participation?” (Bowen et. al., 2011, p. 170). Participant
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responses to this line item included: (a) “I have learned to stop and be mindful in tense
situations, not to be reactionary.”; (b) “Being able to focus better.”; and (c) “Not too
much, having had prior similar [meditation] experience. Have learned more about self.”
(From deidentified study participant data).
Line item three asks: “Was there anything that got in the way of your learning or
growth, or that might have improved the course for you?” (Bowen et. al., 2011, p. 170).
Participant responses to this line item included: (a) “Negative personalities.”; (b) “No”;
and (c) “Nothing.” (From deidentified study participant data).
Line item fours asks: “Other comments?” (Bowen et. al., 2011, p. 170).
Participant responses to this line item included: (a) “I believe this is a universal group
that can help people in all aspects of life.”; (b) “None.”; and (c) “Meeting time of group.
Consider different time for employed [participants]. Evening? Early morning?” (From
deidentified study participant data).
Line item five asks: “On a scale of 1 (not at all) to 10 (very), how important has
this program been to you?” (Bowen et. al., 2011, p. 170). Participant responses to this
line item included: (a) “10. It has taught me to stop, think, observe, and respond
mindfully and calmly.”; (b) “10. Improving coping without drug use overall.”; and (c) “7.
Gave me something that I enjoyed and liked [the] topic.” (From deidentified study
participant data).
Line item six asks: “On a scale of 1 (not at all) to 10 (very), how likely are you to
continue engaging in formal mindfulness practice (e.g., body scan, sitting meditation,

193
mindful stretching/yoga) after this course?” (Bowen et. al., 2011, p. 170). Participant
responses to this line item included: (a) “9. It helps strengthen my patience.”; (b) “10.
Will continue meditation.” And (c) “10. Most definitely.” (From deidentified study
participant data).
Line item seven asks: “On a scale of 1 (not at all) to 10 (very), how likely are you
to continue engaging in informal mindfulness practice (e.g., SOBER breathing space,
mindful eating, walking, daily activities) after this course?” (Bowen et. al., 2011, p. 170).
Participant responses to this line item included: (a) “10. I continually practice informal
mindfulness daily because of this group.”; (b) “8. [No rationale for rating provided].”
(Sooter, 2019). And (c) “9-10. Definitely.” (From deidentified study participant data).
Overall, the preceding line item responses suggest that the MBRP group
participants felt they improved their capabilities for observing their personal experience
and responding to situations they encountered more effectively. One response to line item
four (“Other Comments?”) regarding group meeting scheduling suggests that the
participant saw the need for more scheduling flexibility, likely reflecting an important
study design consideration. The scaled responses for line item five referencing
importance of the group suggest that reporting participants valued their MBRP group
experience highly and gained some meditative and situational coping skills through their
group participation. The scaled responses for line item six referencing likelihood of
engaging in continued formal mindfulness practice suggest that reporting participants
were highly likely to continue formal meditation. The scaled responses for line item
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seven referencing likelihood of engaging in continued informal meditation practice
suggest that reporting participants were highly likely to continue informal meditation.
Taken together, the responses suggest a generally favorable participant perspective
toward the MBRP group experience, despite the fact that none of the respondents were
able to attend every group as scheduled. An important limitation is that despite the
predominantly positive nature of these responses, they do not represent statistically
significant findings.
Further feasibility factors for this study relevant to participant group attendance
likely included the knowledge base, facilitative skill, and therapeutic effectiveness
demonstrated by principal investigator in his role as group facilitator. A broad knowledge
of mindfulness related concepts including methods of formal and informal meditation
practice was essential for effective implementation of the MBRP group manualized
treatment. Facilitator knowledge of cognitive behavioral therapy and its related
therapeutic skills were also necessary, as the MBRP group protocol includes elements of
mindfulness-based meditative practice integrated with CBT based participant exercises
(Bowen et al., 2011). Facilitative practices deemed essential for this group process must
include group process informed by evidence-based theory and extensive clinical practice
(CSAT, 2005). The facilitator must be able to effectively welcome, establish rapport
with, and sustain therapeutic alliances with the individuals in the group in order to
facilitate participant engagement and retention (CSAT, 2005; Miller and Rollnik, 2002).

195
The principal investigator for this study had some 31 years of prior experience in
provision of clinical services to individuals with Opioid Use Disorder (American
Psychiatric Association, 2013), including individual and group counseling for patients
enrolled in the MAT program as well as clinical supervision of program staff. In addition,
the principal investigator completed a Master’s degree in Psychology along with multiple
years of participation in the Walden University Clinical Psychology doctoral program.
Further, the principal investigator completed over 1500 hours of supervised clinical
practice, providing treatment to patients with substance use, psychiatric, and co-occurring
disorders. The principal investigator also provided multiple administrations of the MPRP
manualized treatment to individuals in residential treatment for substance use disorders.
Finally, the study principal investigator has been a practitioner of mindfulness meditation
for some 20 years. Taken together, this constellation of clinical and personal experience
suggests the clinical investigator was well qualified to facilitate the study MBRP group.
This further suggests that ineffective MBRP group facilitation was likely not a feasibility
factor adversely affecting implementation of this study.
MBRP Manualized Treatment Fidelity Considerations
As facilitator, the principal investigator was responsible for assuring fidelity to the
clinical interventions and processes delineated in the MBRP group manual (Bowen et al.,
2011). Given his extensive clinical experience as described above, including that specific
to facilitation of MBRP group services, it is likely that the MBRP group meetings were
for the most part conducted in accord with the manualized treatment requirement. The
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one exception was the previously described one-week interruption in study
implementation caused by a temporary nursing staff shortage in the MAT program
directed by the principal investigator. The resultant adverse feasibility effects on MBRP
group facilitation were not assessed but may have been significant. Bassett et al. (2016)
described treatment fidelity as the level of consistency between the intervention provided
and that specified in the treatment protocol. Clearly, the unanticipated interruption to the
weekly MBRP group schedule was inconsistent with study design and implementation,
and resulted in fidelity adherence liabilities that likely impaired effectiveness of the
MBRP manualized treatment used in this study. Utilizing suitably trained and
experienced research staff for MBRP group facilitation would likely assure improved
fidelity with the MBRP manualized treatment in future studies.
Measures Administration Considerations
An additional consideration in study implementation was the effectiveness of the
principal investigator in administering the measures utilized in the study. These measures
were the ASI Alcohol/Drugs subscale (McLellan et al., 1985), the OCS (McHugh et al.,
2014) and the TMS (Lau et al., 2006). The principal investigator cultivated a knowledge
base reflecting the research outcomes and administration recommendations for these
instruments. Additionally, the principal investigator had several years of experience in
administering, scoring, and interpreting multiple psychological tests. Given the above, it
is likely that strong fidelity existed in administration of the measures used in the study.
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Participant Logistical Considerations
A significant factor impeding consistent group attendance was likely that reported
by one participant in their response to line item four requesting additional comments,
where the participant observed that group meeting time may have conflicted with
participant employment schedules. Although not specifically mentioned in the participant
responses, the recurrent temporal association between no-shows for study group and
measures administration appointments and competing participant schedule requirements,
such as medical, legal, childcare, educational, transportation, and other social needs
suggests these appointments frequently interfered with participant attendance for study
activities. The most immediate approach to address these conflicting scheduling needs
would be to offer several groups each week at times participants are most likely to be
available for group attendance. The frequency of favorable participant responses to the
worksheet line items suggests that overall the MBRP group was a positive experience for
participants, and that the group requirements and procedures as implemented were not a
negative factor. It nevertheless remains possible that the responding participants did not
fully or accurately convey elements of the group experience that other participants who
dropped out may have regarded as reasons for their discontinuance. This again suggests
the need to rule out the known scheduling conflicts in order to better evaluate for possible
unknown confounding factors impeding MBRP group attendance.
Other studies evaluating the effects of mindfulness on substance use and relapse
prevention have identified various feasibility factors during study implementation. In
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their study evaluating the effects of MBRP group participation on substance use Zgierska
et al. (2008) noted that out of 19 participants four dropped out prior to completing the
study. They further noted that out of the remaining 15 participants 89% completed the
full eight weeks of the MBRP group protocol.
In their study of low-income women with substance use disorders in concurrent
substance use treatment Amaro et al. (2014) observed that 36% of the participants
completed the MBRP group protocol. They attributed the dropout rate to multiple factors
including participant relocation, relapse and subsequent treatment program
discontinuance, and participant nonavailability due to conflicting schedules with legal,
social services, and medical appointments.
Bowen et al. (2009) conducted a pilot study evaluating MBRP effectiveness for
individuals with multiple substance use disorders. They reported that 65% of study
participants (n=168) completed all of the MBRP groups sessions, and that 57%
completed a two-month follow-up while 73% completed a four-month follow-up. They
noted that 86% of study participants remaining after completion of the MBRP group
protocol reported continued engagement in mindfulness meditation practices.
In his study of a mindfulness-based treatment adapted from MBSR and used to
treat incarcerated youth with substance use disorders, Himelstein (2011) reported an 80%
completion rate for study participants (n=60). He observed that the participants not
completing the study had been transferred out of the incarceration facility and were thus
unable to complete the mindfulness group protocol.
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Bowen et al. (2017) identified low participant attendance and retention as adverse
feasibility factors in their study examining effects of the MBRP manualized treatment
with MAT program patients maintained on methadone. Out of 15 initial participants,
seven participants completed the study, a dropout rate of 53%. Bowen et al. asserted the
need for further research that might identify ameliorative strategies for these participatory
impediments including examination of factors affecting participant motivation and
otherwise interfering with participant retention.
In their study evaluating MBRP effectiveness for incarcerated persons with
substance use disorders Lyons et al. (2019) reported that out of 189 initial participants
126 completed the study, representing a dropout rate of 34%. While considerably less
dropout than experienced in the present study, an important distinction in this comparison
is that due to their incarcerated status the Lyons et al. study participants could be more
readily accessed and follow-up measures more readily implemented to better support
MBRP group attendance and overall study participant retention. These findings
demonstrate commonality with the participant dropout experienced in this study, and
point to the need for development of design counterstrategies that could reduce this
confound. Such efforts might include logistical support, including establishing
transportation support and adaptive scheduling of study MBRP group appointments to
reduce potential conflicts with participant existential needs.
Taken together, the studies discussed above suggest the finding of various
feasibility confounds also found during implementation of this study. The primary

200
feasibility concern evidenced in most studies was participant dropout, with relocation of
participants posing another observed confound. These studies, however, did not
experience feasibility problems, primarily dropout, of such severity that requisite
implementation requirements and statistical analyses could not be completed. Thus,
generalizability of study outcomes could not be determined. This suggests the need for
further studies examining participant dropout factors and study design methodologies that
may effectively reduce them.
Recommendations
Strategies to Improve Feasibility
The preceding discussion of study design and implementation feasibility problems
suggests the need for consideration of strategies that may effectively reduce or eliminate
them. As previously mentioned, one limitation that impeded implementation of this study
was that the entire study was overseen and implemented solely by the primary
investigator. This meant that there were no additional resources available for participant
pretest, midtest, and posttest data collection, or for facilitating the MBRP group. The
principal investigator, due to having full-time job responsibilities elsewhere, could only
be present at the study site once each week, and had no available qualified personnel
having the requisite knowledge, experience, and skill set for administration of measures
used in the study or MBRP group facilitation.
This availability limitation resulted in the inability of the principal investigator to
offer scheduling of data collection appointments and MBRP group services on multiple
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days and times that might have resulted in improved participant group attendance and
participant study retention, especially in cases where participants no-showed. A viable
solution for addressing participant no-shows and scheduling conflicts would be to assure
that a suitable number of research staff persons is recruited and trained for data collection
and MBRP group facilitation under the supervision of the principal investigator. This
substantial research staff could then offer study data collection and MBRP group
facilitation on differing weekdays and times to best assure participant attendance.
Financial resources sufficient for compensating needed research personnel might
be necessary. As an alternative, research personnel could be recruited from qualified
college and university students who would likely be willing to engage in study
implementation for the learning experience alone, rather than requiring financial
compensation. This student recruitment strategy was utilized to good effect in several
studies referenced earlier that evidenced significantly higher participant retention and
MBRP group attendance rates (Amaro et al., 2014; Bowen et al., 2009: Bowen et al.,
2017; Himelstein, 2011; & Zgierska et al., 2008) then that experienced during the course
of this study. Given the above distinctions in participant retention between this study and
the others, it is likely that availability of more research personnel is essential for effective
study implementation and should be an included element in study design.
An additional feasibility confound encountered in this study involved the
previously discussed difficulty participants reported in understanding several of the TMS
measure line items. The line item reinterpretive solution used by the principal
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investigator in this study was likely ineffective as it introduced several potential line item
administration validity confounds in addition to potential inconsistencies in and
inaccuracy of participant responses. Further, the effects of these confounds could not be
measured, and remain unknown.
To prevent further similar validity concerns for measures evaluating aspects of
participant mindfulness an alternative evaluative measure should be considered. One such
instrument is the FFMQ (Baer et al., 2008) utilized in the Bowen et al. (2009) study. The
FFMQ measure includes 39 line items wherein respondents use Likert scale response
ratings that assess for the presence of five factors thought to be representative of various
aspects of mindfulness: observing; describing; acting with awareness; nonjudging of
inner experience; and nonreactivity to inner experience (Baer et al., 2008). Alpha
coefficients for the five factors of FFMQ range from .67 to .92, suggesting good internal
consistency (Baer et al.). Bowen et al. (2008) reported no difficulties in participant
understanding and successful completion of the FFMQ. These considerations suggest the
FFMQ would likely be an effective alternative measure of participant mindfulness in
studies with design similar to this one.
Inconsistent participant attendance was a feasibility factor that adversely affected
outcomes of this study in both the TAU and MBRP IV levels. It was likely strongly
associated with the marked participant dropout observed during study implementation. In
most situations where a study participant no-showed she or he also no-showed for the
MAT program. In rare instances a small number of participants received MAT program
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services prior to their study implementation activities, and left the study site without
participating as scheduled. The no-show behavior common to both situations reduced
participant engagement with the study, a problem exacerbated by further no-shows with
resultant additional loss of study engagement. Further, in such instances the affected
MBRP group participants were unable to participate and thereby benefit from the group
processes, which likely fostered a correspondent reduction in perceived benefits from
group participation that would further reinforce the no-show behavior. In addition, noshows for the MAT program services tended to destabilize the patient in treatment,
thereby further reducing the likelihood of study participation.
Molfenter (2013) described several methods found to more effectively address
patient no-shows in MAT programs. These included providing appointment reminder
phone calls, creating a welcoming program environment through inclusion of behaviors
such as offering warm patient greetings from program staff, reducing wait times for
receiving program treatment services, utilizing contingency management interventions
and motivational interviewing practices, and creating more supportive relationships with
outside persons and agencies, such as social and legal services. Bowen et al. (2017)
reported similar findings reflecting the effectiveness of study staff engagement with
MAT program staff. Molfenter further found that the most effective of these strategies
was assuring a reduction in wait times for program services. The correspondence between
MAT program no-shows and participant no-shows observed in this study suggests that
employing these strategies to facilitate higher consistency of patient program attendance
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will likely reduce the frequency of participant no-shows for MBRP group meetings and
study measures administration appointments.
Additional procedures for reducing participant no-shows could include assuring
frequent and consistent communication between study research staff and MAT program
staff that would facilitate effective participant attendance monitoring and supportive
intervention where indicated. MAT program counselor staff should be informed of the
requirements for study participation so that they can assist in scheduling MAT program
and outside agency appointments such that they do not conflict with scheduled study
participant appointments. MAT program counselors could further facilitate participant
attendance by assisting them in addressing any relevant situational factors that increase
likelihood of no-shows, such as finding consistent and adequate transportation and
childcare, where applicable.
The effectiveness of the $ 25.00 gift card as participant compensation for study
completion was not evaluated during study implementation. Only three participants
completed the study, and none assigned to the MBRP group attended all eight meetings.
Parkinson, Meacock, Sutton, Fichera, Mills, Shorter, Treweek, Harman, Brown, Gillies,
and Bower (2019) identified three elements of incentive rewards: reimbursement for
participant expenses, reimbursement for participant time spent in study activities, and
additional incentive rewards for study participation and completion as required; the latter
being the reward strategy used in this study. Parkinson et al. (2019) found that providing
incentives during the study recruitment phase or at study conclusion was less effective
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than providing incentives at designated times throughout study implementation.
Parkinson et al. (2019) further found that incentives were significantly more effective at
motivating participation when structured in manner reflective of the context in which the
study occurs, such as assuring the reward is sufficient to be meaningful to the
participants. These findings suggest that rewards could be more effective in facilitating
participant adherence if offered periodically throughout the study and tied to completion
of interim study phases, e.g., pretest, midtest, and posttest in the case of this study. The
value of incentive awards should be carefully considered to assure participants will find
their awards sufficient given the time spent in study activities, and such compensation
should be weighed relative to assessed participant valuing of the reward amount.
In summary, the preceding study design and implementation discussion suggests
that having a sufficient number of well-trained research staff available at the study site is
essential. Additionally, use of a mindfulness measure that is culturally sensitive toward
and readily understandable by all study participants will increase validity in this
evaluative area. Efforts by MAT program staff to more effectively engage and retain
patients and provide more efficient services will likely foster correspondent
improvements in participant attendance for study activities implementation. MAT
program counselor support in resolving study participant problems that contribute to noshows, such as finding consistent transportation and childcare where needed, should be
considered. Finally, compensation to participants for study completion should be awarded
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at suitable intervals over the duration of study implementation, with care taken to assure
such compensation is sufficient to meet participant valuing of the reward amount.
Additional Recommendations for Future Research
This writer suggests that focus for future research include full consideration of
study design elements that may be adversely impacted by the feasibility confounds
experienced during implementation of this study. Participant no-show for MAT program
services was not evaluated in this study although no-shows appeared to exert a strong
adverse effect on study participation, in that participants who no-showed for MAT
program services also no-showed for study activities scheduled for that day. Future study
designs should consider inclusion of collaborative MAT program and research staff
strategies that will likely reduce participant no-shows. These would include reducing wait
times for receiving MAT program treatment services, facilitating collaboration between
MAT program staff and research staff in scheduling and supporting participant studyrelated appointments, providing participant appointment reminder phone calls, assuring a
welcoming program environment, and fostering supportive relationships with outside
persons and agencies.
Other effects of participant no-shows that should be considered in future study
designs include associated increase of participant opioid craving onset and resultant
increased relapse potential, which could destabilize the participant in MAT and
resultantly impede consistency of study participation. Future studies may need to include
use of measures that evaluate for and facilitate effective interventions for patient MAT
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program attendance problems, severity of substance use relapse potential, and further
include ameliorative strategies to minimize the frequency of these potential
implementation confounds.
A further important consideration in future study design is contingency planning
for possible MAT program operational concerns that may arise and interfere with study
implementation. Effective collaboration with MAT program administrative staff is
essential to study implementation, and should be included as a component of study
design.
Future studies should include measures that readily understandable by study
participants to assure fidelity of measures administration. An example of such a measure
could be the FFMQ (Baer et al., 2003) used to measure elements of participant
mindfulness.
Multiple weekly MBRP group meeting times should be utilized to assure
consistent participant attendance. Additionally, alternate media should be considered for
distribution of guided mindfulness mediations to participants. At present CDs are used
less frequently than other media options such as portable computer memory devices, e.g.,
USB (universal serial bus) drives, cell phones, and computer programs that are available
on the internet. Having MBRP group worksheet assignments and meditation exercises
distributed via these more modern communication options would likely facilitate more
consistent participant adherence to these required elements essential to assuring fidelity
to specified MBRP group implementation standards. Use of the mindfulness-based
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relapse prevention adherence and competence scale developed by Chawla et al. (2010)
would likely assure more effective monitoring and evaluation for fidelity during
implementation of the MBRP manualized group treatment.
Alternate participant incentive strategies could be considered in order to reduce
participant no-shows and foster more consistency in participant attendance at scheduled
study group meetings and measures administration activities. In their literature review
Stizer and Petry (2006) found that contingency management practices are effective in
improving patient attendance for medication and therapy sessions in MAT program
settings. Parkinsen el al. (2019) asserted that monetary incentives are more effective than
their alternatives, although some findiings suggest that they can in some cases reduce
intrinsic motivation for participants. Parkinsen at al. observed that timing of incentives is
critical, that payouts should be temporally associated with completion of key study tasks
assigned to participants. Further, they recommended parsing out incentive payouts over
the duration of the study implementation to better sustain participant motivation.
Considered together, these findings suggest that future studies should utilize incentive
compensation over time as important participant requirements are met to enhance
participant motivation, engagement, and retention. Such a strategy would likely more
effectively support consistent rates of participant MPRP group attendance and
attendance for pretest, midtest, and posttest data collection.
An additional study approach could include use of a design similar to this one but
involving two distinct MAT program sites. This would offer the advantages of greater
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initial participant enrollment and likely sufficient retention of enough participants to
achieve sufficient power for statistical analysis. Outcomes of the two sites could be
compared using MANCOVA analysis to determine if significant, distinct effects are
found between the two sites. This approach would likely reduce extant confounds arising
from unique factors affecting study implementation at only one site. The two sites might
exhibit distinct prevalence of participant demographic, social, medical, or psychiatric
conditions that facilitate broader generalization characteristics with the total population of
individuals with opioid use disorder.
Qualitative study design approaches may be considered for future studies. Use of
both structured and unstructured data gathering using naturalistic observation and
participant interviews (Berkwits & Inui, 1998) would foster awareness of feasibility
considerations that could then support subsequent quantitative study design better
structured to avoid those identified feasibility confounds. For example, participant data
could identify factors interfering with participant attendance gathered through direct
observation and interview techniques that when categorized result in study design that
minimizes potential for such quantitative study implementation barriers to occur.
Additionally, MAT program patient interviews might reveal useful information through
soliciting patient observations regarding elements of study implementation that would be
useful for future study design approaches, such as pragmatic factors that influence
participant attendance.
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Future research could consider evaluation of alternative manualized treatment
approaches. It may be that alternative measures of participant mindfulness such as the
FFMQ; (Baer et al., 2003) could be utilized to rule out the understandability problems
encountered with use of the TMS (Lau et al., 2006) measure in this study. Additionally,
multiple measures of mindfulness could be used to evaluate for differences between the
TMS and FFMQ outcomes, for example. The OCS (McHugh et al., 2014) measure used
in this study was readily understood by participants, as was the ASI Alcohol/Drugs
subscale (McLellan et al., 1985), so it may be that these measures could be retained for
use in future studies.
Future research may need to evaluate for the impact of the covid disease 2019
(COVID19) epidemic on frequency and severity of OUD-associated relapse and
overdose. In their study evaluating changes in medical services and treatment outcomes
for Veterans Administration patients with OUD, Abdel-Sattar et al. (2021) found that the
availability of OUD treatment services for veterans was adversely impacted due to
reductions in treatment facility staffing and hours of operation. Abdel-Sattar et al. noted
that VA patients with OUD reported a 25% increase in relapse rates, a 45% increase in
overdose rates, and 45% increase in emergency room visits during the study period.
Abdel-Sattar et al. further noted that multiple patients surveyed expressed a need for
OUD treatment medication dosage increases and greater availability of psychological and
social support services.
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Haley and Saitz (2020) found there were significant increases in opioid misuse
overdoses and deaths during 2019, primarily associated with illegal fentanyl use and the
combined use of opioids and methamphetamine during the year period. However, Haley
and Saitz further found the need for additional studies to confirm these findings. The
Centers for Disease Control (CDC; 2020) reported an increase from prior years to 81,000
drug overdose deaths for the period from June 2019 through May 2020, with reports from
multiple areas across the US revealing a 50% to 98% increase in opioid use related
deaths, depending on the reporting area, the western area of the US showing the highest
frequency of opioid deaths. The CDC further found that the synthetic opioid fentanyl was
the drug most frequently associated with opioid overdose deaths, increasing by more than
38% over the reporting year ending May 2020.
Given the continued presence of the COVID19 epidemic, these findings argue for
effective treatment solutions that incorporate the additional factors individuals with OUD
encounter when isolated and experiencing concomitant conditions such as depression,
anxiety, and trauma associated with the loss of significant others.
Implications
Potential Impact for Positive Social Change
The prevalence of OUD and its associated adverse public health problems,
including overdose deaths, impaired physical and mental health, impairments to social
functioning, and societal costs associated with these conditions has been clearly
established. The CDC (2021) reported that an approximated 500,000 individuals died

212
from an opioid overdose during the period from 1999 to 2000. The CDC described the
opioid use epidemic as occurring in three waves. The first wave began with a marked
increase in opioid prescriptions during the decade beginning in 1990 (CDC). The second
wave ensued in the year 2010 and was characterized by a significant increase in heroin
overdose deaths (CDC). The third wave started in the year 2013, continuing to the
present, and has been characterized by a marked shift to and predominance of synthetic
opioid deaths (CDC). This more recent trend has worsened in association with the
COVID19 pandemic, as noted in the CDC (2020) report describing a 38.4% increase in
opioid overdose deaths for the year period ending in May, 2020. These trends strongly
suggest that opioid misuse in the U.S. is a severe, pervasive, and worsening problem of
epidemic proportions.
There are multiple socioeconomic costs associated with the opioid
epidemic. Florence et al. (2021) observed that the aggregate economic costs of opioid use
in the U.S for the year 2017 were estimated at $1,021 billion dollars, comprised of $471
billion dollars associated with opioid use disorder costs, and $550 billion dollars for
opioid overdose. These costs reflect healthcare including hospitalizations and emergency
room care, opioid use treatment, criminal justice involvement, lost work productivity, and
reduced quality of life for the individuals experiencing OUD (APA, 2013). Persons with
OUD experience the preceding costs at an immediate level, experiencing substantial harm
to their personal well-being, interpersonal relationships, and familial functioning.
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Although MAT programs offer evidence-based, effective treatment for
individuals with OUD, relapse remains a significant risk. These severe and pervasive
problems argue for more extensive research regarding treatments, such as MBRP, that
may increase effectiveness of methadone-maintained MAT program patients. Research
evaluating such potential interventions may ultimately result in establishing clinically
effective treatment options that integrate with existing opioid use disorder treatments,
enhancing the effectiveness of existing opioid use disorder treatment and thereby
reducing the public health, behavioral, social, and legal problems as well as the severe
human suffering concomitant with illicit opioid relapse.
This research supported positive social change through attempted evaluation of
the MBRP (Bowen et al., 2011) manualized treatment used as a treatment adjunct that
can be provided at the MAT program site, with minimal impact on existing MAT
program operations and staffing. The multiple feasibility problems encountered during
study implementation determined information about study feasibility confounds that will
support future research through providing enhanced understanding of study feasibility
problems to be considered when developing future similar study designs.
Conclusion
This study represented an attempt to evaluate effectiveness of participant
exposure to MBRP manualized treatment (Bowen et al., 2011) used as an adjunct to
treatment as usual provided in the context of a MAT program setting. Participants were
voluntarily enrolled in the study and were randomly assigned to either the MBRP group
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or treatment as usual. The ASI Drug/Alcohol subscale (McLellan et al., 1985), OCS
McHugh et al., 2014), and TMS (Lau et al., 2006) measures were administered at pretest,
midtest, and posttest intervals to provide data planned for within and between groups
MANCOVA analysis. Participant retention and inconsistent MBRP group attendance
proved to be severely limiting study implementation feasibility factors such that reliable,
consistent data could not be collected to achieve a valid statistical analysis of study data
outcomes. Several suggestions for future research that may more effectively address
feasibility confounds encountered in this study have been offered for consideration.
The increasingly severe opioid use epidemic observed in the United States over
the past decade strongly suggests that future studies evaluating effectiveness of
adjunctive treatment interventions such as MBRP for individuals with opioid use disorder
concurrently enrolled in a MAT program are essential. It is critical that treatment
effectiveness for persons with OUD is enhanced through research that leads to additional
evidence-based treatments and interventions that will more effectively address the social
and fiscal deficits and, most importantly, the human costs associated with the opioid use
epidemic.
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Appendix A: Outline of the MBRP Manualized Treatment Protocol

Week one, consisting of participant orientation to the course requirements (Bowen et
al., 2011):
•

review of the nature of mindfulness;

•

overview of course structure and approach;

•

clarification of privacy and confidentiality requirements;

•

mindfulness exercise focused on eating a single raisin (similar to that used in
MBSR);

•

the body scan mindfulness exercise (also similar to that used in MBSR), and

•

psychoeducation regarding association between automatized responding and
relapse.

Week two, focused on substance use triggers identification and observation of
associated phenomena (Bowen et al., 2011):
•

review and discussion of challenges encountered during mindfulness
meditation sessions and how to cope with them;

•

the nature of aversion, craving and desire, restlessness and agitation,
drowsiness and sleepiness, and doubt;
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•

guided exercises including body scan meditation; urge surfing meditation (see
description below) for addressing substance use cravings; and mountain
meditation for affective calming;

•

homework assignment involving daily formal and informal meditation
exercises;

•

completion of CBT worksheet focused on substance use trigger identification
and indicating associated responses;

•

completion of daily meditation tracking sheet; and

•

brief closing meditation on silence.

Week three, focused on cultivating a mindful approach to daily living (Bowen et al.,
2011):
•

participant check-in;

•

review of past week’s assignments;

•

guided exercises including awareness of hearing meditation, breath
meditation, and SOBER breathing space meditation (see description below);

•

review of meditation exercise and practice tracking homework assignments;
and

•

brief closing meditation on silence.

Week four, focused on use of mindfulness to cope with substance use and associated
risk behaviors (Bowen et al., 2011):
•

participant check-in;
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•

review and discussion of prior week’s homework assignments;

•

guided exercises including awareness of seeing meditation, sitting meditation
on sound, breath, sensation, and thought, and walking meditation;

•

group discussion of relapse risks;

•

use of SOBER breathing space mediation in an elevated risk situation; review
of homework assignments; and

•

brief closing meditation on silence.

Week five, focused on balancing acceptance and effective behavioral responding
(Bowen et al., 2011):
•

participant check-in;

•

review and discussion of prior week’s homework assignments;

•

guided exercises including sitting meditation on sound, breath, sensation,
thought, and emotion, SOBER breathing space meditation with paired
participants, and mindful movement meditation exercise;

•

group discussion about use of the SOBER breathing space;

•

review of homework assignments; and

•

brief closing meditation on silence.

Week six, focused on understanding the nature of thoughts (Bowen et al., 2011):
•

participant check-in;

•

review and discussion of prior week’s homework assignments;
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•

guided exercises including sitting meditation on thoughts and SOBER
breathing space meditation;

•

group discussion on observing and labeling thoughts;

•

group discussion on association between maladaptive thoughts and substance
use relapse;

•

psychoeducation and group discussion on the relapse cycle, including
elements of adaptive mindful responding to substance use triggers and
maladaptive automatized responding;

•

review of homework assignments;

•

discussion and preparation for end of the course; and

•

brief closing meditation on silence.

Week seven: focused on establishing and assuring continued well-being (Bowen et
al., 2011):
•

participant check-in;

•

review and discussion of prior week’s homework assignments;

•

guided exercises including meditation on compassion and SOBER breathing
space meditation;

•

exercise on creating a daily activities worksheet that compares and contrasts
practitioner affective experience associated with positive and negative
situations;

•

discussion on the nature of relapse: when, where, and how it begins;
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•

exercise on creating individualized relapse prevention strategy reminder cards
for practitioners to carry with them;

•

review of homework assignments; and

•

brief closing meditation on silence.

Week eight: focused on developing and maintaining support systems for continued
mindfulness practice and sustaining recovery from substance use (Bowen et al., 2011):
•

participant check-in;

•

review and discussion of prior week’s homework assignments;

•

guided exercises including body scan meditation and concluding meditation;

•

group discussion of the need for support networks; discussion of participant
perspectives on the course experience;

•

discussion of participant intentions for continuing mindfulness and recovery
work;

•

closing circle exercise; and

•

brief closing meditation on silence.
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Welcome to all MAT program participants!

You are invited to take part in a research study for the doctoral dissertation
of Stephen Sooter, MS, from Walden University that is evaluating the effects
of Mindfulness Based Relapse Prevention (MBRP) on illicit opioid use for
patients participating in this Medication Assistant Treatment (MAT)
program. This study will be used to find out if MBRP participation can help
MAT patients prevent or reduce relapse to illicit opioid use.
If you participate you will be randomly assigned to either a treatment as
usual (TAU) study group or to an experimental study group which includes
TAU and the Mindfulness Based Relapse Prevention (MBRP) weekly group
meetings offered here at the program. If participating, you will be asked to
provide answers to two brief surveys at the beginning of the study, in the
middle, and at the end, and to consent to disclosure of other program
information including your drug use during the study period and your
MBRP session attendance. If you satisfactorily complete the 8-week study
you will be eligible for a $ 25.00 gift card. You may discontinue the study at
any time without penalty, and your MAT program status will not be affected
in any way by discontinuing the study.
Your information will be assigned to a random number. No names or other
private identifying information will be used without your written permission.
All study data will be retained in a way that fully protects your privacy and
confidentiality.
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The study is planned to start on Wednesday, August 21, 2016. Please contact
Stephen Sooter, the principal investigator for the study if you are interested
in finding out more about this study.
Thanks for your consideration.
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Appendix C: Informed Consent Form

INFORMED CONSENT
You are invited to take part in a research study that is evaluating the effects of
participation in Mindfulness Based Relapse Prevention (MBRP) on illicit opioid use for
patients participating in this Medication Assistant Treatment (MAT) program. The MBRP
is designed to find out if mindfulness meditation and other therapeutic practices can
help persons with opioid use disorders prevent relapse to illicit opioid use.
The researcher is inviting persons who are currently enrolled in MAT program treatment
using methadone medication to be in the study. This form is part of a process called
“informed consent” to allow you to understand this study before deciding whether to
take part.
This study is being conducted by a researcher named Stephen Sooter, who is a doctoral
student in the clinical psychology program at Walden University. The MBRP group
facilitation is being offered at the BAART MAT program site and is being conducted by
the study principal investigator.
Background Information:
The purpose of this study is to evaluate the effectiveness of the MBRP treatment in
reducing illicit opioid use for MAT program patients.
Procedures:
If you agree to be in this study, you will be asked to:
•
•

•

•

participate in your MAT program dosing and counseling services as you
normally do;
Meet individually with the principal investigator to take a short test called
the Addiction Severity Index Drug/Alcohol Scale at the beginning, middle,
and end of the study;
Meet individually with the principal investigator to take two very short tests
(15 questions or less) about mindfulness: once at the beginning and again at
the end of the study; and
if you are in the study experimental group:
a. meet once weekly for about 1.5 hours in the MBRP group;
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b. complete weekly homework assignments that are related to the group
process, which require very little time and are easy to do;
c. bring completed homework assignments to the weekly group meetings;
and
d. practice guided meditation exercises on your own for a few minutes each
day; you are provided a CD of the exercises for this purpose, which you
can keep after the study ends.
Here are some sample test questions:
Below is a collection of statements about your everyday experience. Using the 1–6 scale
below, please indicate how frequently or infrequently you currently have each
experience. Please answer according to what really reflects your experience rather than
what you think your experience should be.
1

2

3

4

5

6

Almost

Very frequently

Somewhat

Somewhat

Very

Almost never

frequently

infrequently

infrequently

always
1.

_____It seems I am “running on automatic” without much awareness of what I’m doing.

2.

_____I rush through activities without being really attentive to them.

3.

_____I get so focused on the goal I want to achieve that I lose touch with what I am doing right now
to get there.

4.

_____I do jobs or tasks automatically, without being aware of what I’m doing.

5.

_____I find myself listening to someone with one ear, doing something else at the same time.

6.

_____I drive places on “automatic pilot” and then wonder why I went there.

7.

_____I find myself preoccupied with the future or the past.

8.

_____I find myself doing things without paying attention.

9.

_____I snack without being aware that I’m eating.

Voluntary Nature of the Study:
This study is voluntary. Everyone will respect your decision of whether or not you
choose to be in the study. No one at BAART Programs or at this MAT program site will
treat you differently if you decide not to be in the study. If you decide to join the study
now, you can still change your mind later. You may stop at any time. If you stop
participating in the study your MAT program will not be affected in any way.
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Risks and Benefits of Being in the Study:
Being in this type of study is unlikely to involve any discomfort above and beyond what
you might normally encounter or experience in your daily life. Some persons may
experience a small amount of stress due to the testing and group participation
requirements explained above, although these are not extensive or overly time
consuming. Being in this study poses minimal risk to your safety and wellbeing. The
study includes a reporting and intervention procedure to assist you if you experience
any adverse effects resulting from your participation.
Potential benefits of this study include the completion of initial research for the MAT
program population that may help develop such relapse prevention programs for use in
MAT programs throughout the BAART system and beyond. Any such relapse prevention
methods are likely to improve quality of life for the participants and reduce risk of
relapse and the harm that can follow from it.
Payment:
Each participant that completes the full two-month study period, participating as
required, will receive a $ 25.00 gift card in acknowledgement of his or her study
participation. Should you elect to leave the study before completion, not complete
requested tests, or not participate in all eight MBSR weekly group meetings (if required
for you) you will not receive the gift card. Gift cards will be distributed to all study
participants within two weeks after the study ends.
Privacy:
Any information you provide will be kept confidential and private. The researcher will
not use your personal information for any purposes outside of this research project.
Also, the researcher will not include your name or anything else that could identify you
in the study reports. Hardcopy data will be kept secure by being retained in a locking file
cabinet at the program site. Electronically stored data will be securely retained for a
period of at least 5 years, as required by Walden University.
Contacts and Questions:
You may ask any questions you have any now. Or if you have questions later, you may
contact the researcher via and/or via email at the email address. If you want to talk
privately about your rights as a participant, you can call Dr. Leilani Endicott. She is the
Walden University representative who can discuss this with you. Her phone number is
Insert ONE number depending on location of participant 612-312-1210 (for US based
participants) OR 001-612-312-1210 (for participants outside the US). Walden
University’s approval number for this study is [IRB will enter approval number here] and
it expires on [IRB will enter expiration date].
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The researcher will give you a copy of this form to keep for your records.
Statement of Consent:
I have read the above information and I feel I understand the study well enough to
decide about my involvement. By signing below, I understand that I am agreeing to the
terms described above.
Printed Name of Participant:

____________________________________________________

Date of consent:

____________________________________________________

Participant’s Signature:

____________________________________________________

Researcher’s Signature:

____________________________________________________
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Appendix E: Adverse Event Report

Participant Report of Adverse Event
Participant ID Number: ____________
Date of Event: ____________
Participant Report of Event:

Description of Adverse Effects:

□ Participant Consent to Disclose above information to MAT program physician
obtained (see attached).

□ Participant referral to MAT program physician made.
□ Participant informed of right to discontinue study participation immediately.
□ Participant informed that study discontinuance will not in any way affect continued
enrollment in the MAT program.

□ Program physician provided a copy of this adverse event report.
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I, the undersigned Principal Investigator in this study, hereby certify that the above
documentation is true and accurate, and that all action indicated above has been
implemented in accord with study procedural requirements.

Principal Investigator Signature/Date: ____________________________________
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AUTHORIZATION FOR USE AND DISCLOSURE OF
PROTECTED HEALTH INFORMATION
Name of patient:

Date of Birth:

I hereby authorize the use and disclosure of protected health information about the above patient as
follows:
From (Name of person, class of persons, or organization
authorized to make the requested use or disclosure):
(check whichever is applicable)
Stephen Sooter, MS
Study Principal Investigator

To (Name of person, class of persons, or organization
authorized to receive and use my protected health
information):
Program Physician
BAART Programs
1124 International Blvd.
Oakland, CA 994606

Description of patient’s protected health information to be used or disclosed:
Study participant report of adverse event experienced during study participation.
Principal Investigator’s description of adverse events.
¨ Patient must initial this box if this consent authorizes furnishing HIV test results or other HIV
identifying information.

Patient’s protected health information is being used or disclosed for the following purpose(s):
Provide clinically indicated assessment and intervention in response to reported experiencing by study
participant of adverse event.

I understand that I have the following rights with respect to this Authorization:
1. The recipient of the protected health information may not further disclose the information unless
the recipient obtains another authorization from me or unless the disclosure is specifically required
or permitted by law.
2. I may not be required to sign this Authorization as a condition to obtaining treatment or payment or
my eligibility for benefits.
3. BAART Programs will provide me with a copy of this Authorization.
4. I may revoke this Authorization at any time by mailing or personally delivering a signed, written
notice of revocation to BAART Programs at the clinic where I am a patient. Such revocation will
be effective upon receipt, except to the extent that the recipient has taken action in reliance on this
Authorization.
5. I understand that I am entitled to notice if BAART Programs will use or disclose the protected
health information for marketing and receive payment for the use or disclosure of my protected
health information.
will þ will not receive compensation for the use or disclosure of my protected
health information.
This authorization will expire on/when: within one year of date of signing, unless otherwise
specified.

BAART Programs
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Signature of Patient/Personal Representative*

Describe Personal relationship to patient

Date

Address and Telephone number of Patient/Representative:

*The personal representative is any of the following:
•
A conservator of the patient’s person;
•
An agent appointed by the patient under a power of attorney for health care if
the patient does not have capacity to sign the authorization;
•
Any other individual who has the legal authority to make health care decisions
on the patient’s behalf; or
If the patient is deceased, an executor or administrator of the patient’s estate or, if
none, a spouse or, if no spouse, any responsible family member.
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Appendix G: Curriculum Vita

Stephen Sooter, MS
Objective

To obtain a teaching position as an Addiction Studies Adjunct Instructor

Experience

1993–2019
Antioch, CA
•
•
•
•
•
•

Overall responsibility for all aspects of program operations.
Ensure program compliance with all applicable federal & state regulations.
Facilitation of CARF Accreditation, Medi-Cal Certification, and DHCS Licensing.
Outreach and education to communities, families, and other groups.
Patient group counseling and assessment policies and procedures development.
Directed startup of Oakland program operations in fall, 2007.

2012-2016
•
•
•
•
•
•
•

•
•
•
•

Psychological Assistant

Bay Area, CA

Provision of individual, group, and couples psychotherapy services at multiple sites
under supervision of Dr. Ron Perry, PsyD.
Provision of training, group, and individual supervision to psychological interns.
Provision of individual psychotherapy to adults with psychiatric and co-occurring
disorders at Healthy Partnerships in Fairfield, Ca.
Implementation of mindfulness based relapse prevention group services to pregnant
and parenting women at Wollam House residential treatment, Pittsburg, Ca.
Development and implementation of group psychotherapy services using
Mindfulness Based Stress Reduction therapeutic approaches and interventions.
Development and implementation of group psychotherapy services using Acceptance
and Commitment Therapy therapeutic approaches and interventions.
Provision of Mindfulness Based Relapse Prevention group and individual services.

2012- 2013
University
•

Clinic Director, BAART Programs

Psychological Practicum/Internship

Walden

All services provided under supervision agreement between Walden University and
Dr. Ron Perry, PsyD.
Provision of individual and group psychotherapy services to pregnant and parenting
women at Wollam House residential treatment facility, Pittsburg, Ca.
Provision of individual psychotherapy services for adults with substance use
disorders at Chance for Freedom in Concord, Ca., and Pittsburg, Ca.
Provision of individual, group psychotherapy services for persons with psychiatric
and co-occurring disorders at offices of Drs. Ron Perry, PsyD and Carolyn Schuman,
MD in Berkeley, Ca.
Development of psychological intern training manual.
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2010-2012
University
•
•
•

•

•

•
•
Education

•
•
•
•
•
•
•

Supervising Counselor, BAART Programs

Assist clinic director in managing program operations.
Conduct quality assurance review of patient records.
Orientation, training, and administrative/clinical supervision of counseling staff.
Support of program policies & procedures implementation and adherence
monitoring.

1988–1992
•

Walden

June 16-20, 2010 – orientation in academic residency requirements. Academic
research and writing skills.
January 7-20, 2011 – introduction to cognitive and personality assessment.
Quantitative, qualitative, and mixed-methods research design and implementation
methodologies. Interviewing and observational strategies.
July 15-28, 2011 – psychological testing: research, approaches, and administration
for Brief Symptom Inventory, MMPI-2, NEO-PI, Rorschach, WAIS-IV, WISC-IV,
WIAT, Woodcock-Johnson III; cognitive, behavioral, personality, and mental status
assessment.
August 4-8, 2011 – American Psychological Association ethical principles,
standards, and professional codes of conduct. Evidence-based treatment approaches
and interventions: motivational interviewing practices, integrated group
psychotherapy practices, cognitive behavioral therapy practices, and brief
interpersonal therapy practices.
January 6-19, 2012 – diagnosis, case conceptualization, and psychological report
writing using American Psychiatric Association DSM criteria. APA dissertation
writing style requirements. Statistical design and data analysis. Research
presentation. Group process: clinical approaches, ethical and legal considerations.
Mindfulness in clinical practice.

1992–1993
Pittsburg, CA
•
•
•
•

Academic Residencies

Counselor, BAART Programs

Pittsburg, CA

Provide individual counseling services for up to 40 clients with substance use
disorders.
Maintain patient record documentation in accordance with regulations.
Developed and facilitated pregnant patient support group.
Doctor of Philosophy in Clinical Psychology, Walden University, currently in
progress.
Doctoral dissertation proposal: The Effects of Mindful Attentional Regulation on
Illicit Opioid Use for Individuals Participating in Medication Assisted Treatment: A
Pilot Study
Master of Science, Psychology, Walden University, February 2010.
Certification in Chemical Dependence Studies, CSUH, 2005.
Bachelor of Arts, Music, California State University Hayward, June 1988.
Honors Citation, CSUH Department of Psychology, December 1986.
National Dean’s List, 1987.
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Professional
Affiliations

•

Associate of Arts, with honors, Los Medanos College, June 1984.

•
•
•

Psychological Assistant (PSB36626) California Board of Psychology
Affiliate Member, American Psychological Association (APA; 9006-9898)
Professional Member, National Association for Alcoholism & Drug Abuse Counselors
(NAADAC; 103307)
Member, Western Psychological Association (WPA; 5887400)
Certified Addictions Treatment Counselor, CAADE (S0412271058)
Registered Addiction Specialist certification, Breining Institute (S0412271058)
Composer Member, American Society of Composers, Authors, & Publishers
(ASCAP)

•
•
•
•

Personal
Interests

Psychological, philosophical, neurobiological, and physical sciences;
mindfulness practices; music composition and performance; walking;
baseball; football.
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Appendix H: Letter of Cooperation for Data Management
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Letter of Cooperation For
Data Management
This letter of cooperation describes the components of data collection, procedures to
be followed, and the roles and responsibilities of the organization known as BAART
Programs, Inc. ("BAART Programs") in the doctoral dissertation research study being
conducted by Stephen Sooter, MS as partial fulfillment of his requirements in the
Walden University Clinical Psychology PhD program. It is understood that BayMark
Health Services, Inc. ("BayMark") is the parent organization of BAART Programs, and
that David
K. White, as the Chief Executive Officer of BayMark, is authorized to review and sign
this Letter of Cooperation as required.
Stephen Sooter is the Principal Investigator for this study, and is employed by BAART
Programs and as a Treatment Center Director at the Antioch, California program site.
BAART Programs has reviewed this study design, documentation, and implementation
procedures, as presented by Stephen Sooter. BAART Programs has authorized the release
of certain data to Stephen Sooter pursuant to a Data Use Agreement, for the purpose of
his dissertation analysis. Walden University oversight of this study is limited to the final
dissertation analyses only.
Part I: Participant Consent:
Consent from each potential study participant will be obtained prior to enrollment in the study as
follows:
•

A consent compliant with HIPAA and 42 CFR part 2 to disclose from each participant
authorizing the following:
a. The principal investigator to meet with him or her and review
elements of BAART informed consent and participate in post-data
collection period debriefing;
b. Disclosure to the principal investigator of the pre-test, mid-test, and posttest measures outcomes data used in the study;
c.

Verification of MBRP group participation and homework assignment
completion for the duration of the study by the principal investigator;

d. Verification of each participant's MAT program participation in daily
medication dosing as prescribed by the program physician and individual
counseling services as required by the program;
e. Disclosure by the principal investigator to the on-site BAART Programs
physician of any event or condition associated with study implementation that
exerts adverse effects on the participant; and
f.

Provision that each participant has the right to revoke his or her consent to
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disclose at any time without any adverse action from the principal
investigator, BAART Programs, or BayMark.
•

Informed consent for each participant to participate in the study, which will
authorize the following:
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a.

The principal investigator to meet with him or her and review elements of the BAART
Programs' informed consent and participate in post-data collection period debriefing;

b.

Random assignment of participants by the principal investigator to either the adjunct MBRP
group participation or the treatment as usual only study group levels;

c.

Administration and outcomes data collection, scoring, and analyses by the principal
investigator of the Addiction Severity Index Drug & Alcohol Scale (McClellan et al., 1985) at
pre-, mid-, and post-test intervals;

d.

Test administration and outcomes data collection, scoring, and analyses by the principal
investigator of the Opioid Craving Scale (McHugh et al., 2014) at pre-, mid-, and post- test
intervals;

e.

Test administration and outcomes data collection, scoring, and analyses by the principal
investigator of the Toronto Mindfulness Scale (Lau et al., 2006) at pre-, mid-, and post- test
intervals;

f.

Disclosure to the principal investigator of each adjunct MBRP group-assigned participant's
MBRP group participation and homework assignment completion for the duration of the study;

g.

Verification of each participant's continued MAT program participation for the duration of the
study as determined by methadone medication dosing and individual counseling session
participation;

h.

Hard copy participant data collection by the principal investigator that is securely stored in a

i.

locking file cabinet retained at the program site where the principal investigator works;
Electronic participant data collection that is used and stored by the principal investigator

using methods that assure the privacy and confidentiality of each study participant;
j.

Disclosure of any event or condition associated with study implementation that exerts adverse

k.

Each participant's right to discontinue his or her participation in the study without any

effects on the participant to the program physician at the study site; and
adverse action from principal investigator, BAART Programs, or BayMark.
Part II: Provision of the MBRP Group Services:

•

Once all requisite participant consents have been effected, the principal investigator will use a random
number table to assign study participants to either the treatment as usual (TAU) control group or the
TAU plus MBRP group experimental group, resulting at the outset in equal or approximately equal
numbers of participants in each group;

•

The MBRP Group services will be provided at the study site by the principal investigator;

•

The principal investigator will be responsible for administering test measures and collecting pre- test (prior
to beginning MBRP group), mid-test (after four weeks of MBRP group) and post-test (after final week of
MBRP group) MBRP group participation and homework completion data. This data consists of
verification of MBRP group attendance (or absence} and verification of MBRP group homework
assignment completion .
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Part Ill: Pre-Test, Mid-Test, and Post-Test Data Collection Measures:
The principal investigator is responsible for administration and data collection of the following measures at pre-test, mid-test
(after four weeks of MBRP group services), and post-test (after eighth week of MBRP group services)intervals:
•

The Addiction Severity Index (ASI) Alcohol/Drugs subscale (McClellan et al., 1985);

•

The Opioid Craving Scale (OCS; McHugh et al., 2014); and

•

The Toronto Mindfulness Scale (TMS; Lau et al., 2006).

Part IV: Pre-test Data Analysis:

•

Given the complexity of multivariate data gathered over distinct periods in this study,

•

Software used for data analysis in this study implementation phase will be the Statistical Package for the

Multivariate Analysis of Covariance (MANCOVA) statistical testing will used.
Social Sciences version 24 (SPSS; International Business Machines, 2018), with the alpha value set at .OS
for all statistical procedures used. All outcomes data will be uploaded into a computer running SPSS
software and results that will be calculated by the SPSS program.
•

De-identified statistical data outcomes will used by the principal investigator to create data tables
for further study data analysis and outcome reporting.

•

After pre-test computerized data entry is completed, the principal investigator will run a statistical data
analysis comparing the Opioid Craving Scale outcome pre- and mid-test scale scores, and comparing
the ASI Alcohol/Drugs subscale pre- and mid-test scores.

•

Each participant data entry record will be crosschecked against the original documentation provided
by the study site coordinator to assure data entry integrity.

•

A complete descriptive data analysis procedure will be run on all study variables using the SPSS program,
thereby crosschecking to assure that data outliers or entry errors are not significantly skewing data outcomes.

•

Finally, the SPSS Data Validation procedure will be run to assure that missing or erroneous data entries are
not influencing data analyses outcomes.

•

The principal investigator will be responsible to assure that all outcomes data are accurately
transcribed, that appropriate statistical tests are run, and that inferences made from these results are
interpreted accurately in accord with the statistical model used (MANCOVA) and experimental
design utilized.

•

De-identified statistical data outcomes will used by the principal investigator to create data tables
for further study data analysis and outcome reporting.

Part IV: Mid-Test Data Analysis:

•

Given the complexity of multivariate data gathered over distinct periods in this study,
Multivariate Analysis of Covariance {MANCOVA) statistical testing will used.

•

Software used for data analysis in this study implementation phase will be the Statistical Package for the
Social Sciences version 24 (SPSS; International Business Machines, 2018), with
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the alpha value set at .OS for all statistical procedures used. All outcomes data will be uploaded into a
computer running SPSS software and results that will be calculated by the SPSS program.
•

After mid-test computerized data entry is completed, the principal investigator will run a statistical data
analysis comparing the Opioid Craving Scale outcome pre- and mid-test scale scores, and comparing
the ASI Alcohol/Drugs subscale pre- and mid-test scores.

•

Should any significant (p= .05) increases in either the Opioid Craving Scale scores or the ASI
Alcohol/Drugs subscale scores be determined, the principal investigator will proceed with
implementation of data safety measures (see Data Safety Agreement).

•

Each participant data entry record will be crosschecked against the original documentation provided
by the study site coordinator to assure data entry integrity.

•

A complete descriptive data analysis procedure will be run on all study variables using the SPSS program,
thereby crosschecking to assure that data outliers or entry errors are not significantly skewing data outcomes.

•

Finally, the SPSS Data Validation procedure will be run to assure that missing or erroneous data entries are
not influencing data analyses outcomes.

•

De-identified statistical data outcomes will used by the principal investigator to create data tables
for further study data analysis and outcome reporting.

•

The principal investigator will be responsible to assure that all outcomes data are accurately
transcribed, that appropriate statistical tests are run, and that inferences made from these results are
interpreted accurately in accord with the statistical model used (MANCOVA) and experimental
design utilized.

•

De-identified statistical data outcomes will used by the principal investigator to create data tables
for further study data analysis and outcome reporting.

Part V: Post-Test data Analysis:
•

Given the complexity of multivariate data gathered over distinct periods in this study,
Multivariate Analysis of Covariance (MANCOVA) statistical testing will used.

•

Software used for data analysis in this study implementation phase will be the Statistical Package for the
Social Sciences version 24 (SPSS; International Business Machines, 2018}, with the alpha value set at .OS
for all statistical procedures used. All outcomes data will be uploaded into a computer running SPSS
software and results that will be calculated by the SPSS program.

•

After post-test computerized data entry is completed, the principal investigator will run a statistical data
analysis comparing the Opioid Craving Scale outcome pre- and post-test scale scores, and comparing
the ASI Alcohol/Drugs subscale pre- and post-test scores.

•

Should any significant (p= .OS} increases in either the Opioid Craving Scale scores or the ASI
Alcohol/Drugs subscale scores be determined, the principal investigator will proceed with
implementation of data safety measures (see Data Safety Agreement).

•

Assuming there are no significant post-test increases in participant opioid use or cravings, the principal
investigator will run statistical analyses of the data on the password protected, encrypted computer.
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•

A complete descriptive data analysis procedure will be run on all study variables using the SPSS
program, thereby crosschecking to assure that data outliers or entry errors are not significantly
skewing data outcomes.

•

Finally, the SPSS Data Validation procedure will be run to assure that missing or erroneous data

•

De-identified statistical data outcomes will used by the principal investigator to create

entries are not influencing data analyses outcomes.
data tables for further study data analysis and outcome reporting.
Part VI: Data Retention and Destruction:

•

All hard copies of study test measures will be retained in a secure locking file cabinet located
at the BAART Programs Antioch location, which will be accessible only to the principal
investigator and to BayMark Administrative personnel so authorized by the Chief
Executive Officer of BayMark Health Services.

•

All hard copy test measure data will be randomly assigned a participant identification
number that will be used for organizing participant records in the computerized study
database.

•

A data key will be securely retained in a separate password protected, encrypted computer file
retained by the principal investigator that links participant names to their unique ID
numbers. Aside from this procedure, no participant names, birthdates, social security numbers,
addresses, phone numbers, email addresses, or other information that could potentially be
used by unauthorized persons to identify any participant will be collected, stored, or used as
part of the study implementation procedures.

•

The principal investigator will enter the participant pre-test, mid-test, and post-test data onto
a secure, password protected and data encrypted computer file system stored on a computer
accessible only to the principal investigator.

•

Similarly, the principal investigator will enter MBRP group attendance (number of
groups attended) and homework completion (number of homework assignments
completed) data .

•

At time of entry, the principal investigator will crosscheck data to assure accuracy of
the computerized data entries.

•

After the requisite five-year study data retention period has expired, the principal
investigator will assure secure destruction of all hard-copy and electronic study data
records.

•

In the event that the employment relationship between BAART/BayMark and the principal
investigator is terminated, Stephen Sooter will destroy all study data no later than the final
day of his employment, unless otherwise directed by BAART and BayMark..

----

Signature and Date of Pri ncipaI Investigator:
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Signature and Date of BAART Programs/BayMark CEO :
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Notification of Study Approval
by
BayMark Pilot Study Research Committee
The BayMark Pilot Study Research Committee has reviewed and approved the proposed
study of Stephen Sooter, a graduate student at Walden University enrolled in the Clinical
Psychology PhD Program, based on his research proposal entitled "The Effects of Mindful
Attentional Regulation On Illicit Opioid Use For Individuals Participating in Medication
Assisted Treatment: A Pilot Study." Reviewed and approved constituent elements of the study
intended for implementation at the designated BAART Programs site include, but are not
necessarily limited to, the following:
•

Summary of Study Design and Procedures

•

Letter of Cooperation for Data Management

•

Outline of the Mindfulness Based Relapse Prevention (MBRP) treatment protocol

•

Participant Informed Consent

•

Study Information for Participants letter

•

Participant Report of Adverse Event

The principal investigator, Stephen Sooter, will assure that the BayMark Pilot Study Research
Committee is fully informed regarding all aspects of study design, implementation, and
effects on participants throughout the study implementation and data analyses periods.
The BayMark Pilot Study Research Committee will monitor all aspects of study
implementation and data outcomes as determined necessary.
BayMark Pilot Study Research Committee:

Jason Carmichael, VP Quality and Clinical Compliance
/

Patrice Oliver, Director Nursing Education and Compliance
Frank Bauman, COO

